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ABSTRACT 
 
VENITA GRESHAM WATSON:  
A Familial Genetic Strategy for Determining Mechanism of Action 
(Under the direction of Howard McLeod, Pharm.D.) 
 
One of the greatest challenges in anticancer drug development is the discovery of 
molecular targets and biochemical interactions required for drug action. Lapses in drug 
efficacy and unanticipated toxicity, the two biggest causes of drug failure in clinical 
trials, are often attributed to our limited understanding of drug mechanism and cost the 
pharmaceutical industry millions. Genomics is rapidly emerging as tool for mechanism 
elucidation.  
Our approach is one of the latest to link drugs to the genes which influence their 
activity. This ex vivo familial genetics strategy uses a collection of extensively 
genotyped, normal, healthy, human cell lines from multigenerational families. Cell lines 
are phenotyped for cytotoxic response to anticancer agents, heritability analysis gives a 
measure of the degree to which genetics influence response, and linkage analysis 
suggests regions of the genome which are associated with the observed variation in 
response.  
To evaluate this strategy as method for mechanism elucidation, we first asked 
whether the system could produce pharmacological and genomic profiles related to a 
shared mechanism for a class of structurally related compounds. The in vitro sensitivity 
of CEPH cell lines to the camptothecins, a class of Topoisomerase 1 inhibitors (Top1), 
 iv
was studied. Heritability analysis estimates that genetics accounts for as much 20% of the 
observed variation in cytotoxic response to these drugs. Linkage analysis revealed a 
pattern of seven quantitative trait loci (QTLs) that were shared by all of the 
camptothecins and independently replicated with a second set of camptothecin analogues. 
The pattern of QTLs observed with the camptothecins was compared to those of the 
indenisoquinolines, a structurally distinct class of Top1 inhibitors. The objective was to 
identify which if any QTLs are related to the general mechanism of Top1 inhibition or 
should be considered class-specific. Finally, the model was assessed for its ability to 
stratify compounds by mechanism based on their biological and genomic profiles. Cell 
lines were phenotyped for response to approximately 30 drugs belonging to 8 mechanistic 
classes. Intraclass biological and genomic profiles were more similar to each other than to 
compounds belonging to distinct mechanistic classes. 
This work could have a significant impact on drug discovery and development as 
it provides a strategy for not only making predictions about mechanism of action for 
novel therapies, but for identifying genes involved in variable response to 
chemotherapeutic agents as well. 
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Abstract 
The inability to predict the pharmacology and toxicology of drug candidates in preclinical studies 
has led to the decline in the number of new drugs which make it to market and the rise in cost 
associated with drug development. Identifying molecular interactions associated with therapeutic 
and toxic drug effects early in development is a top priority. Traditional mechanism elucidation 
strategies are narrow, often focusing on the identification solely of the molecular target. Methods 
which can offer additional insight into wide-ranging molecular interactions required for drug 
effect and the biochemical consequences of these interactions are in demand. Genomic strategies 
have made impressive advances in defining a more global view of drug action and are expected to 
increasingly be used as a complimentary tool in drug discovery and development. 
1. Predicting Drug Variability Requires Knowledge of Mechanism 
There is significant interpatient variability in response to anticancer agents; different patients may 
experience therapeutic benefit, no effect, or even life-threatening side effects from identical doses 
of the same drug. Very few methods are available to prospectively distinguish those who will 
benefit from those who may be harmed. Consequently, the number of adverse events associated 
with cancer therapy remains high. While clinical and environmental variables (e.g., age, gender, 
diet, organ function, concurrent medications) have been associated with variation in drug 
response, genetics has been estimated to account for as much as 20-95% of the variability in a 
broad range of drugs [1] . A drug’s activity is the result of interactions with molecular targets and 
proteins involved in uptake, metabolism, and elimination. Genetic variations in any one of these 
proteins can have a significant affect on drug response. 
The field of pharmacogenomics examines the inherited variations in genes that dictate drug 
response. It seeks to identify those variations associated with differential responses between 
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patients. In the past, pharmacogenomic studies used the candidate gene approach to identify 
factors responsible for variable response. These studies required some a priori knowledge about a 
drug’s mechanism of action and the proteins it interacts with to elicit a pharmacological or toxic 
effect. For example, many cancers overexpress the epidermal growth factor receptor (EGFR) 
which, when ligand bound, triggers cell proliferation. Gefitinib was developed specifically to 
inhibit EGFR and suppress tumor growth. Early clinical trials revealed that most patients who 
received gefitinib saw no therapeutic effect [2] . However, 10% of the patients had a dramatic 
positive response to therapy [3].  It was subsequently discovered that the tumors of patients 
experiencing therapeutic benefit had specific activating mutations in the EGFR gene that made 
them susceptible to the chemotherapeutic agent. Understandably, it was concluded that 
administering this drug to patients whose tumors did not possess the EGFR mutations was neither 
medically or financially practical. Knowledge of the mechanism of action and protein interactions 
required for a drug’s pharmacological effect can aid in the identification of patients likely to 
receive therapeutic benefit or suffer from adverse events. 
Unfortunately, many drugs currently in use were developed without knowledge of their 
underlying molecular mechanisms. Predicting the mechanism of action has proven very difficult 
for both old and new drugs for several reasons. In many cases the target is unknown; as a result, 
the biochemical consequences of the drug-target interaction remain elusive. Even when the target 
is known, the cellular consequences of drug-target interactions remain vague. Moreover, drugs 
are often capable of binding to more than one target (considered off-target proteins), many of 
which have not been characterized. The end product is concurrent changes in many different 
known and unknown biochemical pathways. Our limited understanding is further confounded by 
unpredictable drug absorption, distribution, and metabolism. Drug action is a very complex 
process and clearly difficult to untangle. Our inability to elucidate a drug’s mechanism is a 
significant cause for the high failure rates and high costs associated with drug development. 
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Methods that can provide information on direct targets, indirect targets, affected cellular 
pathways, and proteins involved in the uptake, metabolism, and elimination of a drug would be 
powerful tools in drug discovery and development.  
A wide variety of technologies have been developed for unraveling drug mechanism (Table 1-1). 
Traditional approaches fall broadly into two categories: proteomic methods, which involve the 
identification of a target on the basis of direct binding, and biological strategies, which use 
bioactivity data to compare the profiles of compounds with known targets or mechanisms to those 
of the compound of interest. This review will summarize the strategies currently being employed 
and will use recent case studies to highlight the advantages and limitations of the different 
approaches. Based on this discussion, genomics will be presented as a new tool for circumventing 
some of the technical challenges associated with traditional mechanism elucidation strategies. 
2. Limitations of Current Methods of Mechanism Elucidation 
While drug action is the result of complex biochemical cascades following interactions with a 
drug’s interaction with metabolizing enzymes, transporters, and intracellular targets, traditional 
mechanism elucidation approaches tend to strictly focus on establishing a single molecular target 
responsible for a drug’s therapeutic activity. Proteomic methods such as affinity chromatography, 
phage display, and protein microarray involve the direct identification of the target by binding to 
the compound of interest. In silico target prediction is an indirect method of protein target 
identification which suggests likely biological targets of small molecules via data mining in 
target-annotated chemical databases. Biological methods, such as cellular phenotyping, which 
compares the pharmacological profiles of compounds with known targets to those of the 
compound of interest, are also indirect methods of target identification.  
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2. 1. Proteomic Methods 
2. 1. 1. Affinity purification of targets 
Affinity chromatography is a powerful and classic method used to identify target proteins for 
small molecules [4-6]. While a number of successes have been reported, results are often 
variable. In this approach, a protein extract is passed over a packed column consisting of drug 
immobilized to a solid support (Figure 1-1). Following repeated washing to remove unbound 
proteins, the bound protein is eluted using denaturing conditions or elution with mobile ligand. In 
principle, this method is applicable only to small molecules that can be derivatized without 
disrupting their biological activity; biological activity and molecular targets have been shown to 
change with chemical modification for immobilization on solid supports [7]. For detection, this 
method requires high affinity ligands and a high abundance of the target protein in the cell 
extract. Compounds isolated following high throughput screens are typically not very potent, and 
low abundance target proteins are difficult to detect over background non-specific binders. 
Detection of weaker biologically relevant interactions is hampered by a number of factors. For 
example, many bioactive molecules are somewhat hydrophobic which predisposes them to non-
specific binding when coupled at high density to a solid support. Consequently, highly stringent 
wash conditions are required to reduce the likelihood of detecting weak interactions. 
The yeast three-hybrid system [8], phage display [9-11] and mRNA display [12-13] are three 
relatively new protein based methods for small molecule target discovery. They all utilize affinity 
chromatography but were developed to counter problems with low affinity ligands and the low 
abundance of the target protein in extracts. These methods involve the in vitro synthesis of a 
library or a pool of proteins which are then submitted to a selection process that entails repeated 
amplification and enrichment to isolate proteins of interest. The probability of finding a binding 
protein with high affinity increases as the library size increases in these systems. In addition, that 
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probability is also influenced by both the ability to diversify the library, and then isolate and 
characterize selected proteins from the library. A library lacking diversity or possessing 
underrepresented binding proteins may inadvertently be missing the target. The isolation and 
characterization of binding proteins in phage display or mRNA display can be difficult. Binding 
proteins must be expressed in E. coli, where they may fold improperly and form insoluble 
inactive aggregates or inclusion bodies, which can not be easily purified. The steps needed to 
solubilize and refold the protein can be highly variable and may not always result in high yields 
of active protein. The yeast three-hybrid system is limited to the study of proteins which can be 
expressed in yeast. 
2. 1. 2. Protein microarray 
Another method of identifying the molecular targets of small molecules is the protein microarray. 
Protein microarrays are prepared by spotting purified proteins on chemically derivatized glass 
slides. The binding profile for a small molecule across an entire proteome can be achieved by 
incubating the array with a fluorescent or radiolabelled form of the small molecule [14-15]. After 
rigorous washing, labeled proteins are identified. In a study to identify the cellular targets of 
SMIRs, small molecule inhibitors of rapamycin, which suppress rapamycin’s inhibitory effects on 
cell growth, Huang et al. prepared a microarray of nearly the entire yeast proteome [16]. SMIRs 
were biotinylated and binding to protein targets was detected using fluorescently labeled 
strepavidin. Thirty binding proteins were identified, among them Ybr077cp, a protein of 
previously unknown function. Yeast strains with a Ybr077cp deletion (Ybr077cpΔ) were 
hypersensitive to rapamycin. Ybr077cp-induced hypersensitivity was reversed when the 
Ybr077cpΔ cells were transfected with TOR1-1, a functional variant of the target of rapamycin 
protein which cannot bind rapamycin. The authors concluded Ybr077cp is likely a component of 
the TOR signaling network. Unfortunately, targets identified using the yeast proteome may not be 
relevant to human biology; for example there is no known human homolog for Ybr077cp.  
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The natural transition would be the use of arrays prepared from the human proteome. A number 
of technological advances are still needed before the whole human proteome can be applied to 
protein microarrays for drug discovery endeavors. To date only small scale human protein arrays 
have been used for study [15]. Moreover, while protein microarrays have advantages over affinity 
chromatography, there are limitations which can hinder target identification. For example, the 
discovery of potential targets by affinity chromatography is hampered by low levels of natively 
expressed proteins, while protein microarrays expose all proteins equally. However, placement on 
the array may result in steric hindrance which would prevent small molecule binding. In addition, 
small molecule target proteins might not be identified since the protein incorporated on arrays 
will lack post-translational modifications, or involvement in complex formation with other 
proteins which would contribute to their affinity for a ligand.  
2. 1. 3. In silico target prediction 
Since it is currently unfeasible to screen all proteins expressed by the human genome, 
chemoinformatics has sought to develop computational methods which can predict the proteins to 
which a drug is likely to bind. One of the latest techniques towards this goal was reported by 
Keiser et al. [17]. They computationally screened the chemical structures of approximately 3,600 
FDA approved and investigational drugs against the thousands of known ligands for 1,400 protein 
targets. Chemical similarities between drugs and ligands suggested thousands of known and novel 
drug-target associations. A subset of these drug-target associations were further examined (n = 
184) and nearly 150 were predicted which had no literature precedent. The authors used in vitro 
binding assays to validate 30 of these new drug-target predictions. Twenty-three of these drugs 
(77%) bound with affinity less than 15 uM and 5 of these had sub-100 nM affinities for the 
previously unknown targets. Some of these novel targets were suspected to contribute to drug 
action. For example, the sigma receptor (σ1) receptor was previously implicated as the target 
responsible for the hallucinogenic properties associated with N,N-dimethyltryptamine (DMT). 
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However, other non-hallucinogens bind the σ1 receptor with higher affinity than DMT and prior 
research indicates the hallucinogenic characteristics associated with DMT more closely resemble 
an interaction with serotonergic (5-HT) receptors. The study by Keiser et al. predicted multiple 5-
HT interactions and binding studies confirmed DMT binds nine serotonin receptors with affinities 
ranging from 39 nM to 2.1 uM. Unfortunately, there is no rapid and simple method of identifying 
and validating which, if any, of the nearly 4000 new predicted drug-target interactions are 
biologically relevant and associated with a drug’s primary activity or side effects. 
2. 2. Biological Methods 
2. 2. 1. Cellular Phenotyping 
A considerable number of drugs in use today were discovered by screening phenotypic changes 
induced by candidate drugs in cells, tissues, or model organisms. One of the most noteworthy 
examples of drug discovery and indirect target prediction was developed at the National Cancer 
Institute (NCI). Compounds are evaluated for their ability to inhibit cell growth in a panel of 60 
human cancer cell lines. The COMPARE algorithm then matches a test compound’s cell growth 
inhibition pattern across all 60 cell lines (referred to as the fingerprint) with one or more of the 
thousands of other compounds in the NCI database [18]. A high degree of correlation between 
two fingerprints suggests that the compounds share a molecular target. This model identified the 
novel drug kenpaullone as a cyclin dependent kinase (CDK) inhibitor when its fingerprint 
matched with other CDK inhibitors that had been through the screen previously [19]. The model 
is unsuccessful in assigning a mechanistic classification when the fingerprint for a drug candidate 
is too distinct from the patterns of other compounds with known mechanisms in the database, a 
scenario suggesting a novel molecular target. 
2. 2. 2. High Content Screening 
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Advances in automated microscopy and fluorescence have enabled the simultaneous screening of 
multiple cellular phenotypes in a method referred to as high content screening (HCS). Several 
phenotypic markers obtained from a single cell or cellular subpopulation can be combined to 
generate a multidimensional biological fingerprint. This fingerprint provides a more cohesive 
profile of the action of a drug and enables compounds of similar activity to be grouped together. 
Young and colleagues recently describe a methodology for the integration of HCS data with 
chemical structure information to make mechanisms of action inferences [20]. The authors 
screened a library of > 6,000 compounds using a cellular-proliferation assay which also measured 
30 cytological phenotypes. Factor analysis was used to reduce these cytological features to six 
categories: nuclear size, DNA replication, mitosis, nuclear morphology, nuclear ellipticity, and 
EdU texture. A mean response score was calculated for each compound. Compounds with 
response factors in the upper 5% were considered biologically active. Hierarchal clustering of 
biologically active compounds by factor scores revealed seven broad clusters termed phenotypes. 
Since similar structures tend to possess similar mechanisms, phenotypic clusters were 
investigated for structurally related compounds. Approximately 96% of compounds with similar 
structures showed similar phenotypic readouts. Conversely, 4% of compounds with slight 
changes in structure showed large changes in phenotypic readouts and suggested a change in 
mechanism. Compounds from distinct structural classes which were known to share common 
molecular targets via the same or different binding sites, or perturbed different components of 
common pathways also produced similar phenotypic readouts. Further analysis using a subset of 
compounds with known shared targets revealed that phenotypes correlated better with predicted 
compound targets than with the compound structures themselves. Finally, the authors investigated 
whether the methodology could make predictions about molecular targets. A chemogenomic 
database with known-ligand target associations based on molecular substructure was used to 
generate a model which could predict the targets of the 211 active compounds. The authors 
focused on the predicted targets for four groups of phenotypically similar yet structurally distinct 
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compounds. The group consisted of colchicine derivatives, novel kinase inhibitors, a quinoline 
derivative and a pseudolarix acid B derivative. Colchicine is a well known microtubule inhibitor 
and the majority of the compounds were predicted to share the common target, tubulin. Follow-up 
in vitro assays confirmed all compounds caused microtubule depolymerization. 
These phenotypic screening based approaches were designed to identify any compound which 
ameliorates a disease phenotype in an animal or cell-based model. Consequently, a vast number 
of compounds could be discovered to act on a substantial number of known and presently 
undiscovered targets and pathways associated with a disease. However, a fundamental limitation 
of these methods is that clustering or correlation on its own does not reveal the mechanism of 
action of compounds of interest. To infer mechanism, compounds with known mechanisms must 
be used to serve as markers for comparison. However, the number of compounds with clearly 
defined mechanisms of action is limited. Consequently, as a mechanism elucidation strategy, 
phenotypic screening is restricted to existing target knowledge. Moreover, many drugs have many 
targets and consequently a complicated resulting biochemical cascade. Finally, marketed drugs 
are only using a small portion of the potential protein targets of pharmacological interest [21]. A 
method built strictly on making predictions using compounds with known molecular targets is 
inherently limited. 
3. Genomics Broadens Understanding of Drug Action 
To meet the challenging problem of identifying the MOA for drug candidates, novel methods are 
constantly being developed and old methods increasingly improved upon. Some impressive 
successes have been attributed to the use of genetics as a tool in the identification of mechanisms 
of action for drugs. The innovative genetic models that follow have several advantages over the 
target identification assays described above. Compounds with known molecular targets are not 
required as landmarks for mechanism elucidation. Moreover, they require no a priori knowledge 
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about the compound mechanism of action [22]. This allows the activities of novel drugs to be 
determined in a systematic and unbiased method. These processes allow the discovery of 
biological pathways involved in drug action (including proteins associated with metabolism, 
distribution, and off target effects) in addition to the precise mechanism of action to be 
determined. Traditional methods of elucidating mechanism are restricted by a static view of drug 
action: they oversimplify and focus the search on a single molecular target. By allowing the 
biology to reveal the genes influencing activity, genomic tools offer a more dynamic and global 
perspective of a drug’s mechanism. 
3. 1. Applications 
3. 1. 1. Yeast genomics 
Enhanced knowledge of yeast genomics has enabled the use of the budding yeast Saccharomyces 
cerevisiae as a powerful tool for mechanistic discovery. There are different types of yeast mutant 
libraries which have been employed in mechanistic studies: heterozygous deletions, homozygous 
deletions, and overexpression libraries. An example of these libraries is the collection of genome-
wide heterozygous deletion strains developed with molecular barcodes. When these libraries are 
grown in the presence of drug, the deletions that sensitize cells to a particular drug will cause a 
decrease in cell growth relative to control [23]. The barcode associated with each strain is used to 
quantitate growth and identify genes involved in the drug’s mechanism. This method has been 
used to explore the cellular pathways and processes for a collection of compounds with known 
and unknown modes of action [23-24]. Hierarchal clustering of compounds with similar genomic 
profiles suggests common molecular targets and pathways [24]. For example, the genomic 
profiles of amiodarone, an antiarrythmic drug, and the chemotherapeutic agent tamoxifen which 
targets the estrogen receptor, were quite similar. Amiodarone acts through perturbation of 
calcium homeostasis. In three independent validation assays, tamoxifen was also shown to disrupt 
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calcium homeostasis confirming published evidence that the drug increases calcium 
concentrations in a variety of mammalian cells [24]. Moreover, the system could be used to 
identify unknown targets for novel agents. The target of the antifungal, papuamide B (PapB), was 
identified by assessing both drug resistant and sensitive mutants. Sensitive mutants affected by 
exposure to PapB had gene deletions related to cell wall organization. A single gene, the enzyme 
required for synthesis of phosphatidylserine (PS) in yeast cell membranes, was associated with 
the growth of resistant wild type cells in the presence of PapB. Investigators proposed that papB 
binds PS and acts on membrane integrity and permeability. A comparison of the genomic profile 
of PapB with known membrane permeabilizers and agents which bind other phospholipids 
revealed a match. Yeast genomic profiling is exceptional because it can be used to identify 
primary and secondary targets via sensitivity as well as loss-of-function mutations that result in 
drug-resistance [25].  
3. 1. 2. Human cancer cell lines 
Some of the earlier limitations of cell-based phenotypic screening have been circumvented with 
the incorporation of a genomics component. Scherf et al. were the first to use genomics to make 
predictions regarding targets critical to drug action in the cancer cell lines (Figure 1-2) [26]. They 
recognized that patterns in cellular sensitivity in the NCI60 could be linked to differences in gene 
expression between the cell lines, and might provide information about a compound’s mechanism 
of action. The group measured gene expression levels in the untreated NCI60 cell lines. Patterns 
of gene expression across the NCI60 panel were then correlated to the biological activity of 1,400 
compounds across the same cell line panel. Cells expressing higher levels of a gene were less 
sensitive to a compound and visa versa. For example, the expression of dihydropyrimidine 
dehydrogenase (DPYD) was negatively correlated (r = -0.53) to the potency of 5-fluouracil (5-
FU) across the NCI60 panel; cell lines which expressed low levels of DPYD, the enzyme which 
inactivates 5-FU, were more sensitive to the drug. Finally, since drug design and discovery is 
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often concerned with identifying which structural features might yield a particular mechanism, 
Blower et al. expanded on the work reported by Scherf [27]. The structural characteristics of 
compounds were linked to their biological fingerprints and the gene expression profiles of the 
NCI60. This model now serves as a valuable resource for identifying compounds which have 
anticancer activity and providing testable hypotheses about genes (and gene products) associated 
with that drug’s mechanism of action. 
 
3. 1. 3. Rodent models 
Another noteworthy example involves the use of mouse haplotype computational genetic analysis 
to identify genes that affect drug metabolism or response. This method was recently used to 
identify genes and the resulting proteins affecting the overall metabolism of warfarin in mice 
(Figure 1-3) [28]. Warfarin, a commonly prescribed anticoagulant, is metabolized by many 
different pathways and by a variety of enzymes into different metabolites. 14C-labeled R-warfarin 
was administered to 13 inbred mouse strains and both parent compound and metabolites 
quantified in plasma for up to 24 h following dosing. Strain specific differences were observed in 
the production of warfarin metabolites. Of all the metabolites studied, inbred strains had the 
largest difference in the rate of formation of 7-hydroxylated warfarin. Computational genetic 
analysis was used to look for patterns of genetic variation that correlated with the observed 
differences in rate of formation of 7-hydroxywarafin across mouse strains. The two strains of 
mice with the lowest rates of warfarin metabolism differed from the other strains in a region on 
chromosome 19 that encodes for the metabolizing enzyme cytochrome P450 2C (Cyp2c). To 
confirm the role of Cyp2c in murine warfarin metabolism, the formation of the major metabolite 
7-hydroxywarfarin was inhibited in murine liver microsomes following the administration of a 
Cyp2c specific inhibitor [28]. Moreover, the expression of Cyp2c29 in liver extracts were 2-7.4 
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fold lower in the two strains with the low rate of metabolite generation. Although there are a 
number of genetic variables that contribute to the interstrain differences in R-warfarin 
metabolism, Cyp2c9 was identified because it was a rate-limiting enzyme in a major elimination 
pathway for warfarin. 
The impact of this tool extends beyond evaluating drug metabolism. For example, this approach 
has also been used to link the beta-2-adrenergic receptor to increased pain sensitization, a side 
effect associated with the administration and subsequent withdrawal of opioids [29]. In this 
model, the pain response threshold was measured at baseline and following four days of exposure 
to morphine in 15 inbred mouse strains. There was a significant difference in the extent of pain 
sensitization observed between the mouse strains following morphine treatment and withdrawal. 
Computational genetics was used to identify genes which might be responsible for the observed 
differences. A haplotype block on chromosome 18, specifically within a region of the β2-
adrenergic receptor gene, was the most strongly correlated with the observed phenotypic 
difference. Administration of a β2 receptor antagonist caused a dose-dependent reversal of pain 
sensitization. Contrary to wild type mice, knockout mice for β2 receptor had no pain sensitization 
following morphine withdrawal. The authors concluded that the β2 adrenergic receptor was the 
likely receptor subtype responsible for the pain sensitization following morphine withdrawal. 
Studies like this which attempt to identify novel genetic factors affecting dependence on 
opioids are essential to the discovery of methods for the prevention or treatment of 
increased pain sensitivity and other symptom of opioid addiction. 
4. 1. Conclusions 
Drug activity is clearly a tangled and complex process. Gaining a clear understanding of drug 
action specifically a drug’s interaction with direct and indirect targets and proteins involved in 
transport and metabolism remains a formidable task in drug discovery and development. The 
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analysis of the various proteomic and biological mechanism elucidation methods clearly 
demonstrates that each approach has its specific strengths and limitations. Genomics is an under 
utilized tool that can strengthen current efforts in identifying mechanisms of action. It has the 
potential to directly link drugs which produce a desired phenotype in a validated model to a more 
global view of their mechanism early on in the development process. However, the limitations 
associated with the above genomic strategies for mechanism elucidation are worth mentioning.  
The most critical flaw is the fact that the extent to which these results can be translated to humans 
remains unclear. Yeast are primitive organisms whose intracellular conditions such as protein 
folding and post-translational modifications can differ significantly from mammalian cells. 
Likewise, some mammalian targets are absent in yeast and visa versa. Inconsistencies in the data 
between humans and yeast may even suggest compounds might affect an entirely different 
process in yeast [30]. Moreover, compounds can have a lower permeability in yeast cells as 
compared to mammalian cells. As a result, only a subset of compounds of interest may be 
evaluated in yeast. Similarly, genes and the resulting proteins identified as contributors to drug 
action in murine models may not always reflect events in humans. For example, drug metabolism 
in rodents can differ from humans due to major differences in P450 isoforms, expression, and 
catalytic activity. 
Cancer cell lines are not always representative of primary tumors. Auman and McLeod compared 
genome wide expression data of human colorectal cancer cell lines to clinical colorectal tumors 
[31]. Hierarchal clustering on gene expression revealed that cancer cell lines formed a single 
cluster separate from clinical tumor samples. The group concluded that the cell lines did not 
accurately represent the genetic heterogeneity present in clinical tumor samples [31]. In another 
example, human prostate cancer cell lines do not exhibit features commonly seen in human 
prostate cancer. Prostate-specific antigen (PSA) is synthesized almost exclusively in the human 
prostate and is androgen regulated. High levels of PSA are indicative of prostate cancer. The two 
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prostate cancer cell lines used in the NCI60 panel, PC3 and DU145, do not express PSA and are 
not androgen sensitive [32]. Genomic studies based on gene expression patterns in cancer cell 
lines may suggest molecular mechanisms critical to drug action which are distinct from those in 
the clinical setting. 
Moreover, in vitro cell line work using gene expression analysis is often inadequate. Microarray 
studies of gene expression will reveal some of the genes associated with drug effect but it may 
miss many other relationships. For example, not all of the changes will be under transcriptional 
control. Some will be controlled using post-translational modifications such as phosphorylation 
and glycosolation; gene expression techniques such as DNA microarray will be unable to detect 
these endpoints.  
Considering these drawbacks, an ideal model for a genomic mechanism elucidation strategy 
would satisfy the following conditions:  
1. performed in a human model 
2. quantitative and reproducible 
3. high throughput screening capability 
4. amenable to database generation 
5. can cover broad range of biology (targets, pathways, physiology, and diseases) 
6. can provide links between chemistry and biology 
7. mechanistically open such that changes MOA can be recognized with changes in 
structure 
8. can give clinical indications about efficacy and toxicity 
9. can give information about secondary or off-target activity and effects 
10. can screen more than 1 concentration of a drug 
11. can link differences in response to genetic heterogeneity 
A new strategy for identifying genes critical to drug action has the potential to satisfy many of the 
aforementioned criteria. This tactic employs an ex vivo human familial genetic model to identify 
inherent mutations in genes involved in drug action which are associated with differences in 
response . The genes influencing the cytotoxicity of chemotherapeutic agents have been studied 
using immortalized lymphoblastoid cell lines (LCLs) derived from Centre d’Etude du 
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Polymorphisme Humain (CEPH) populations. The CEPH cell lines are a collection of 
multigenerational families that have been extensively genotyped. Cells from these families are 
phenotyped for response to a given anticancer agent then linkage analysis is used to correlate 
variation in response to variation in regions of the genome referred to as quantitative trait loci or 
QTLs (Figure 1-4). Watters et al. phenotyped sensitivity to increasing concentrations of 5-
fluorouracil in 427 CEPH cell lines across 38 families [34]. Significant variation was noted across 
individual cell lines at each dose. Heritability, the degree to which a trait can be explained by 
genetic factors, ranged from 26% at the lowest concentration of 5-fluorouracil to 65% at the 
highest concentration. Dose-dependent QTLs associated with 5-fluorouracil cytotoxicity were 
observed on chromosomes 5 and 9. Further studies are expected to narrow these broad QTLs 
down to the genes which are involved in drug action. This model has also been applied to the 
study of the anticancer agents, cisplatin [35], etoposide [36], docetaxel [34], and daunorubicin 
[37]; cytotoxic response to each of these agents was a heritable trait in human families with 
genomic regions associated with observed differences in response. To date, this model has only 
been used as a pharmacogenomic tool to evaluate which genes and variations in the genome are 
responsible for the disparity in response to a single drug. Future studies are needed to evaluate the 
predictive genomic capacity of this model, specifically to use the pharmacological and genomic 
response profiles of numerous drugs, rather than those of one small molecule at a time, to provide 
incisive information about their mechanisms of action.  
4. 2. Introduction to Dissertation 
Tools for identifying genes and gene products critical to drug action early in development are in 
great demand. The primary objective of this dissertation project was to investigate the potential 
use of our ex vivo familial genetics model in CEPH cell lines as a tool for mechanism elucidation. 
The following chapters describe an initial investigation into using the CEPH cell lines to relate 
genes or regions of the genome identified as influencing the cytotoxicity of a compound across 
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compound classes to inherited response and mechanisms of action. The purpose of Chapter 2 was 
to investigate the model’s ability to establish specific patterns of QTLs related to a shared 
mechanism for a class of structurally related compounds, the camptothecins, which are 
Topoisomerase 1 (Top1) inhibitors. In Chapter 3, the genomic profiles of structurally unrelated 
Top1 inhibitors were compared to those established for the camptothecins, to assess which 
regions might be associated with compound class versus the general mechanism of Top1 
inhibition. The goal of Chapter 4 was to demonstrate that biological and genomic data generated 
from phenotyping the CEPH cell lines can be used to stratify compounds by mechanism of action. 
We predicted that intraclass pharmacological and genomic profiles would be more similar to each 
other than to compounds belonging to distinct mechanistic classes.  
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Figure 1-1. Affinity chromatography based methods for target identification. Affinity 
chromatography makes use of the highly specific binding sites usually present in biological 
macromolecules, separating molecules on their ability to bind a particular ligand. Covalent bonds 
attach the drug (ligand) to an insoluble, porous support in a manner that presents the ligand to the 
protein sample. The protein mixture is passed over the medium, and the target protein binds to the 
drug tethered to the solid support. A buffer is used to wash or remove impurities and unbound 
material. Finally, denaturing conditions are used elute the bound proteins from the column. 
 
1. Drug immobilized 
to solid support 
2. Application of 
cell lysate 
3. Unbound 
proteins eluted 
4. Target protein 
isolated 
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Figure 1-2. Schematic overview of mechanism prediction model using NCI60 human cancer cell 
lines. The target database is composed of relative gene expression measurements on the 60 
human cancer cell lines. Each row of the activity database represents the pattern (sensitivity or 
resistant) of biological activity of a particular compound across the 60 cancer cell lines. The 
structure database contains the 2D or 3D chemical characteristics of the compounds investigated 
using the NCI60 cell line panel. Coupling of genomic, biological, and chemical information 
might allow genes that are selectively expressed in a tumor to be correlated not only with the 
compounds themselves but also with the subclasses and substructures of these compounds. The 
target, activity, and structure databases can then be used to make predictions about potential 
targets or activity patterns of a compound given its molecular substructure. 
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Figure 1-3. Murine haplotype computational pharmacogenetic analysis. This computational 
method allows for the rapid identification of genes involved in drug metabolism. Upper panel. A 
single IP dose of 10 mg/kg 14C-R-warfarin was administered to thirteen mouse strains and parent 
compound and metabolites analyzed in pooled blood samples. Strain specific differences were 
observed in the formation of the major warfarin metabolites 7-hydroxywarfarin (7-OH) and its 
glucoronidated metabolite (M8). The correlation between the measure phenotype variation and 
genomic variation between strains was evaluated using haplotype blocks. It was noted that the 
two strains with the lower rates of warfarin metabolism also shared a haplotype block on 
chromosome 19 distinct from the other strains of mice studied. Haplotype blocks were then 
analyzed to identify a list of genes potentially influencing warfarin metabolism. The list was then 
reduced to genes expressed in the liver. Strain groupings for Cyp2c which is expressed in the 
liver best correlated to the observed phenotypes for warfarin metabolism. Lower panel. To 
confirm Cyp2c involvement, the effect of a Cyp2c specific inhibitor on the rate of formation of 7-
OH and M8 was examined. The genomic region associated with the Cyp2c haplotype block 
suggested that genetic variation in the CYP450 enzymes Cyp2c55, Cyp2c39, or Cyp2c29 may be 
responsible for the observed phenotypic variation. Gene expression levels of the Cyp enzymes 
were evaluated in the livers of the 13 mouse strains. Cyp2c55 and Cyp2c39 were not expressed in 
the livers, and Cyp2c29 gene expression varied greatly among strains. Finally, differences in 
protein expression for Cyp2c29 were shown to correlate to the differences in warfarin 
metabolism. 
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Figure 1-4. Discovery of genetic loci involved in the cytotoxic effect of chemotherapeutic agents. An 
ex vivo familial study was used to identify genes associated with docetaxel cytotoxicity. A) 
Variability at increasing concentrations of docetaxel was assessed in a collection of lymphoblastoid 
cell lines derived from CEPH pedigrees. Each pedigree consists of 5-10 offspring per family. B) A 
dose-response curve shows significant variation in cell viability at all concentrations across the entire 
CEPH population. Data points are mean cell viability and bars are standard deviations across the 
entire population. The degree to which observed variation in cell viability can be explained by genetic 
factors (heritability) is represented by numbers. C) Linkage analysis correlated a region on 
chromosome 9 with the observed variability in cytotoxic response. Furthermore, as drug dose 
increased the LOD score (probability the observed phenotype is related to the variation in a specific 
region) also increased.  
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CHAPTER 2: 
 
 
 
 
Genome-wide Approach for Differentiation of the Camptothecins 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ABSTRACT 
 
Differences in biological activity and ADME profiles are often observed for compounds within a 
mechanistic class bearing slight modifications on a structural theme. We propose that these 
changes can be detected by examining the changes in genes which influence the cytotoxicity of 
these compounds using HTS in collections of genotyped human familial (CEPH) cell lines. 
Moreover, this genomic strategy can be used to establish a specific pattern of genes related to the 
shared mechanism for a class of structurally related compounds. The camptothecins were chosen 
as model drugs since extensive studies reveal differences in antitumor activity, metabolism, and 
transport with changes in structure. A simultaneous screen of six camptothecin analogues resulted 
in cytotoxicity profiles and orders of potency which were in agreement with the literature. We 
estimated the heritability for cytotoxic response to the camptothecins to be approximately 0.23. 
Nonparametric linkage analysis was used to identify a relationship between genetic markers and 
the response to camptothecins. An initial screen of the six camptothecin analogues revealed ten 
shared quantitative trait loci (QTL) on chromosomes 1, 3, 5, 6, 11, 12, 16 and 20. In a separate 
validation experiment with 3 additional camptothecins, nine of the ten QTLs were replicated. 
Subtle distinctions in significant and suggestive QTLs were also observed between drugs. These 
results provide a step towards streamlining the anticancer drug development process by 
simultaneously enabling phenotypic screening and identifying genes critical to drug action which 
impact patient sensitivity or toxicity. 
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 INTRODUCTION 
Prior to the 1990s, the phenotypic based drug discovery approach dominated the pharmaceutical 
industry. In this approach, small molecules were screened against cells, tissues, or even whole 
organisms for their ability to enhance or suppress a specific phenotype desired in humans. The 
apparent advantages of this method over the existing target-based drug discovery paradigm have 
resulted in a renewed interest in phenotypic screening. One of the greatest advantages of this 
approach is that it enables the discovery of novel therapeutic targets for a disease. Compounds are 
screened for a biological effect rather than perturbation of a single molecular target, linking 
chemistry with biology and driving the serendipitous discovery of numerous structures with novel 
mechanisms of action (MOA).  
Despite the recent revival in phenotypic screening, there are noteworthy limitations which can 
create a considerable bottleneck in the drug discovery process. Mechanism elucidation following 
the identification of biologically active compounds remains the most important weakness. A 
number of methods are being developed and optimized for mechanism elucidation; however, they 
are fraught with limitations which have been reviewed extensively elsewhere [1]. Since the 
typical phenotypic screening methods are unable to suggest key information about the mechanism 
of biologically active compounds, there is no way to distinguish between them other than by 
potency. Without a clear understanding of MOA, problems arise in lead optimization, drug safety, 
and efficacy. Structure activity relationship (SAR) studies for lead optimization become quite 
complicated with phenotypic screens. Binding to an unknown target can be influenced by cell 
absorption and transport, additional protein binding, secondary target interactions, drug 
metabolism, etc. These sites of compound loss can vary significantly within a series of 
structurally related compounds. Most current methods of mechanism elucidation are also unable 
to account for or convey changes in mechanism (ie primary and secondary targets) with changes 
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 in structure. As a result SAR patterns become difficult to interpret and use during lead 
optimization. Finally, when mechanism is unclear, our ability to assess the risks of mechanism-
based toxicity, side effects associated with secondary targets, or lapses in efficacy are also quite 
limited. 
Genetic and genomic methods which screen all possible targets of compounds of interest are 
being developed to surmount issues associated with target identification following phenotypic 
screens. These methods which simultaneously screen compounds for a desired biological effect 
and provide information about molecular targets and SAR patterns are rising as powerful tools in 
drug discovery and development. Some of the most prominent examples of this approach use the 
budding yeast Saccharomyces cerevisiae [2, 3] or human cancer cell lines [4, 5] as in vitro model 
systems. In both cases, inconsistencies in data between humans and the model are a significant 
drawback. An ideal genomic strategy would investigate drug activity in a normal healthy human 
model. Recently, an ex vivo familial genetic strategy involving lymphoblastoid cells lines (LCLs) 
derived from Centre d'Etude du Polymorphisme Humain (CEPH) reference pedigrees was 
employed to quantify the impact of genetics on drug response and to identify quantitative trait 
loci (QTLs) harboring genes critical to drug action [6, 7]. Here we asked whether this ex vivo 
familial genetics model could be used to establish specific patterns of QTLs related to a shared 
mechanism for a class of structurally related compounds. 
The camptothecins were chosen as a model class of compounds to investigate for a number of 
reasons (Figure 2-1).  Intensive efforts in medicinal chemistry have led to the generation of a 
large number of camptothecin derivatives. Two of these, topotecan and irinotecan, are being used 
in the clinic as antitumor agents, and many are in preclinical and clinical development. In spite of 
the identification of a number of analogs with improved therapeutic activity, (intrinsic and 
acquired) resistance and toxicity remain major limitations to camptothecin therapy. While 
extensively studied, the mechanisms of resistance and toxicity remain unclear [8]. In addition, 
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 though it is firmly established that the key molecular target of all of the camptothecins is 
Topoisomerase 1 (Top1), the post target interaction events responsible for antitumor activity are 
vague [9]. It is reasonable to suggest that a clearer understanding of the biochemical cascade 
associated with camptothecin cytotoxicity might lend answers to the questions surrounding 
mechanisms of activity, toxicity, and resistance. To this end, the CEPH model system was used to 
a) assess variation in response to the camptothecins across normal healthy human LCLs, b) 
evaluate the genetic contribution to variation in response and c) establish a pattern of multiple 
QTLs common to a class of compounds suggesting a shared mechanism of action. 
MATERIALS AND METHODS 
Cell lines. One hundred twenty-five Epstein-Barr virus-immortalized lymphoblastoid cells 
derived from 14 CEPH reference pedigrees (35, 45, 1334, 1340, 1341, 1350, 1362, 1408, 1420, 
1447, 1451, 1454, 1459) were purchased from Coriell Cell Repositories (Camden, New Jersey). 
Cells were maintained in RPMI medium 1640 (Invitrogen, Rockville, MD) supplemented with 
15% fetal bovine serum, incubated in a 5% CO2 atmosphere at 37◦C, and passaged 2-3 times per 
week. Exponentially growing lymphoblastoid cell lines with greater than 85% viability, at 
passages 3-7 were used for experimentation.  
Drugs. The following panel of camptothecins was purchased from LKT Labs (St Paul, MN): 
camptothecin (CPT), irinotecan (CPT11), 7-ethyl-10-hydroxycamptothecin (SN38), topotecan 
(TPT), 9-aminocamptothecin (9AC) and 9-nitrocamptothecin (9NC). Dr. Daniel Comins (North 
Carolina State University, Raleigh, NC) kindly provided 10-methoxycamptothecin (mCPT), 10-
hydroxycamptothecin (hCPT), and 7-chlorocamptothecin (ClCPT). All camptothecins were 
prepared in 10 mM working solutions of DMSO (Sigma-Aldrich, St Louis, MO). Since 
camptothecins have a labile lactone form that exists in a pH dependent equilibrium with the 
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 inactive carboxy form (present at basic pH), drugs were serially diluted in citrate-phosphate 
buffer at pH 3. Final concentrations of DMSO were 0.1% in all experiments. 
Cytotoxicity Profiling. The conditions for drug preparation and phenotyping were optimized 
prior to this investigation (Appendix 1). The cytotoxic effect of the panel of camptothecins was 
determined by using the nontoxic colorimetric-based assay, alamar blue [6]. Plates (384 
well,Corning, Corning, NY) were preloaded with vehicle (citrate-PBS, 0.1% DMSO), 10% 
DMSO, and increasing concentrations of each drug (n = 9 doses per drug). Each plate contained 6 
replicates for each drug-dose combination. Cells were then plated at a density of 4000 cells in 45 
ul per well. Following 72 h incubation, 5 ul alamar blue was added. Fluorescence was read at Ex 
535nm and Em 595nm using a DTX880 plate reader (Beckman Coulter) at 96 h drug exposure. 
Raw fluorescence values for each set of replicates of a drug-dose combination were considered 
outliers if there was more than a ten-fold increase or decrease in the fluorescence signal of a 
single replicate. Cell viability (survival) relative to untreated controls was determined according 
to the manufacturer’s protocol. The final percent survival at each concentration was averaged 
from six replicates of two independently plated experiments (n = 12). Additionally, growth rate in 
vehicle was calculated as previously described [10]. The IC50 (the dose needed to inhibit cell 
viability by 50%), was calculated based on a sigmoidal dose-response curve using the nls package 
in R (www.r-project.org) [11]. 
Hierarchical Clustering. LogIC50s for each cell line-drug combination were z-score 
transformed prior to clustering. The data was loaded into Cluster 3.0 (http://bonsai.ims.u-
tokyo.ac.jp/~mdehoon/software/cluster/) and clustered using uncentered correlation and complete 
linkage. To stabilize clusters, a self organizing map (SOM) was calculated using 100,000 
iterations for cell lines and 20,000 iterations for drugs. Clusters were visualized using Java 
TreeView. 
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 Heritability Analysis. Heritability estimates of the proportion of variation in cytotoxic response 
due to inherited factors were calculated using variance components analysis using MERLIN 1.1.2 
[12] (http://www.sph.umich.edu/csg/abecasis/Merlin/index.html). The degree of heritability 
associated with growth rate in vehicle was also calculated, and the heritability calculation for 
each drug-dose combination was adjusted using growth rate as a covariate in the variance 
components analysis [12]. 
Genotype Data and Error Checking. Genotype data for each cell line were downloaded from 
V10 of the CEPH database (ftp://ftp.cephb.fr/ceph_genotype_db/ceph_db/Ver_10/mkr/) [13] 
using error checked markers. Genetic map information was downloaded from the Marshfield 
database (http://research.marshfieldclinic.org/genetics) [14]. Error checking for Mendelian 
incompatibility, misspecified relationships and unlikely recombinations was performed, as 
previously described [14]. A combined total of 8269 single nucleotide polymorphisms (SNPs) 
and microsatellite markers were used for linkage analysis. 
Linkage Analysis. Drug-dose combinations were considered the phenotypes of interest for 
linkage analysis (n = 54). For each phenotype, non-parametric linkage analysis was performed 
using MERLIN which constructs a likelihood ratio test for linkage based on inheritance vectors.  
For quantitative traits, scores used to calculate the likelihood ratio test are defined as follows: 
S(ν) = Σ founder alleles Sallele(ν)2, 
Sallele(ν) = Σ all carriers of allele (yi - μ), 
where S(ν) is the score for each inheritance vector, Sallele(ν) is the score for each founder allele, 
yi is the phenotype for each individual, μ is the mean phenotype for the population, and ν is the 
list of individuals who carry a specific founder allele such that the score for each inheritance 
vector is the summation of the squared score for each founder allele, and the score for each found 
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 allele is the sum of square deviation from all individuals that carry that allele. For each phenotype 
of interest, QTL maps were generated by displaying the logarithm of odds scores from the 
likelihood ratio tests across each chromosome. 
Peak Identification, Prioritization, and Replication. Guidelines for interpreting LOD scores 
have suggested viewing LOD scores of 2.2 as suggestive and 3.6 as significant [15]. However, 
since such a categorization is inexact, the data in this study was used to dictate at which threshold 
results would no longer be considered due to chance and most likely occur as a result of linkage. 
To estimate the probability of obtaining false-positive evidence of linkage for each drug-dose 
combination under the null hypothesis of no linkage to observed phenotypes, gene-dropping 
permuations were conducted using Merlin [12]. Marker data were simulated under the null 
hypothesis of no linkage or association to the observed phenotypes while retaining the same 
pedigree structures, maps, marker allele frequencies, and missing data patterns. Ten thousand 
replicates were simulated for each of the 54 phenotypes, resulting in a total of 54,000 simulated 
datasets. Nonparametric linkage analysis was conducted as described above for each replicate set. 
Based on these simulations, permutation distributions were generated across the chromosomes for 
each phenotype and then used to determine genome-wide LOD score cut-offs for statistical 
significance corresponding to p-values less than or equal to .05 for each phenotype. Additionally, 
cutoffs for suggestive linkage were determined for each drug-dose combination for an alpha of 
0.05 for each chromosome. The start and end of a peak was defined as the region with LOD 
scores that were above the suggestive threshold or LOD minus one, whichever was greater. QTLs 
observed for a drug-dose phenotype were considered significant if the highest LOD score in that 
region surpassed the LOD score threshold for significance for that drug-dose phenotype. QTLs 
observed for a drug-dose phenotype were considered suggestive if the highest LOD score in that 
region surpassed the suggestive LOD score threshold for that drug-dose phenotype on that 
chromosome. For all statistically significant QTLs, the total number of replications was 
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 calculated. Across drug-dose phenotypes, the number of replications was calculated as the total 
number of drug-dose phenotypes that demonstrate evidence of linkage at any point of the peak 
regions at either the significant or suggestive level. Table A2-1 contains a list of QTLs identified 
as significant for camptothecin drug-dose phenotypes. 
RESULTS 
Variation in Camptothecin-Induced Cytotoxicity. Sensitivity to the camptothecins was 
assessed in 125 lymphoblastoid cell lines derived from 14 CEPH pedigrees. Cells were exposed 
to increasing concentrations (9 doses) of each camptothecin for 96 h and cell viability relative to 
vehicle control was determined. Variation in cytotoxic response to each camptothecin within and 
between the CEPH pedigrees was observed (Figure 2-2). For example, 9AC, which had the 
widest range of IC50s, had a population mean IC50 of 93 nM and the IC50 ranged from 7 nM to 
4 uM. Both the order of potency and IC50s in the CEPH cell lines are consistent with literature 
values in cancer cell lines such as the NCI60 cell line panel (NCI Developmental Therapeutics 
Human Tumor Cell Line Screening data, 
.jsp [16]. 
This data was also used to identify individuals and/or families which were hypersensitive or 
resistant to the camptothecins. Further genetic and genomic studies with these individuals might 
lend insight into mechanisms of activity and resistance. A hierarchical clustering analysis of z-
score transformed logIC50 values (where IC50 is the concentration required to inhibit viability by 
50%) was performed keeping family structure intact (Figure 2-3). The clusters matched the 
overall potency (SN38>CPT>9NC>TPT>9AC>CPT11) in the cell lines studied. CPT11 is most 
divergent from the other camptothecins studied. Since CPT11 is the prodrug of SN38 and 
requires submicromolar concentrations for effective cell kill, IC50s across the panel of CEPH cell 
lines are considerably higher for CPT11 than other camptothecins investigated. Of note, there are 
http://dtp.nci.nih.gov/dtpstandard/InvivoSummary/index
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 individuals who are sensitive to some but not all camptothecins and whole families which are 
resistant or sensitive to all camptothecins. For example, pedigree 1408 appears resistant to all 
camptothecins with the exception of 9AC. All but two members of pedigree 1362 are sensitive to 
all camptothecins; two offspring (11982 and 11983) are resistant to all camptothecins.  
Heritability Analysis. Heritability was estimated to quantify the impact of genetic factors on the 
cytotoxic response to each of the camptothecins at each dose. There is a known correlation 
between cellular sensitivity to many chemotherapeutic agents and growth rate [10, 17]. As a 
control, heritability was calculated for growth rate in the presence of vehicle. The heritability 
estimate for growth rate was low (1.60%) which suggests that environmental factors play a much 
larger role than genetics in growth rate [17]. For each drug, the growth-rate adjusted heritability 
estimates at each dose are featured in Figure 2-2. Heritability estimates at the asymptotes of the 
sigmoidal dose-response curve are low as there is little to no variability in cytotoxic response at 
these points. For all camptothecins studied heritability estimates averaged 23.1 ± 2.6 % for doses 
within the linear phase of the sigmoid curve. Since heritability estimates were approximately 20% 
for all camptothecins this reinforces the idea that inherited genetic variation is an important 
determinant of the cytotoxic response to camptothecins. The heritability associated with the 
cytotoxicity of these compounds is analogous to heritabilities reported for other common human 
phenotypes such as systolic and diastolic blood pressures [18], and for the cytotoxic response to 
daunorubicin in CEPH cell lines [19].  
Genome-wide Linkage Analysis. Nonparametric linkage analysis was performed using mean 
cell viability at each dose for each drug, which is referred to as the drug-dose phenotype. For each 
drug-dose phenotype statistically significant LOD score thresholds corresponding to a genome-
wide p-values less than or equal to 0.05 were determined using gene-dropping permutations under 
the null hypothesis that no linkage exists. Regions of the genome referred to as quantitative trait 
loci (QTLs) were considered significant if the highest LOD score in the region was greater than 
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 or equal to the predetermined LOD score cut-offs for each drug-dose combination on a given 
chromosome. The mean LOD score cut-off across all phenotypes and chromosomes indicating 
significant linkage was 1.37 (range: 0.83-1.72). Additionally, cutoffs for suggestive linkage were 
determined for each drug-dose combination for an alpha of 0.05 for each chromosome. A region 
identified as significant to one drug-dose phenotype was considered replicated in another drug-
dose phenotype if the maximum LOD score in that region surpassed the suggestive LOD score 
threshold. The mean LOD score cut-off across all phenotypes and chromosomes indicating 
suggestive linkage was 0.59 (range: 0.41-0.72).  
To establish a pattern of QTLs significant to a class of compounds, regions of the genome which 
were overrepresented across the camptothecins were examined. Figure 2-4 illustrates significant 
and suggestive QTLs identified in one camptothecin which were replicated in other 
camptothecins. The results of a sign test (p<0.5) indicated there was a significant 
overrepresentation of overlapping QTLs compared to the null hypothesis that QTLs were 
randomly distributed across the genome amongst all drugs. Ten linkage peaks were identified as 
significant in a given drug-dose combination and replicated in all of the camptothecins at a 
number of concentrations (Table 2-1). This implies that the same linkage regions influence the 
cytotoxic response to all camptothecins over a broad range of concentrations. The highest LOD 
score with genomic significance (2.13) was observed with the 8.0 nM SN38 phenotype and was 
located on chromosome 20 between 42 and 101 cM (20p12.1-20q13.32), and presumably 
associated with Top1 (20q12-q13.1) the primary target of the camptothecins. All camptothecin 
analogues studied (at multiple dosages for each drug) had a peak at chromosome 20 centered 
around 49 cM (Table 2-1, Figure 2-5). Unlike the other significant linkage peaks, the QTL on 
chromosome 6 from 0 to 29 cM is only associated with high concentrations of the camptothecins, 
resulting in greater than 80% growth inhibition. 
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 Moreover, notable distinctions between significant QTLs associated with camptothecin analogues 
have been observed and are summarized in Figure 2-4. For example, TPT is the only 
camptothecin with a linkage peak extending from 0 to 19.6 cM on chromosome 13 (LOD = 
1.365). Interestingly, 9NC is considered to be the prodrug of 9AC and there is one linkage peak 
which was identified exclusively in these drugs on chromosome 5 [20]. Chromosome 1 has two 
QTLs centered at 70 and 129 cM respectively which are shared exclusively by camptothecins 
possessing a nitrogen bearing substituent on carbon 9: 9AC, 9NC, and TPT. No peaks were 
identified which were unique solely to SN38 and its prodrug CPT11. However, a QTL on 
chromosome 4 is only present in CPT11 and 9AC. Regions suggested to influence the cytotoxic 
response to CPT11 were not always replicated in SN38 or vice versa. This was also observed for 
9AC and 9NC. This is unsurprising since for example, the prodrug CPT11 must undergo 
activation by carboxylesterases (CESs) to the active SN38 and SN38 is not subsequently 
metabolized by CES. Only suggestive QTLs for CPT11 where located on chromosome 16 from 
1-69 cM; CES1 and CES2 are centered around 73 cM on chromosome 16. Finally, to compare the 
overall QTL patterns a similarity matrix was constructed using a binary assessment of peaks 
present at either the significant or suggestive level for each camptothecin. R squared correlations 
are bound by 0 and 1 and the greater the value the more related the patterns are to each other 
(Table 2). The majority of the correlations are above 0.5, indicating a strong association between 
overall QTL patterns and similar mechanisms of action. The highest correlations (highest degree 
of similarity) are between the 9AC and 9NC, CPT11 and CPT, and CPT11 and SN38. While the 
biological profile of CPT11 appears different from the remaining camptothecins, the genomic 
profile of TPT appears most distinct. 
Independent Validation of Shared QTLs. We next asked whether QTLs identified as shared 
among all camptothecins could be replicated independently. In a separate phenotyping 
experiment, the same 14 CEPH pedigrees were exposed to a dosing spectrum of a second set of 
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 camptothecins: mCPT, hCPT, and ClCPT. Variation in sensitivity to this set of camptothecins 
was then used to calculate heritability estimates at each drug-dose phenotype. Heritability 
estimates were highest in the linear phase of the sigmoid curve. Growth rate adjusted heritability 
estimates for doses within the sigmoid curve for mCPT, hCPT, and ClCPT were comparable to 
estimates for the first set of camptothecin analogues. The highest heritability estimates for mCPT, 
hCPT, and ClCPT were 20.2%, 18.7%, and 20.7% respectively. Linkage analysis, peak 
prioritization, and peak replication assessment were repeated with this second set of 
camptothecins. Nine of the ten QTLs identified as characteristic of camptothecin activity were 
subsequently validated in multiple doses of mCPT, hCPT, and ClCPT (Figure 2-4). While no 
concentrations of mCPT or hCPT possessed the shared QTL on chromosome 6 from 0-29 cM, 
seven of the nine doses of ClCPT possessed this shared QTL. Variation in response across the 
broad dosing spectrum for mCPT, hCPT, and ClCPT was not linked to the QTL on chromosome 
12 from 0-6 cM.  
Comparison to Topoisomerase 2 Inhibitors. To illustrate class specific patterns could be 
established, the same cell lines were phenotyped for sensitivity to the Topoisomerase 2 (Top2) 
inhibitors, etoposide and teniposide. Genetics plays a greater role in cytotoxic response to the 
Top2 inhibitors compared to Top1 inhibitors. The maximum heritability estimates for a Top1 
inhibitor (TPT) was 25.9% compared to 42.4 and 32.9% for etoposide and teniposide 
respectively. When comparing cytotoxic response to the camptothecins across the entire 
population of CEPH cell lines IC50s were used to visualize patterns of sensitivity and resistance. 
We chose another mode of comparison between the Top1 and Top2 inhibitors since IC50s could 
not be obtained for more than 80% of the cell lines treated with teniposide. Hierarchal clustering 
using the dose which yields a population mean viability closest to 50%, ( )50GI , for each drug 
reveals that overall patterns of sensitivity and resistance between the Top1 and Top2 inhibitors 
are indeed distinct and form two clusters corresponding to differences in mechanism (Figure 2-6). 
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 The same is true for the dose which yields a population mean viability of 40 and 60% (data not 
shown). Nonparametric linkage analysis was performed using cell viability at each drug-dose 
combination of the Top2 inhibitors. Four QTLs present on chromosomes 6 (32-113 cM), 12 (9-30 
cM), 13 (0-25 cM), and 18 (58-76 cM) were identified as significant and replicated (considered 
replicated if LOD > suggestive threshold) in both Top2 inhibitors at multiple dosages. This 
pattern of QTLs for the Top2 inhibitors was quite distinct from those established for the 
camptothecins (Table 2-1). 
DISCUSSION 
Early models for chemogenomic studies have used cancer cell lines [4, 5], mutant yeast strains [2, 
3], and rodents [21, 22]. The biggest limitation with these systems is that data does not always 
correlate to humans. For example, some mammalian targets are absent in yeast and vice versa. 
Targets which produce a desired phenotype in rodents may not exhibit the same phenotype in 
man [23]. In addition, cancer cell lines can differ morphologically and genetically from primary 
tissues [24]. 
This is one of the first genomic studies to use a healthy human cell line model to identify class 
specific pharmacological and genomic profiles. While cancer cell line panels such as the NCI60 
are prepared from 4-5 cell lines of a given tissue origin, this study uses a large collection of cell 
lines of the same type. Moreover, just as genetic heterogeneity across the cancer cell lines has 
been used to stratify compounds by mechanistic class, natural genetic variation in the CEPH cell 
lines can be used to identify a class-specific profile for the camptothecins [4, 25]. In fact, 
heritability analysis demonstrates that 23.1 ± 2.6 % of human variation in sensitivity to the 
camptothecins is due to a genetic component. Not only were heritability estimates replicated 
across multiple doses, but they were replicated across multiple camptothecin analogues and 
experiments. 
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 Using this system to investigate compounds within a structural class and sharing the same 
mechanism one would expect a pattern of QTLs related to the cytotoxic activity of all compounds 
within that class. Indeed, ten QTLs across eight chromosomes were replicated in the first six 
camptothecin analogues studied suggesting a pattern of QTLs associated with a general and 
shared mechanism of action. We consider the fact that these QTLs were replicated across 
multiple analogues and doses within the first screen a form of internal validation. In a separate 
phenotyping experiment using three additional camptothecins, nine of those ten QTLs were again 
independently replicated. The remaining QTL on chromosome 12 shared by all camptothecins in 
the initial screen was only present in ClCPT, but present in seven of the nine doses. Replication 
of QTLs both across multiple drug-dose combinations within the first screen and multiple drug-
dose combinations within a second screen of different camptothecins is very exciting. Finally, 
both the biological and genomic profiles generated in CEPH for the camptothecins and the 
Topoisomerase 2 inhibitors, etoposide and teniposide were very distinct. Hierarchal clustering on 
biological data generated two clusters in agreement with the two distinct mechanisms of action. 
Moreover, the overall pattern of shared QTLs differed significantly between the two groups; no 
QTLs were present in the same regions for the two classes. 
Figure 2-4 highlights regions which might contain genes that contribute to the cytotoxic activity 
of all of the camptothecins. There are more than 4000 candidate genes for follow-up under the 
nine QTLs shared by all nine camptothecin analogues alone. Indentifying which of these genes 
are critical to camptothecin-induced cytotoxicity can be a challenging and time-consuming 
process. To maximize success, a tiered approach is recommended when choosing QTLs for 
further investigation. QTLs shared by all nine camptothecins are considered the most promising 
(Table 2-1). QTLs shared by the first set of six camptothecins should be investigated next, 
followed by the QTLs identified as significant and shared by all three camptothecins in the 
validation set. Those significant QTLs which have been identified as unique to 1 or more drugs 
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 but are not replicated even at the suggestive level in all camptothecins should be considered next. 
Examples of this class include the QTL on chromosome 1 at 145-168 cM which is present at the 
significance level in multiple concentrations of 9AC, and at the suggestive level in 1-2 doses of 
9NC and TPT and the linkage peak on chromosome 13 (0-19 cM) that is observed solely with the 
10 nM TPT phenotype. Finally, since the average LOD score threshold for a suggestive QTL is 
0.59, suggestive QTLs present in all 9 camptothecins at multiple doses should be pursued last. 
Using these prioritization criteria, the QTL on chromosome 20 which is common to all 
camptothecins is considered the most important for follow-up investigations. There are 453 
protein coding genes within this region of the genome. The functional annotation clustering tool 
from the web-accessible program Database for Annotation, Visualization, and Integrated 
Discovery (DAVID) was applied to identify over-represented gene ontology terms (GO) and 
KEGG pathways within this gene list (Table 2-3) [26, 27]. Out of the over-represented biological 
processes in this gene list, five of the top eight biological processes may be related to 
camptothecin activity: response to stimulus, bioregulation, protein binding, cell differentiation, 
and regulation of cell growth. Table A2-2 lists the genes related to these GO terms that are 
present under the QTL on chromosome 20. Association studies could be used to fine map QTLs 
and pinpoint genes associated with drug response; however, limited statistical power prevents us 
from doing so here. The presence of Top1, the sole molecular target of all camptothecins, in this 
region is encouraging. Top1 expression levels have previously been correlated with cellular 
sensitivity to the camptothecins; low levels of Top1 confer resistance to cancer cell lines such as 
lymphomas [9]. Smirnov et al. performed microarray experiments to measure human gene 
expression levels in CEPH [28] (data accessible at NCBI GEO database [29], accession 
GSE12626). Baseline measures of Top1 gene expression varied as much as 2 fold in this dataset. 
(Limited overlap between cell lines used in the studies prevented direction association analysis in 
the current study.) Admittedly, since linkage analysis produced a broad QTL spanning hundreds 
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 of genes, it cannot be assumed that a single gene under this QTL is influencing the activity of 
these compounds. Bcl-xl, is another promising gene within this region. Down-regulation of Bcl-
xl, which inhibits apoptosis, has been shown to enhance cytotoxic response to the camptothecins 
[30, 31].  
Unlike the other QTLs which are shared between the camptothecins, the peak on chr12 (0-6 cM) 
is relatively small and consists of only 24 protein coding genes. The most intriguing genes in this 
region are FBXL14 and RAD52. FBXL14 is a member of the F-box protein family. Proteasomal 
degradation of Top1 has been implicated as a major pathway in the repair of Top1 mediated DNA 
damage. Resistance to camptothecin can occur following overexpression of a component of the 
SCF complex (SCF components: Skp, Cullin, F-box) leading to increased ubiquitination and 
proteasomal degradation of Top I [32, 33]. RAD52 is involved in DNA double-strand break 
repair and homologous recombination and hypersensitizes cells to camptothecins [34]. 
Observing significant or suggestive LOD scores for a given drug across a number of doses has 
been previously reported as replication and suggestive of a shared genetic component 
contributing to the cytotoxic effect at all concentrations [6, 19]. The same regions of interest were 
not identified as significant or suggestive for all drug-dose combinations of the camptothecins. In 
fact, some QTLs were apparent only in the higher concentrations of the camptothecins. One 
plausible explanation for changes in patterns of observed QTLs with differences in dose might be 
different mechanisms of action predominating at different concentrations. The cytotoxic effect of 
camptothecins in cancer cells and yeast are typically related to replication-mediated DNA lesions. 
However, protection by aphidicolin, a DNA polymerases inhibitor associated with replication, is 
only apparent at the lowest concentrations of camptothecin (submicromolar) in cancer cell lines 
[35]. When DNA replication is blocked, cell death at higher concentrations of camptothecin is 
suggested to occur by transcription-mediated DNA lesions. It has been reported that the 
anticancer activity of the camptothecins can switch from replication-dependent to transcription-
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 dependent solely at higher concentrations in normal lymphoblasts and other highly proliferative 
cell lines [9]. Also different DNA repair, cell cycle checkpoint, and cell-death signaling pathways 
have been implicated following DNA damage at different doses (Figure 2-7). These dose 
dependent effects have been associated with differences in gene expression profiles [36] and cell 
cycle responses [37]. For example, low doses of camptothecin result in reversible G2 delay while 
high doses cause S-phase delay and G2 arrest [37]. Without a doubt, there a number of complex 
mechanisms associated with the cytotoxic activity of the camptothecins that can occur 
simultaneously or selectively given certain intracellular conditions [38]. Work is ongoing to 
identify the conditions that dictate which pathways are preferred and why.  
Future studies with this dataset should begin to ascertain which genes under shared QTLs are 
influencing the cytotoxic activity of the camptothecins. Recently, RNA interference (RNAi) 
screens in model organisms and human cells have successfully identified genes that modulate cell 
growth, apoptosis, chemoresistance, and chemosensitivity [39-43]. Large scale RNAi in the form 
of high throughput screens using small interfering RNAs (siRNA) can be used to systematically 
screen all genes under a QTL of interest. Known and novel genes whose loss of function confers 
decreased or increased sensitivity to the camptothecins can be identified. 
We have demonstrated that specific patterns of biological response and QTLs could be 
established for a class of structurally related compounds sharing a mechanism of action. Most 
importantly, we have identified a set of QTLs associated with the sensitivity to the camptothecins, 
validated those QTLs internally, and with a second replication set. Future studies should compare 
the genomic profiles of the camptothecins with other structurally unrelated Top1 inhibitors and 
ascertain which if any shared QTLs are the result of the general mechanism of Top1 inhibition. 
Moreover, as the ultimate goal of this research is correlate biological response to genes involved 
in drug action, work is needed to pinpoint the genes under these QTLs which are influencing 
response. Thousands of genes are present in the six QTLs shared by all of the camptothecins. 
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 RNAi mediated inhibition of gene expression can be used to prove the contribution of a gene to 
these QTLs. Taken together, these results lay the groundwork for using the ex vivo familial 
genetic strategy in CEPH cell lines for drug discovery efforts. 
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 Figure 2-1. Camptothecin analogues. 
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Figure 2-3. Hierarchal clustering of 
CEPH cell lines by camptothecin 
logIC50s. LogIC50s were z-score 
transformed. Clustering based on 
drugs holding family structure 
intact (black and white bar indicates 
each of 14 families). Yellow 
indicates positive Z-scores 
(resistance), blue indicates negative 
Z-scores (sensitive), black indicates 
Z-score = 0 (median resistance 
value). The brighter the color the 
greater the value from 0, with max 
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Figure 2-4. Genome wide pattern of QTLs for camptothecin analogues. Each chromosome was 
partitioned into 25cM regions. Each drug-dose combination that resulted in a significant QTL (LOD 
>significance threshold) is indicated in blue. Intensity of the shading indicates the number of doses 
replicating that QTL at either the suggestive or significant level. Regions which also had a suggestive 
QTL (LOD > suggestive threshold) are indicated in green with color intensity referring to the number 
of doses replicating this peak. 
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Figure 2-5. QTL shared across all camptothecins on chromosome 20. The QTL on chromosome 20 
contains the gene for Top1, the sole molecular target of all camptothecins. Each drug is represented 
by a different color. Multiple doses for each drug were identified as significant and suggestive at this 
location. The drug-dose combinations with the highest LOD score are represented here. 
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Figure 2-6. Hierarchical 
clustering of Top1 and Top2 
inhibitors based on cell 
viability at the GI50, the dose 
which yields a population 
mean closest to 50%. 
Clustering was done on both 
drugs and cell lines. 
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Figure 2-7. Molecular pathways involved in cytotoxic response to camptothecins. Green lines refer to 
activation, red lines to inhibition and black lines to conversion. Molecular processes are indicated in 
yellow boxes. Proteins implicated in cytotoxic response to the camptothecins are in blue boxes. 
Camptothecins are actively pumped out of cells by the ATP-binding cassette transporters Pgp and 
MRP. Several camptothecin analogues are actively metabolized by CYP3A. Only irinotecan is 
metabolized to the active SN38 by UGT1A1. Reversible Top1 cleavage complexes are induced by 
camptothecins and DNA damage. These cleavage complexes are converted to irreversible TOP1 
covalent complexes by replication and transcription. DNA damage resulting from irreversible TOP1 
covalent complexes can be repaired, induce cell-cycle arrest, or apoptosis. DNA repair involves five 
pathways: base excision repair (BER), homologous recombination (HR), non-homologous end 
joining (NHEJ), non-homologus recombination (NHR), and nucleotide excision repair (NER). Cell-
cycle arrest involves checkpoint kinases such as ataxia telangiectasia mutated (ATM), ataxia 
telangiectasia and RAD3 (ATR), and DNA-dependent protein kinase (DNA-PK). Regulators of the 
checkpoint kinase pathway include histone H2AX, RPA2, MRE11–RAD50–NBS1 (MRN complex) 
and BRCA1. The Bloom syndrome helicases (BLM)–TOP3α pathway suppresses homologous 
recombination when activated by the checkpoint kinase pathway. Cell-cycle arrest facilitates DNA 
repair. p53 activates apoptosis both directly and by transactivating pro-apoptotic genes. TOP1 
inhibitors tend to suppress apoptosis by activating nuclear factor κB (NFκB) which increases the 
expression of anti-apoptotic genes such as XIAP (chromosome X-linked inhibitor of apoptosis) and 
BCL-X. Blocking of the PI3K/Akt pathway enhances apoptosis induced by camptothecins. 
Camptothecins also increase de novo synthesis of FAS/FAS ligand and ceramide which leads to 
apoptosis. Modified from[9] 
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Table 2-1. QTLs shared by camptothecins. 
Chromosome Peak Start (cM) Peak End (cM) LOD* 
1† 229 252 1.855 
3† 36 82 1.682 
3† 137 180 1.638 
5† 104 194 1.709 
6† 0 29 1.528 
6† 42 65 1.652 
11† 115 131 1.352 
12 0 6 1.705 
16† 0 75 1.345 
20† 42 101 2.134 
*Maximum LOD score observed in region.  
†QTLs which were also present in the second set of camptothecins 
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Table 2-2. Similarity matrix of overall QTL patterns for each camptothecin.  
  9AC 9NC CPT CPT11 SN38 TPT 
9AC 1.000 0.724 0.517 0.483 0.552 0.483 
9NC   1.000 0.517 0.483 0.621 0.483 
CPT     1.000 0.759 0.690 0.448 
CPT11       1.000 0.655 0.517 
SN38         1.000 0.586 
TPT           1.000 
Constructed from binary evaluation of presence of significant and suggestive QTLs. 
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Table 2-3. Top overrepresented GO terms for the QTL on chromosome 20 (42-101 cM). 
Over-represented biological processes ES 
Enzyme inhibitor activity 8.24 
Response to stimulus 
Response to chemical stimulus 
Response to drug 
Response to DNA damage 
3.61 
Embryonic development 2.33 
Biological regulation 
Nucleic acid binding 
DNA binding 
Transcription 
Gene expression 
2.11 
Protein binding 1.93 
Reproduction 1.53 
Cell differentiation 
Apoptosis 
Programmed cell death 
Cell cycle 
1.24 
Regulation of cell growth 0.74 
ES: Enrichment Score. Underlined terms are parent terms of related GO terms beneath. 
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Biological and Genomic Profiling in CEPH Distinguishes  
Between Structurally Distinct Topoisomerase 1 Inhibitors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
We have attempted to use an ex vivo familial genetics strategy to study mechanisms of 
Topoisomerase 1 (Top1) inhibition. Investigations have steadily been chipping away at the 
pathways involved in cellular response following Top1 inhibition for more than 20 years. Our 
system-wide approach, which phenotypes a collection of genotyped human cell lines for 
sensitivity to drugs, interrogates all possible targets and cellular pathways simultaneously. 
Previously, we characterized the in vitro sensitivity of several families of CEPH cell lines to nine 
camptothecin analogues, including the FDA approved drugs topotecan and irinotecan. Linkage 
analysis revealed a pattern of nine quantitative trait loci (QTLs), regions of DNA which were 
associated with the observed variation in cytotoxic response, and these loci were shared by all of 
the camptothecins. In this study, we repeated phenotyping using seven of the original 
camptothecin analogues, to determine whether these QTLs could be independently validated. 
Seven of the nine QTLs on chromosomes 1, 5, 6, 11, 16, and 20 were replicated. Finally, to 
identify which, if any, QTLs are related to the general mechanism of Top1 inhibition or should be 
considered camptothecin-specific, we characterized the in vitro sensitivity of the CEPH cell lines 
to the indenisoquinolones, a structurally distinct class of Top 1 inhibitors. Four QTLs on 
chromosomes 1, 5, 11, and 16 were shared by both the camptothecins and the 
indenoisoquinolines and are considered associated with the general mechanism of Top1 
inhibition. The remaining three QTLs (chromosomes 6 and 20) are considered specific to 
camptothecin-induced cytotoxicity. Finally, eight QTLs were identified which were unique to the 
indenoisoquinolines.  
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INTRODUCTION 
Much of the cost of drug development can be attributed to a poor understanding of a drug’s 
mechanism of action. The practice of target-based drug discovery has produced many promising 
drug candidates. Unfortunately, most ultimately fail in the clinic due to lapses in efficacy and 
unanticipated side-effects. As a result, screening based on phenotypic changes induced by 
candidate drugs in cells or model organisms, is experiencing a resurgence. The greatest limitation 
of phenotypic screening is determining the mechanism for biologically active compounds. 
Genomic tools that interrogate all targets and cellular pathways simultaneously are being included 
with the phenotypic screen to provide insight into a drug’s mechanism.  
Our own ex vivo familial genetics strategy is one of the latest examples of these phenotypic 
screens. In this model, genes influencing drug action are studied using the Centre d’Etude 
Polymorphisme Humain (CEPH) cell lines, a collection of extensively genotyped, immortalized 
human cell lines from multigenerational families. These lymphoblastoid cell lines (LCLs) are first 
phenotyped for sensitivity to a drug. Linkage analysis is then used to identify regions of the 
genome referred to as quantitative trait loci (QTLs) where genetic variation correlates with the 
observed variation in response. 
Most recently, we have used this model to establish a specific pattern of QTLs related to a shared 
mechanism for a class of structurally related compounds, the camptothecins (Chapter 2). Nine 
QTLs were shared by six camptothecin analogues and then independently validated in a second 
set of three additional camptothecins (Chapter 2). The camptothecins are excellent model for 
study. More than 25 years after the discovery that the primary molecular target for the 
camptothecins is Topoisomerase 1 (Top1), investigations are still underway to define the 
pathways involved in cellular response [1-4]. Two of these analogues are FDA approved for use 
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in cancer chemotherapy. A clearer understanding of mechanism of action can be used to find 
genetic markers of drug susceptibility and resistance in patient populations. 
The objective of this study was to determine which QTLs are specific to camptothecin-induced 
cytotoxicity and which are related to the general mechanism of Top1 inhibition. Drug-to-drug 
comparative studies between structurally distinct compounds sharing a molecular target have 
been used to identify genes and pathways which are involved in a shared general mechanism and 
those which are class-specific and suggest subtle differences in mechanism [5]. We chose to 
phenotype the CEPH LCLs for sensitivity to the indenoisoquinolines, a new class of non-
camptothecin Top1 inhibitors, and compare the resulting genomic profile with the camptothecins 
(Figure 3-1). While sharing the same molecular target, there are notable pharmacological 
distinctions between the two classes [6]. The indenoisoquinolines are chemically stable. They trap 
Top1cc at different genomic sites which suggests potentially different gene targeting [7-9]. 
Cleavage complexes stabilized by indenoisoquinolines are more persistent than those induced by 
the camptothecins [7, 10]. Additionally, they are not substrates for ABC transporters which may 
be useful in the treatment of camptothecin resistant malignancies [11]. By comparing the 
biological and genomic profiles of the indenoisoquinolines with the camptothecins we can 
demonstrate that this model can establish a pattern of QTLs (a) related to the general mechanism 
of Top1 inhibition, (b) specific to camptothecin-induced cytotoxicity, and (c) associated with 
indenoisoquinoline activity.  
MATERIALS AND METHODS 
Chemicals. The indenoisoquinolines, NS 706744 (Ind1), NSC 725776 (Ind2) and NSC 724998 
(Ind3), were generously supplied by Drs. Stephen Frye and Jian Jin of the Center for Integrative 
Chemical Biology and Drug Discovery (University of North Carolina, Chapel Hill, NC). All 
drugs were dissolved in DMSO. Final concentrations for working solutions were 1% DMSO. For 
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validation purposes, cellular phenotyping using the following camptothecins was repeated in this 
study (referred to as Camptothecin set 1+2):  
Camptothecin set 1: 9-aminocamptothecin (9AC), 9-nitrocamptothecin (9NC), topotecan 
(TPT), camptothecin (CPT), and 7-ethyl-10-hyrdroxycamptothecin (SN38) 
Camptothecin set 2: 10-methoxycamptothecin (mCPT) and 10-hyrdoxycamptothecin 
(hCPT)  
The camptothecins were diluted to the same concentrations outlined in Chapter 2. 
Cell lines. CEPH cell lines (Corriell Repositories) from the following pedigrees were used for 
this study: 35, 45, 1334, 1340, 1341, 1345, 1350, 1362, 1408, 1420, 1447, 1451, 1454, 1459, 
1463. The cells were cultured in RPMI 1640 supplemented with 10% fetal bovine serum at 37°C 
in humidified air containing 5% CO2.  
Measurements of Cell Growth Inhibition and Data Analysis. Experimental plates were 
prepared containing a panel of both the indenoisoquinolines and the camptothecins. Drugs were 
serially diluted and plated in 384 well plates and frozen at -20 C prior to experimentation. Each 
plate contained four replicates of each drug-dose combination. On the day of experimentation, 
cells were plated at a density of 4000 cells/well in RMPI 1640 with 10% FBS. Alamar blue was 
added at 72 h and fluorescence read after 24 h alamar blue exposure (96 h exposure to drug, Ex 
535 nm, Em 595 nm). Raw fluorescence values for each set of replicates were considered outliers 
if there was a ten-fold change in signal (in either directions) for a single replicate. Cell viability 
relative to untreated controls was determined using the manufacturer’s protocol. Final percent 
survival at each drug-dose combination was averaged from 4 replicates of 2 independently plated 
experiments (n =8 replicates). Pearson correlation coefficients were used to determine the degree 
of similarity between biological activity profiles of the Top1 inhibitors. 
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Genomic Profiling. Phenotypes were defined as cytotoxic response at each drug-dose 
combination. Heritability estimates, which quantify the genetic contribution to observed variation 
in cytotoxic response at each drug-dose combination, were calculated using MERLIN as 
described in Chapter 2 [12]. The degree of heritability associated with growth rate was calculated 
and all heritability estimates for all drug-dose phenotypes were adjusted for growth rate. The 
genotype data for each cell line were downloaded from V10 of the CEPH database using error 
checked markers. The genetic map information was downloaded from the Marshfield database. 
Error checking and nonparametric linkage analysis was performed as previously described 
(Chapter 2). Quantitative trait loci (QTLs), regions of the genome linked to each phenotype, were 
identified using the same criteria as previously reported (Chapter 2). Gene-dropping permutation 
testing was used to identify LOD score thresholds for significant and suggestive QTLs for each 
drug-dose combination on each chromosome. QTLs observed for a drug-dose phenotype were 
considered significant if the highest LOD score in that region surpassed the significance LOD 
score threshold for that drug-dose phenotype. The start and end of a significant QTL region was 
defined as regions with LOD scores that were above either the suggestive LOD score threshold or 
peak LOD score minus one, whichever was greater. QTLs observed for a drug-dose phenotype 
were considered suggestive if the highest LOD score in that region surpassed the suggestive LOD 
score threshold for that drug-dose phenotype on that chromosome. QTLs which were identified as 
significant in one drug-dose phenotype were considered replicated in the remaining drug-dose 
phenotypes if they surpassed the LOD score suggestive threshold. A complete list of QTLs which 
were significant in the indenoisoquinolines can be found in Tables A3-1. 
The goal of this study was to establish a pattern of QTLs (a) related to the general mechanism of 
Top1 inhibition, (b) specific to camptothecin-induced cytotoxicity, and (c) associated with 
indenoisoquinoline activity. To achieve this, the following analysis plan was undertaken. In 
Chapter 2, ten QTLs were indentified as shared among all of the camptothecins in the first panel 
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(Camptothecins set 1: 9AC, 9NC, TPT, CPT, CPT11, SN38). These QTLs were then queried for 
replication in a second set of 3 additional camptothecins (Camptothecins set 2: mCPT, hCPT, Cl-
CPT). QTLs which weren’t replicated in the Camptothecins 2 data set were excluded from further 
analysis. In this study, drugs from both Camptothecin set 1 and Camptothecin set 2 were 
reevaluated for sensitivity in the CEPH cell lines; the aim was to determine if any of the 
remaining QTLs could be replicated independently. QTLs which weren’t replicated across both 
data sets (Camptothecin set 1 + Camptothecin set 2) were excluded from further analysis in this 
study. To identify QTLs associated with the general mechanism of Top1 inhibition, the remaining 
QTLs were filtered for replication in the indenoisoquinolines, a structurally unique class of Top1 
inhibitors. Finally, QTLs which had been removed from this last stage of replication were 
considered specific to camptothecin-induced cytotoxicity. Figure 3-2 provides a detailed 
summary of this analysis plan. Rules for replication were as follows: 
Within a data set: A QTL identified as significant for one drug-dose phenotype must be replicated 
at the significant or suggestive level in all drugs within that data set 
Between data sets: A QTL identified as significant and replicated in all drugs of one data 
set must be replicated at the significant or suggestive level in all drugs within a second 
data set. When there are drugs which are shared between data sets, a QTL which was 
identified as significant for a given drug-dose phenotype does not need to be detected at 
the significance level for that same drug-dose phenotype within the second data set. To 
be considered replicated in the second data set, the QTL must be present at the significant 
or suggestive level in all drugs belonging to that data set. 
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RESULTS 
Variation in Biological Response Between Top1 Inhibitors. Some have argued that molecular 
& pharmacological distinctions between the camptothecins and the indenoisoquinolines could 
result in clinical differences [6]. In this study, we used EBV-transformed LCLs derived from 15 
CEPH pedigrees to evaluate differences in cytotoxic activity between the indenoisoquinolines and 
the camptothecins. Sensitivity to the indenoisoquinolines, Ind1 (NSC70644), Ind2 (NCS725776), 
and Ind3 (NSC724998), were evaluated in CEPH LCLs (n = 142) using the alamar blue assay. 
Ind1, Ind2, and Ind3 all showed dose-dependent cytotoxicity (Figure 3-3). We also observed 
considerable interindividual variation in sensitivity to the indenoisoquinolines (Figure 3-3).  
Concentrations were insufficient to reach below the IC50, the concentration which inhibits 
viability by 50%, for 30% of the cell lines exposed to each of the idenoisoquinolines. As a result, 
a new parameter was chosen to compare variability in cytotoxic response between the 
camptothecins and the indenoisoquinolines. The cell viability at the dose which yielded a 
population mean viability closest to 50% was compared for all cell lines across each drug 
(referred to as the ( )50GI . Boxplots of cell viability at the ( )50GI  for each drug are depicted in 
Figure 3-4. Cell lines which had a mean viability greater than the 90th percentile of viabilities at 
the ( )50GI  were considered resistant. Cell lines which had a mean viability less than the 10th 
percentile of viabilities at the ( )50GI  were considered sensitive. Viability data for the six 
camptothecin analogues were handled in the same manner. Using there parameters, we were able 
to observe changes in sensitivity patterns between the two classes of Top1 inhibitors for some 
CEPH pedigrees (Figure 3-5). In pedigree 1451, six out of ten individuals were resistant to all 
three indenoisoquinolines. Five of these same individuals were sensitive to four or more 
camptothecins. Likewise, pedigree 1463 possessed six out of sixteen individuals who were 
sensitive to all three indenoisoquinolines; those cell lines were also resistant to 5 or more 
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camptothecin analogues. A single individual within this pedigree (GM12885) was resistant to all 
three indenoisoquinolines and sensitive to all six camptothecin analogues. This same pattern was 
observed for GM10846. Members of pedigree 1340 appeared sensitive to all six camptothecin 
analogues and all three indenoisoquinolines. While both the indenoisoquinolines and 
camptothecins act by a similar mechanism, i.e. Top1 inhibition, a correlation matrix on cell 
viability at the ( )50GI  for each drug suggests distinctions between the two classes. The three 
indenoisoquinolines are highly correlated with each other (PCC > 0.8) and distinct from the 
camptothecins (PCC < 0) (Table 3-1).  
Heritability analysis. There exists a significant relationship between growth rate and sensitivity 
to chemotherapeutic agents; cell lines which grow more rapidly are more sensitive to these 
cytotoxic agents [13]. As a control, we estimated the genetic contribution to growth rate in the 
presence of vehicle alone. Growth rate was found to be heritable (h2 = 8.65%). The growth rate 
adjusted heritability estimates for each drug-dose phenotype are indicated in Table 3-2. Overall, 
21 of the drug-dose phenotypes had a maximum heritability at or below that observed for growth 
rate. Sensitivity to Ind1 (100 nM) and Ind3 (5 uM) were found to be heritable traits with estimates 
of 15.7 and 14.1% respectively. A number of doses were found not to be heritable in this sample 
(h2 = 0). Taken together, these heritability estimates were lower than those reported for the 
camptothecin analogues which averaged 23.1%± 2.6% at doses within the linear phase of the 
sigmoid curve (Chapter 2). While the heritability estimates for the indenoisoquinolines varied 
considerably by dose (Table 3-2), heritability estimates for multiple doses and a number of 
camptothecin analogues were consistently approximately 20% for doses within the linear phase of 
the sigmoid curve.  
Independent Replication of QTLs from Camptothecin data sets 1 and 2.  Ten QTLs were 
identified as replicated within all six camptothecin analogues of Camptothecin set 1 (Chapter 2). 
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In a separate validation experiment using 3 additional camptothecin analogues, Camptothecin set 
2, nine of those QTLs were replicated (Chapter 2). In this study, we sought to further refine this 
list by performing a third independent validation study with nine drugs from Camptothecin sets 1 
and 2 (Camptothecin set 1+2). Any QTLs which could not be replicated at the significant or 
suggestive level for all drugs within this independent validation study were excluded from further 
analysis. Seven of the nine QTLs were replicated in Camptothecin set 1+2. The peak on 
chromosome 16 was identified as significant in multiple doses of CPT just as previously reported 
(Chapter 2). In fact, this QTL was replicated at the significance level in all camptothecins (for n ≥ 
1 doses) from Camptothecin set 1+2. The QTL on chromosome 11 was only present in two doses 
of CPT11 when studying Camptothecin set 1. In this study, it was present in all camptothecins at 
the significance level. Multiple doses of both SN38 and CPT11 (Camptothecin set 1) had QTLs 
on chromosome 20 which surpassed the significance LOD score thresholds in our earlier work. 
The QTL on chromosome 20 was replicated at the significance level in multiple doses of SN38 
and at the suggestive level of all other camptothecin analogues in the Camptothecin set 1+2. In 
our earlier work, a QTL on chromosome 5 was significant in multiple doses of 9NC, CPT, mCPT, 
and hCPT. In this study, that same region was replicated at the significance level for multiple 
doses of hCPT, SN38, CPT, 9AC, and 9NC. Figure A3-1 is a genome-wide map detailing these 
findings. Table 3-3 lists the QTLs shared by all camptothecin analogues which were replicated in 
this study.  
QTLs associated with Top1 inhibition. The next objective was to identify which peaks might be 
class-specific and which might be associated with the general mechanism of Top1 inhibition. 
Seven QTLs were replicated across all drugs in Camptothecin set 1, Camptothecin set 2, and 
Camptothecin set 1+2 (Table 3-3). We compared this pattern of QTLs to the QTLs associated 
with indenoisoquinoline sensitivity. A peak was considered replicated if it was found in all three 
indenoisoquinolines at the significant or suggestive level. Four of the seven predefined QTLs 
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were shared by all of the camptothecins and all of the indenoisoquinolines. These QTLs are 
summarized in Table 3-3. Peaks on chromosomes 11 and 16 were present at the significance level 
in multiple doses of all three indenoisoquinolines. The QTL on chromosomes 5 was significant at 
multiple doses of Ind2 and met the suggestive threshold for multiple doses of all three 
indenoisoquinolines. Finally, the QTL on chromosome 1 was shared by multiples doses of all 
three indenoisoquinolines at the suggestive level only. Most notably, the peak on chromosome 20, 
which contains Top1 and is shared by all of the camptothecins, was not present at the significant 
level in any indenoisoquinoline. However, it was present at the suggestive level in at least one 
dose of Ind1 and Ind3. These results are illustrated in Figure 3-6, a genome wide map of QTLs at 
the significant and suggestive level for both the camptothecins and indenoisoquinolines. We 
consider the remaining QTLs on chromosomes 6 and 20, which were not replicated in the 
indenoisoquinoline, camptothecin-specific (Table 3-3). 
QTLs associated with indenoisoquinoline-induced cytotoxicity. There are also QTLs which 
appear specific to the indenoisoquinolines alone. These QTLs are not replicated in the 
camptothecins and are summarized in Table 3-4. Of note, the QTLs on chromosomes 6 and 16 
were identified in multiple doses of all three indenoisoquinolines with LOD scores that exceeded 
the significance thresholds (maximum LOD score 2.286 for Ind3 at 7uM and 2.139 for 3 uM 
Ind2). Similarly, the QTL on chromosome 13 was also present in multiple doses of all three 
indenoisoquinolines (maximum LOD score 1.44 for 10 uM Ind3). At least two 
indenoisoquinolines had significant peaks on chromosomes 4 and 10 at multiple doses which 
were replicated at the suggestive level in n ≥ 1 doses of the third indenoisoquinoline. There are 
also subtle distinctions between the indenoisoquinolines. Multiple doses of Ind1 and Ind3 had a 
QTL with significant LOD scores on chromosome 14 (98-134 cM); this QTL was not present in 
drug-dose combinations of Ind2. A QTL on chromosome 19 (52-77 cM) surpasses the 
significance threshold for multiple doses of Ind1 but is not shared by the other members of that 
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class. Regions with significant peak LOD scores for growth in vehicle did not overlap peaks with 
any of the significant QTLs associated with sensitivity to the indenoisoquinolines (Figure 3-6) 
with the exception of a peak on chromosome 7 that is present in all three indenoisoquinolines. 
This suggests that the remaining QTLs are associated with cytotoxicity rather than the genetic 
effects from growth rate. 
DISCUSSION 
Drugs with common molecular targets can have very different therapeutic activities. For example, 
while the vinca alkaloids and colchicines are structurally distinct classes of tubulin destabilizing 
drugs, they are used in the treatment of cancer and gout respectively. The vinca alkaloids and 
taxanes target microtubules, but have distinct antitumor profiles, post-target interaction events, 
and mechanisms of resistance [14]. Differences in the expression of the molecular direct and 
indirect targets, metabolizing enzymes, and transporters between tumor types have been also been 
attributed to these observed differences in activity [14]. The similarities and differences in 
mechanisms between classes of compounds sharing the same molecular target have been 
characterized using genomic profiling [5]. In the present study, we used pharmacologic and 
genomic profiling in the CEPH cell lines to investigate two classes of Top1 inhibitors, the 
camptothecins and the indenoisoquinolines. Reports indicate that while sharing the same 
molecular target, the indenoisoquinolines exhibit unique properties which may set them apart 
clinically from the camptothecins. We previously used our ex vivo familial genetics model to 
study mechanisms of camptothecin-induced cytotoxicity (Chapter 2). The goal of this study was 
identify regions of the genome which were correlated to class-specific cytotoxicity and shared 
mechanisms of action. 
For profiling, we evaluated the biological activity of each class of drugs using a growth inhibitory 
assay. We compared the sensitivity of the CEPH cell lines to the indenoisoquinolines and the 
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camptothecins. Cell viability at the dose which produced 50% population mean viability ( )50GI  
for each drug was used as an endpoint. Interindividual variation in response to the 
indenoisoquinolines was found to be positively correlated (Table 3-1). An inverse correlation was 
noted when viability at ( )50GI  for each cell line was compared between the two structural 
classes. A number of cell lines which were resistant to all camptothecins were sensitive to all 
indenoisoquinolines and vice versa (Figure 3-5). These differences in cytotoxic activity suggest 
that while they share the same molecular target, there may be subtle distinctions in the 
biochemical cascade required for drug action (e.g. uptake mechanisms, metabolism, and 
secondary molecular interactions). Pommier suggests that (a) the differential genomic targeting of 
Top1 cleavage complexes by the camptothecins and indenoisoquinolines, (b) the differences in 
chemical structure and chemical stability of the indenoisoquinolines compared with 
camptothecins, and (c) the low cross-resistance to camptothecins based on drug efflux and Top1 
point mutations, make it likely that indenoisoquinolines will exhibit unique clinical and molecular 
properties which distinguish them from the camptothecins [6]. Even with a shared mechanism of 
action, mutations may render a cell sensitive or resistant to these distinct structural classes. For 
example, Antony et al. reported that human leukemic cells which were resistant to the 
camptothecins as a result of a Top1 point mutation were sensitive to Ind1 [9]. Not only can 
mutations in genes shared between these two classes change sensitivity, but this data suggest that 
there might be subtle distinctions in genes critical for action between the two classes (Table 3-4). 
While heritability analysis was not essential to the objective of this study, the results merit 
discussion. Sensitivity to individual concentrations of the indenoisoquinolines seems to be under 
some genetic control with a maximum heritability estimates of 0.15 (Table 3-2). Heritability 
estimates for drug-induced cytotoxicity by dose in CEPH cell lines have ranged from 0.06-0.70 
[15-17]. A number of the indenoisoquinoline drug-dose combinations have heritability estimates 
that are low (0 ≤ h2 ≤10) which had significant linkage peaks. The overall heritability of a trait is 
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typically considered evidence of a genetic contribution to phenotypic variation and implies that 
regions of the genome might be mapped which are responsible for this variation. In turn, this 
suggests that traits with low or no heritability values will not possess significant linkage. This 
was not the case in this study. Heritability has been described as an inconsistent predictor of 
significant linkage in the CEPH LCL model before [18-20]. In a study to identify regions of the 
genome influencing the expression profiles of CEPH cell lines, Huang et al uncovered 422 
expression traits with significant linkage. Of these 89 (21%) traits had low estimates (h2 ≤10), 23 
of which had h2 = 0. QTLs for gene expression traits with h2 = 0 were not false positive at the 0.5 
significance level. 
Nonparametric linkage analysis was used to identify regions of the genome which are specific to 
the general mechanism of Top1 inhibition, and distinct regions associated with the drug-induced 
cytotoxicity of camptothecins and indenoisoquinolines. We used permutation testing to determine 
empirical LOD score thresholds for significant and suggestive linkage for each drug-dose 
combination on each chromosome. Four QTLs were shared by all camptothecin analogues and 
replicated at the significant and/or suggestive level in all indenoisoquinolines (chr 1, 5, 11, 16; 
Table 3-3). We consider these QTLs specific to the general mechanism of Top1 inhibition, while 
QTLs in Table 3-4 are considered specific to the indenoisoquinolines. Different DNA cleavage 
patterns, biological activity within the CEPH, and unique QTLs patterns suggest some genes 
may be more selectively targeted by one compound class than the other [7, 10]. While 
Ind1, Ind2, and Ind3 depend on Top1 for cytotoxic effect, siRNA knockdown of Top1 (at 80-90% 
efficiency) does not completely reverse growth inhibition which suggests additional targets [9, 
10]. Moreover, Ind2 and Ind3 have weak activity against Top2 [10]. It’s too early to begin 
making hypotheses about what genes under those class-specific QTLs might be critical to the 
activity of the indenoisoquinolines. Since the discovery that this class of compounds acts on Top1 
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in 1998, our search of Pubmed reveals only 34 articles about the class. These articles 
predominately involve studies to optimize Top1 binding and potency. 
This study does open the doorway for the investigation of molecular pathways associated with 
cytotoxicity which are shared by the two structural classes. We used the functional categorization 
tool from the web-accessible program Database for Annotation, Visualization, and Integrated 
Discovery (DAVID) to stratify the protein-coding genes under each shared QTL from Table 3-3 
according to gene ontology (GO) terms. Table 3-5 lists genes under each QTL associated with 
GO terms related to camptothecin activity. The bolded gene names have been previously 
associated with camptothecin activity in yeast and/or mammalian cell lines. For example, the 
QTL on chromosome 1 contains PARP1 (poly(ADP-ribose) polymerase 1), an abundant nuclear 
protein that is activated by DNA strand breaks to modify proteins with poly(ADP-ribose) (PAR). 
PARP1 recruits DNA repair and checkpoint proteins to sites of DNA damage. Knockdown of 
PARP1 using siRNA sensitizes cells to camptothecin-induced cytotoxicity [21]. The SCF (Skp, 
Cullin, F-box) ubiquitin ligase complex degrades Top1 following Top1 mediated DNA damage. 
Overexpression of components of the SCF complex, such as Cul3 (on chromosome 1) and Skp2 
(on chromosome 5) have been associated with resistance [22, 23]. Inhibition of Chk1 
(chromosome 11), a serine/threonine kinase that is activated following DNA strand breakage 
from Top1 inhibitors, sensitizes cells to camptothecin analogues [24-26]. Rad50 (chromosome 5) 
belongs to the DNA repair complex MRE11-RAD50-NBS1 (MRN) complex which is activated 
in the presence of camptothecin-induced DNA double strand breaks [27, 28]. The overexpression 
of NDRG1 (chromosome 16) suppresses camptothecin-induced apoptosis, while inhibition of 
expression potentiated apoptosis in camptothecin treated cells [29]. An shRNA gene knockdown 
experiment using this gene list would make an excellent follow-up study for clarifying the 
molecular consequences of Top1 inhibition.  
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The identification of QTLs on chromosomes 6 and 20, which are specific to the camptothecins, is 
also intriguing. The fact that the QTLs were shared by all camptothecins but not present at the 
significant or suggestive level in any of the indenoisoquinolines also suggests distinctions in 
mechanism. The QTLs on chromosomes 20 and 6 have been validated in three independent 
studies. In Chapter 2, we used the functional annotation clustering tool from DAVID to identify 
Gene ontology (GO) terms which were enriched for genes within the QTL on chromosome 20 
(Table 2-3, Table A2-2) [30, 31]. The top over-represented GO terms were: response to stimulus, 
DNA binding, transcription, protein binding, cell differentiation, and regulation of cell growth. 
Some of the genes associated with these GO terms may be relevant to the camptothecin 
mechanism (Table 2-3, Table A2-2). A literature search reveals that many have yet to be 
evaluated for their effect on camptothecin-induced cytotoxicity. In Chapter 2, we indicated that 
Bcl-xl, an anti-apoptotic protein which promotes cell survival, and Top1 were two genes with 
known involvement in camptothecin cytotoxicity that were present in the QTL on chromosome 
20. It is possible that neither gene is responsible for this QTL. This QTL was not shared by the 
indenoisoquinolines, which also target Top1. Downregulation of Bcl-xl using siRNA prior to 
treatment increases sensitivity to SN38 and other camptothecin analogues, while overexpression 
of Bcl-xl results in resistance to camptothecins analogues [32] [33]. There are also contradictory 
reports regarding changes in Bcl-xl expression following treatment with the camptothecins. While 
Bcl-xl expression was induced in MCF-7 cells treated with increasing concentrations of 
camptothecin, expression was down-regulated in HepG2 cells with increasing concentrations of 
TPT [34, 35]. The most overrepresented GO terms for genes under the QTL on chromosome 6 at 
0-29 cM were cell differentiation (subcategory GO terms: apoptosis and cell death), protease 
inhibition, cell proliferation, and regulation of biological processes (subcategory GO terms: 
transcription, gene expression, DNA binding). Of the genes associated with these GO terms, there 
have been reports for the involvement of both WRN and FOXQ1 in camptothecin-induced 
cytotoxicity [36, 37]. The QTL on chromosome 6 from 42-65 cM is enriched with genes 
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associated with chromatin assembly, response to chemical stimulus, and NF-kappa binding. NF-
kappa B interferes with the effect of most anti-cancer drugs through induction of anti-apoptotic 
genes. Blocking NF-kappa B activation sensitizes cells to camptothecin analogues [38]. NF-
kappa B tumor expression seems to be negatively correlated with response to irinotecan [39]. A 
number of genes involved in the NF-kappa B signaling pathway are present in this QTL. This 
QTL also contains 22 members of the histone H1 family. The histones are proteins which 
package and order DNA into nucleosomes. Phosphorylation of histone H2AX is an extremely 
sensitive marker for double strand breaks induced by DNA damaging agents, such as the 
camptothecins and indenoisoquinolines [10, 40]. It has been suggested that other histones are 
involved in DNA repair and cell proliferation [41]. Studies indicate that histones are ADP-
ribosylated in vivo in response to DNA damage [42]. All core histones, including H1, can be 
mono-ADP ribosylated [41]. 
We have characterized a method for clarifying the mechanism of action for Top1 inhibition 
associated with the camptothecins and indenoisoquinolines. More than 25 years of research have 
been devoted to identifying the molecular pathways associated with camptothecin-induced 
cytotoxicity. Regions of the genome which contain known and potentially novel genes critical to 
their action have identified and validated. The QTLs shared by both the indenoisoquinolines and 
camptothecins (Table 3-3) are considered the most important for followup, followed by the 
camptothecin-specific QTLs, and finally the QTLs unique to the indenoisoquinolines. QTLs 
related to the general mechanism of Top1 inhibition may not only lead to predictions about 
camptothecin sensitivity and resistance in patient populations but could provide valuable insight 
into proposed functions of mammalian Top1 [43]. Whole genome association studies using LCLs 
should be used next to narrow down these broad QTLs. Most importantly, we’ve described a 
system-wide genomic method for delving into drug action which could surmount some of the 
limitations of existing mechanism elucidation strategies. 
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Figure 3-1. Chemical structures of camptothecin (A) and the indenoisoquinolines (B). The lead 
compound NSC 706744 (Ind1) led to two derivatives, NSC 725776 (Ind2) and 725998 (Ind3), 
which are being pursued for clinical development. 
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Figure 3-2. Genomic profiling of Topoisomerase 1 inhibitors. A) The CEPH cell lines were 
phenotyped for sensitivity to a panel of six camptothecin analogues (Camptothecin set 1). 
Nonparametric linkage analysis was used to identify 10 QTLs which were shared by all six 
camptothecin analogues. B) A phenotyping study with three distinct camptothecin analogues 
(Camptothecin set 2) was performed. QTLs which were shared in Camptothecin set 1 were 
queried for replication in Camptothecin set 2. QTLs which were not shared by all drugs in 
Camptothecin set 2 were excluded. C) For additional validation, a third independent phenotyping 
experiment was performed using seven of the nine camptothecin (Camptothecin set 1+2). Seven 
QTLs were independently validated in this study. QTLs which were not shared by all drugs in 
Camptothecin set 1+2 were excluded. D) To stratify QTLs as specific to camptothecin-induced 
cytotoxicity or the general mechanism of Top1 inhibition, CEPH cell lines were phenotyped for 
sensitivity to the jndenoisoquinolines, noncamptothecin Top1 inhibitors. E) Four of the seven 
QTLs were shared by both the camptothecins and indenoisoquinolines and considered to be 
associated with the general mechanism of Top1 inhibition. F) Three QTLs which were shared by 
all camptothecins were not replicated in the indenoisoquinolines.  
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Figure 3-3. Dose–response curve for (A) Ind1, (B) Ind2, and (C) Ind3. Data points represent the 
overall population mean (n=142) for viability relative to untreated controls at each dose. Vertical 
bars represent the standard deviation for cell viability across the population. 
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Figure 3-4. Boxplot of mean viabilities for CEPH cell lines at ( )50GI , the dose closest to a 
population mean viability of 50%. Line represents mean viability across cell population, box 
represents the 90th and 10th percentiles, and whiskers are the maximum and minimum values. 
 
82
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5. Sensitivity patterns for camptothecins and indenoisoquinolines in select CEPH 
pedigrees. Red indicates resistance ie. mean viability > 90th percentile of viabilities at the 
( 50GI ), green indicates sensitivity ie. mean viability < 10th percentile of viabilities at the 
( 50GI ), and black indicates mean viability between 10-90th percentile at the ( 50GI ). 
Pedigree Cell ID In
d1
In
d2
In
d3
9A
C
9N
C
TP
T
C
P
T
SN
38
C
P
T1
1
12772 2 0 0 0 0 0
12767 2 0 0 0 0 0
12771 0 0 2 2 2 0
12773 1 1 1 0 2 0 2 2 2
12769 1 1 1 0 2 0 2 2 2
12766 1 1 1 0 2 2 2 2 2
12770 1 1 1 0 2 2 2 0 2
12768 1 1 1 2 2 2 2 2 2
12774 0 1 1 0 0 0 0 0 0
12848 1 1 1 1 1 1 0 0 0
12877 0 0 0 0 0 0 0 0 0
12879 0 0 0 0 0 0 0 0 0
12880 0 0 0 0 0 0 0 0 0
12882 0 0 0 0 0 0 0 0 0
12883 0 0 0 0 0 0 0 0 0
12885 1 1 1 2 2 2 2 2 2
12886 0 0 0 0 1 1 1 1 1
12887 0 0 0 1 0 1 1 1 1
12888 2 2 2 1 1 1 1 1 1
12889 0 2 2 1 1 1 1 1 1
12890 0 2 2 1 1 1 1 1 1
12892 2 2 2 1 1 1 1 1 1
12884 2 2 2 1 1 1 1 1 1
12893 2 2 2 1 1 1 1 1 1
11821 2 2 2 2 2 2 2 2 2
7008 2 2 2 0 2 2 2 2 2
7053 2 2 2 2 2 2 2 2 2
7062 0 2 2 0 2 2 2 2 2
7342 0 2 2 2 2 2 2 2 2
7027
7029
7019
1451
1463
1340
2
2
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Figure 3-6. Genome wide pattern of QTLs for the camptothecins and indenoisoquinolines. Each 
chromosome was partitioned into 10 cM regions. For each drug, any significant QTL regions 
(LOD>permutation threshold for significance) is indicated in blue. The intensity of the shading 
indicates the total number of additional doses that were replicated at either the suggestive or 
significant level. Regions which also had at least a suggestive QTL are shown in green. Color 
intensity of the color represents the number of dose replications. Drugs are grouped according to 
their structural class, where the groups are labeled as follows: Group A: Camptothecin set 1and 
Group B: indenoisoquinolines.  
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Table 3-1. Results of correlation analysis for cell viability at GI50 for camptothecins and 
indenoisoquinolines 
 
PCC Ind1 Ind2 Ind3 9AC 9NC CPT CPT11 SN38 TPT 
Ind1 1 0.88 0.84 -0.14 -0.14 -0.12 -0.15 -0.17 -0.14
Ind2  1 0.82 -0.11 -0.09 -0.10 -0.13 -0.14 -0.10
Ind3   1 -0.09 -0.05 -0.06 -0.11 -0.15 -0.10
9AC   1 0.65 0.65 0.65 0.65 0.65
9NC   1 0.77 0.76 0.73 0.78
CPT   0.94 0.88 0.86
CPT11   1 0.91 0.86
SN38    1 0.85
TPT     1
Pearson Correlation Coeﬃcient, (PCC) 
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Table 3-2. Heritability estimates for the indenoisoquinolines 
Drug 
Concentration 
(M) 
Growth rate adjusted 
heritability estimate 
Ind1 
3.00E-06 2.21 
5.00E-07 0.00 
3.00E-07 11.75 
2.00E-07 3.18 
1.00E-07 15.68 
5.00E-08 0.45 
3.00E-08 0.00 
1.00E-09 0.00 
Ind2 
3.00E-05 0.00 
1.00E-05 4.42 
3.00E-06 6.72 
1.00E-06 2.24 
5.00E-07 0.00 
2.30E-07 0.00 
1.60E-07 0.00 
1.00E-08 0.00 
Ind3 
5.00E-05 6.84 
3.00E-05 6.85 
1.00E-05 6.86 
7.00E-06 0.00 
5.00E-06 14.10 
3.00E-06 4.13 
1.00E-06 0.00 
1.00E-08 0.00 
 
86
 
 
 
 
 
 
Table 3-3. QTLs found in Camptothecin set 1+2 and indenoisoquinolines 
Chromosome Peak Start (cM) Peak End (cM) LODb LODc 
1a 229 252 1.855 0.870 
5a 125 194 1.709 1.551 
6 0 29 1.528 - 
6 42 65 1.652 - 
11a 115 131 1.352 2.421 
16a 0 75 1.345 2.139 
20 42 101 2.134 - 
a QTLs which were also shared by the indenoisoquinolines  
b Maximum LOD score observed in this region associated with the camptothecins  
c Maximum LOD score observed in this region associated with the indenoisoquinolines 
 
87
 
 
 
 
 
 
Table 3-4. QTLs shared by all Indenoisoquinolines 
Chromosome Peak Start (cM) Peak End (cM) LOD* 
2 1 34 2.024 
4 192 211 1.483 
6 100 192 2.286 
10 118 155 1.775 
13 67 114 1.44 
16 27 108 2.139 
18 0 31 1.574 
18 90 96 1.554 
* Maximum LOD score observed in this region 
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Table 3-5: Genes under QTLs shared by camptothecins and indenoisoquinolines* 
chr GO terms GENES 
1 
GO:0016055 Wnt receptor signaling pathway WNT3A, WNT10A, WNT6, WNT9A,  
GO:0006974 response to DNA damage stimulus 
TNP1, NHEJ1, C1orf124, PARP1, BARD1, 
DTL, XRCC5,  
GO:0003677 DNA binding 
MIXL1, BATF3, PROX1, TAF1A, SP110, 
ZNF142, ESRRG, HIST3H3, IKZF2, 
SMARCAL1, HIST3H2BB, ZNF678, TSNAX, 
TAF5L, LBR, HIST3H2A, FEV, RCOR3, 
TIGD1, PAX3, HLX, SP100, ATF3, SP140, 
NCL,  
GO:0006350 transcription KCNH1, RCOR3, PTMA, HLX, EGLN1, IHH, STK36 
GO:0006915 apoptosis 
COL4A3, CUL3, SCG2, IL8RB, AGT, INHA, 
INPP5D, SPATA3, TP53BP2, PECR, PSEN2, 
TGFB2, TRAF5,  
GO:0030154 cell differentiation 
USH2A, ERBB4, MREG, NGEF, EFHD1, 
ITPKB, ACTA1, SERPINE2, OBSCN, SCG2, 
COL4A4, DNER, SPEG, LEFTY2, 
5 
GO:0030154 cell differentiation 
NRG2, NME5, ISL1, NAIP, HSPA9, DND1, 
MAP3K1, CYFIP2, ZNF346, AGGF1, UNC5A, 
TSSK1B, CTNNA1, NPM1, DRD1, SLIT3, 
PDLIM7, FST, POU4F3, PURA, F2R, AP3B1, 
PIK3R1, PRKAA1, NKX2-5, GPR98, CD74, 
PRDM6, NEUROG1, PPP2CB, NR2F1, JMY, 
MEF2C, CSF2, GZMA, MAP1B, ADRB2, 
FGF10, VDAC1, UBE2B, IL12B, CARD6, 
CARTPT, ATG12, IL3, MRPS30, SEMA6A, 
SMAD5, EFNA5, HDAC3, SMN2, PROP1, 
AFF4, ERAP1, C9, GDNF, SPINK5, EGR1, 
PPP2R2B, DDX41, PRLR, FGF1, HAND1, 
SFXN1, HNRPAB, HSD17B4, RASA1, IL4, 
ACSL6, FGF18, CD14, DBN1, GFRA3,  
GO:0006915 apoptosis PROP1, PPP2CB, ADRB2,  
GO:0008283 cell proliferation 
FABP6, SKP2, APC, CNOT8, TGFBI, 
B4GALT7, DAB2, IL9, HTR1A, L6ST, 
ADRA1B, SPOCK1, PPAP2A, LIFR, FGF1, 
CSF1R, HBEGF,  
GO:0006512 ubiquitin cycle 
FBXL17, FBXO4, RNF14, TRIM23, SKP1, 
ENC1, CDC23, RNF145, TSPAN17, ERCC8, 
FBXO38, MARCH3, KLHL3, FBXW11, 
UBE2D2, FBXL21,  
GO:0000079 
regulation of cyclin-
dependent protein 
kinase activity CDC25C, CDK7, CCNG1, CCNH,  
GO:0006974 
response to DNA 
damage stimulus 
CCNO, POLK, RAD17, PTTG1, XRCC4, 
RAD50, GTF2H2, MSH3,  
89
chr GO terms GENES 
5 
GO:0043122 
regulation of NF-
kappaB cascade F2R, PLK2, CXXC5, NDFIP1, TICAM2,  
GO:0007049 cell cycle 
PAM, MCC, IRF1, CETN3, NIPBL, DUSP1, 
CCNB1, PFDN1, ERBB2IP, SEPT8, CDC20B, 
RASA1 
GO:0003682 chromatin binding NSD1, H2AFY, CHD1,  
11 
GO:0050896 response to stimulus 
TIRAP,CHEK1,OR10G4,MFRP,BSX,C1QTNF5
,OR10G7,OR10G9,PVRL1, POU2F3, 
R8A1,ROBO3,HSPA8,CRTAM,OR10S1,OR8G5
OR6T1,OR4D5, OR6M1,EI24,OR8B8, 
OR8B12,OR8B2,OR8B3,OR8D1,OR8B4,OR8D
2,OR8D4, PATE4,OR6X1 
GO:0030154 cell differentiation 
PVRL1,POU2F3,DDX25,CDON,ROBO4,TIRAP
ROBO3,THY1,FEZ1 
GO:0022402 cell cycle process HEPACAM,HEPN1,TBRG1,CHK1 
GO:0048522 
positive regulation of 
cellular process 
BSX,EI24,CRTAM,POU2F3,CBL,ARHGEF12,T
HY1 
GO:0003677 DNA binding 
PKNOX2,BSX,POU2F3,TRIM29,CBL,TBRG1,
ZNF202 
16 
GO:0005524 ATP binding 
ERN2, PDPK1, PLK1, ATP2A1, NOD2, 
ATP6V0C, CREBBP, DNAH3, TAOK2, NME3, 
PRKCB1, NUBP2, KIFC3, WDR51B, NUBP1, 
PHKG2, RAB26, CIITA, EEF2K, MYH11, 
EARS2, PKMYT1, SEPHS2, TRAP1, BCKDK, 
CHTF18, NLRC5, ACSM1,  
GO:0007049 cell cycle 
AXIN1, CORO1A, CYLD, CP110, SEPT1, 
CSNK2A2, DNAJA2, RBL2, TSC2, PAPD5, 
PRM2, KATNB1, PRM1, SIAH1, CCNF,  
GSPT1, MAPK3,  
GO:0051092 
activation of NF-
kappaB  
transcription factor 
PYCARD, NLRC3 
 
GO:0006974 
response to DNA 
damage stimulus 
C16ORF35, NTHL1, SMG1, ERCC4, KCTD13, 
KIF22, MPG, GIYD2,  
GO:0042493 response to drug ABCA3, ABCC6, ABCC1, MVP,  
GO:0030154 cell differentiation 
SOX8, TRAF7, NTN2L, CACNA1H, TBX6, 
SALL1, IRX5, GNAO1, NUPR1, BBS2, 
METRN, TNP2,  MT3, MKL2, MYST1, IL27, 
NDRG4,  
GO:0008219 cell death 
CLN3, TNFRSF12A, CIAPIN1,  DNAJA3, 
LITAF, PDIA2, EMP2, BFAR, 
DNASE1, SPN,  
GO:0006512 ubiquitin cycle 
RAB40C, TCEB2, SOCS1, AMFR, FBXL16, 
STUB1, RNF40, USP7, FBXL19, AKTIP,  
chr GO terms GENES 
90
16 GO:0003677 DNA binding 
ZNF646, GTF3C1, ZNF213, HN1L, ORC6L, 
ZNF174, CARHSP1, MAZ, UBN1, 
IRX3, ALG1,  IRX6, ZNF597, ZNF75A, 
ZNF434, FUS, SRCAP, TFAP4, CHD9, ZNF263, 
POLR2C, DNASE1L2, ZNF500, ZNF267, 
POLR2K, MRPL28, ZNF319, ZNF205, E4F1,  
GO:0006350 transcription 
RPUSD1, NUDT21, TUFM, RPL3L, EIF3C,  
TRAF7,  RSL1D1, RNPS1, RPS2, 
TBL3, POLR3E, ZNF720,  C16ORF33, RPS15A, 
SRRM2,    
GO:0010467 gene expression ZNF200,  RRN3,  
*Gene names in bold indicate genes which have previously been associated with camptothecin-
induced cytotoxicity. 
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ABSTRACT 
The objective of this work was to demonstrate pharmacological and genomic profiling in CEPH 
cell lines can be used to stratify chemicals according to mechanism of action. A panel of 22 
anticancer agents belonging to 8 major mechanistic classes was evaluated for cell growth 
inhibition in the CEPH cell lines. We propose that intraclass biological and genomic profiles will 
be more similar to each other than to compounds belonging to distinct mechanistic classes. 
Considerable phenotypic variation was observed across and within families. For each compound, 
cell viability at the dose closest to a population mean viability of 50%, ( 50GI ) was analyzed by 
hierarchal clustering and resulted in clusters in agreement with the distinct modes of action. 
Pearson correlation coefficients (PCC) were calculated for all compounds based on cell viability 
at the 50GI ; while compounds within a class were highly correlated (PCC>0.65), PCC ranged 
from 0.00-0.55 between compound classes. The cytotoxic response to each agent was shown to 
be a heritable trait with genetics estimated to account for 5-60% of the observed variation in 
response. Genome-wide linkage analysis was then used to identify QTLs influencing the effect of 
each of the anticancer agents. QTLs with moderate peak LOD scores (maximum LOD scores = 
1.5- 2.3) were identified which were unique to each of the mechanistic classes. Results suggest 
that compounds belonging to distinct mechanistic classes can be distinguished on the basis of 
pharmacological and genomic profiling in CEPH cell lines.  
  
INTRODUCTION 
Predicting the sensitivity and toxicity of individual patients is important in improving the safety 
and efficacy of cancer chemotherapy. An approach to this end is to understand the genes that 
determine sensitivity. Many genes which have been indicated to influence the response to 
chemotherapeutic agents include drug transporters [1, 2], metabolizing enzymes [3-5], and 
molecular targets [6]. An analysis of genes which are already known to be involved drug action is 
not sufficient to explain all of the observed variation in patient response. Our understanding of the 
global action of an anticancer agent, all of its direct targets, indirect targets, affected cellular 
pathways, and proteins involved in ADME, is severely lacking. Increasing our knowledge of the 
global mechanism can lead to the identification of additional genes which can predict sensitivity 
and toxicity to chemotherapeutic agents. 
Recent attempts to predict chemosensitivity and identify genes critical to drug action have 
involved high throughput phenotypic screening and genome-wide expression profiling in cancer 
cell lines. The most prominent approach enables mechanism oriented evaluation of anticancer 
agents in the National Cancer Institute’s panel of human cancer cell lines (NCI60). Cell lines are 
screened for sensitivity or resistance to a compound whose mechanism is unknown. The GI50 
(molar concentration inhibiting 50% cell growth) is reported for each of the cell lines and used to 
generate an activity profile, referred to as the compound’s fingerprint. The COMPARE algorithm 
then enables mode of action predictions by comparing the fingerprint of a compound of interest to 
others of known mechanisms [7, 8]. A high degree of correlation suggests that the two agents 
share a similar antiproliferative mechanism [9]. Since its beginning, thousands of compounds 
have been evaluated for cytotoxicity in these cell lines. Compounds have been successfully 
classified by their mechanisms of action by hierarchal clustering using their activity profiles [1]. 
Recognizing that variation in genes critical to drug action might be responsible for the variation 
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in susceptibility to anticancer agents, the genome-wide expression profiles of all 60 cell lines 
were generated [2]. The gene expression database was combined with the activity database and 
Pearson correlation analysis was used to identify genes with expression patterns that showed 
significant correlation to patterns of sensitivity. Indeed, variations in the transcript levels of 
particular genes correlated well to cell line sensitivity or resistance. Subsequently, patterns of 
gene expression and compound activity have been used to provide incisive information about the 
mechanism of action of compounds of interest, and guide our understanding of which genes 
influence response.  
While extremely powerful, the limitations of the NCI60 genomic model necessitate the 
exploration of additional supportive strategies for mechanism elucidation. It has been fairly 
controversial whether tumor cell activities can predict human patient chemotherapeutic responses 
[10]. Furthermore, all important tumor types were not included in the NCI-60. For example, there 
are no lymphomas, sarcomas, head and neck tumors, or small cell lung cancers. Even if these 
types could be added to the panel now, all compounds screened over the past 20 years would have 
to be tested again in the updated panel to gain the full predictive power of the database. 
Moreover, RNA levels are not always correlated with the expression data for the protein it 
encodes [11]. It is widely appreciated that protein levels can vary significantly among genes that 
have similar mRNA-expression profiles, and, that there can be a significant variation in the 
mRNA levels of proteins that are expressed with comparable abundance [11, 12]. Finally, post-
translational modifications, such as phosphorylation and acetylation, which may be required for 
drug-target interaction would not be detected. Taken together, this suggests that the linking of 
expression profiles and compound activity in cancer cell lines may miss meaningful information 
for mechanism elucidation and for predicting the susceptibility of a cell or an organism to a 
compound. 
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Additional methods for indentifying genes influencing drug action are needed to support existing 
mechanism elucidation strategies such as the NCI60 cell line model. An ex vivo familial genetics 
model using lymphoblastoid cell lines (LCLs) derived from multigenerational human families has 
been used as a model for the discovery of genes involved in the cytotoxic action of anticancer 
agents [13, 14]. We have illustrated that a pattern of quantitative trait loci (QTLs) associated with 
the activity of a mechanistic class of drugs, the camptothecins, a group of Topoisomerase 1 
inhibitors, could be established (Chapter 2). Moreover, both the biological and genomic profiles 
of the camptothecins could be used to distinguish these compounds from Topoisomerase 2 
inhibitors, a mechanistically distinct class of compounds (Chapter 2). The objective of this study 
was to evaluate whether this model is generally effective for stratifying anticancer agents 
according to mechanism of action using biological and genomic profiling. 
MATERIALS & METHODS 
Cell lines and Culture Conditions. One hundred twenty-five Epstein-Barr virus-immortalized 
LCLs derived from 14 CEPH pedigrees (35, 45, 1334, 1340, 1341, 1350, 1362, 1408, 1420, 1447, 
1451, 1454, 1459 were purchased from Coriell Cell Repositories (Camden, New Jersey). Cells 
were incubated in a 5% COR2R atmosphere at 37 P◦PC in RPMI medium 1640 (Invitrogen, Rockville, 
MD) supplemented with 15% fetal bovine serum. Cells were passaged 2-3 times per week and 
used for experimentation at passages 3-7.  
Drugs. For the in vitro drug sensitivity test 22 drugs in 8 mechanistic classes were used 
(summarized in Table 4-1). All the drugs were dissolved in dimethyl sulfoxide (DMSO) or water 
and printed on 96 well plates using a Biomek 3000 fluid dispenser robot (Beckman). The same 
robot was then used to generate 384 well experimental plates (Corning, Corning, NY) containing 
vehicles (water and 0.1% DMSO), 10% DMSO, and increasing concentrations of each drug in 
quadruplicate. For each drug, four different concentrations were chosen to yield the slope of the 
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dose-response curve (approximately 20, 40, 60, and 80% viability) and are reported in Table A4-
1. Final concentrations of DMSO for all drug solutions in experimental plates were no more than 
0.1%.  
Cytotoxicity Profiling. Growth inhibition experiments were performed as previously described. 
Briefly, cells were plated at a density of 4000 cells in 45 ul media per well in 384 well 
experimental plates preloaded with drug. Following 72 h incubation, the non-toxic colorimetric 
dye, alamar blue, was added and fluorescence read at 96 h. The cell count at each replicate was 
screened for outliers, where an outlier was defined as more than a ten-fold increase or decrease in 
cell count of a single replicate. Cell viability (survival) relative to untreated controls was 
determined according to the manufacturer’s protocol. The final percent survival at each 
concentration was averaged from four replicates of two independently plated experiments (n = 8). 
Additionally, growth rate in vehicle was calculated as previously described (Chapter 2). 
Hierarchical Clustering on Biological Activity. Viability for each cell line was assessed at the 
dose closest to the population mean of 50%, referred to as the ( )50GI . Raw viability scores were 
z-score transformed and loaded into Cluster 3.0 (HTUhttp://bonsai.ims.u-
tokyo.ac.jp/~mdehoon/software/cluster/UTH) [15, 16]. A self organizing map (SOM) was calculated 
using 100,000 iterations for cell lines and 20,000 iterations for drugs to stabilize clusters and then 
the data clustered using uncentered correlation and complete linkage clusters. Clusters were 
visualized using Java TreeView. 
Genomic profiling. Genomic profiling, which consisted of heritability estimates, linkage 
analysis, peak identification and peak replication analysis, was performed as described in 
(Chapters 2 and 3). Briefly, heritability estimates (h P2P), the degree of variation in cytotoxic 
response which can be explained by genetics, were calculated for each drug-dose phenotype using 
MERLIN [17]. Heritability estimates were calculated using cellular growth rate as a covariate. 
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The genotype data were downloaded from CEPH [18] and Marshfield [19] databases and used for 
nonparametric linkage analysis in MERLIN [17]. Permutation testing was used to identify LOD 
score thresholds for significant and suggestive QTLs for each drug-dose combination at each 
chromosome (Chapters 2 and 3). A QTL was defined as significant if the maximum LOD score 
within that region surpassed the LOD score significance threshold for that drug-dose combination 
on that chromosome. Regions identified as significant peaks for a given drug-dose combination 
were evaluated for replication at the suggestive or significant level for all dosages of that drug. A 
region was considered replicated in another dose if any LOD score in that region surpassed the 
suggestive LOD score threshold. Finally, to establish a pattern of QTLs specific to a mechanistic 
class, QTLs which were identified as significant in one drug were queried for replication at the 
suggestive level in all drug-dose combinations belonging to that mechanistic class. 
RESULTS 
Biological activity profiling. CEPH cell lines (n = 125) belonging to 14 pedigrees were tested 
for sensitivity to 22 anticancer agents belonging to 8 mechanistic classes. With the exception of 
the camptothecins, four doses were chosen for each drug to capture the anticipated most variable 
region within the linear portion of the sigmoid curve. Boxplots illustrating variation across 
individual cell lines at each drug-dose phenotype can be found in Figure A4-1. The 
antimicrotubule drugs vincristine, docetaxel, and vinrolebine were only active at the highest 
concentrations investigated. The anthracyclines, TYMS inhibitors, Top1 and Top2 inhibitors 
were highly effective across all concentrations. The observed sensitivity patterns are consistent 
with those reported previously in lymphoblastoid cell lines with a few exceptions [13, 20, 21]. 
Bleomycin, vinblastine, and topotecan were reported as inactive in healthy normal lymphoblast; 
however, the concentrations used were 10-1000 fold lower than those used in this study [20]. 
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Typical studies stratifying drugs based on their biological activity in a cell panel use the GI50 
[22-28]. However, a GI50 could not be determined for 61% of the drugs in at least 93 (75%) of 
the CEPH cell lines. Hierarchical clustering analysis was performed using the dose which yielded 
a population mean viability closest to 50% for each drug, which will be referred to as 50GI  
(Table A4-1). The mean viability for each cell line was compared at the 50GI  of each drug. A 
boxplot of cell viability at the 50GI  for the anticancer agents shows that the data appears to be 
evenly distributed (Figure 4-1). The 90PthP and 10PthP percentile viability thresholds were calculated 
for each drug. Cell lines which had a mean viability greater than the 90PthP percentile for a drug at 
50GI  were identified as resistant. Similarly, cell lines with a mean viability less than the 10PthP 
percentile were considered sensitive. Some families and individuals were consistently sensitive or 
resistant to the test compounds (Table A4-2). Pedigree 1408 has six out of 10 members who were 
sensitive to more than 50% of the drugs and they were consistently sensitive to the same drugs. 
Five out of 10 members of pedigree 35 are also sensitive to approximately 50% of the anticancer 
drugs studied and resistant to another 45%. The individual CEPH cell lines 12766 and 12767 
(pedigree 1451) was resistant to 16 (72%) of the drugs. 
An analysis of z-score transformed viabilities at 50GI  by hierarchal clustering on drugs and cell 
lines was performed (Figure 4-2). Most anticancer agents tested clustered by their mechanistic 
class. The camptothecin analogues all clustered together and share the same molecular target, 
Topoisomerase 1 (Top1). A cluster was generated which contained the anthracyclines 
(daunorubicin, doxorubicin, idarubicin, and epirubicin) and the podophyllotoxins (etopiside and 
teniposide). The podophyllotoxins are Top2 inhibitors and the anthracyclines are DNA 
intercalators which are also reported to inhibit Top2 [29]. Agents which act on microtubules, 
specifically docetaxel, paclitaxel, vinorelbine and vincristine, all belong to the same cluster. 
Interestingly, vinblastine, a microtubule destabilizing agent, sorts distinctly from the other 
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antimicrotubule drugs. This is in accordance with the boxplot shown in Figure 4-1. Bleomycin 
which is mechanistically distinct from the other agents is in a cluster of its own. Floxuridine 
exceptionally belonged to the cluster bearing the antimicrotubule agents, not the cluster with 
5FU, although both are considered thymidylate synthase (TYMS) inhibitors. Pearson correlation 
coefficients (PCC) were calculated for all compounds based on cell viability at 50GI ; while 
compounds within a class were highly correlated (PCC>0.65), PCC ranged from 0.00-0.55 
between compound classes (Figure 4-3). 
Genomic profiling. The family data demonstrates a genetic component in the explanation of 
inter-individual differences for sensitivity to chemotherapeutic agents. Growth-rate adjusted 
heritability estimates were calculated for each drug-dose phenotype and ranged from 0-64% 
(Table 4-2, Table A4-3). The heritability estimates for cellular growth rate did not exceed 14%. 
Estimates for 5-fluoruracil, docetaxel, and daunorubicin are comparable to previously reported 
values (Table 4-2). Heritability estimates for compounds within a mechanistic class were also 
similar. For example, heritability estimates for doses within the linear portion of the sigmoid 
curve averaged 23.1 ± 2.6 % for the Top1 inhibitors. 
Nonparametric linkage analysis was used to identify QTLs for each drug-dose phenotype. 
Permutation testing was used to identify statistically significant LOD score thresholds for each 
drug-dose phenotype on each chromosome. Thresholds indicating suggestive linkage across each 
chromosome for each drug-dose combination were also calculated using permutation testing. The 
average significant and suggestive LOD score thresholds for drug-dose phenotypes across all 
chromosomes were 1.43 (range: 0.94-1.74) and 0.59 (range: 0.46-0.64) respectively. Peaks 
identified as significant at one drug-dose phenotype were queried for replication at the suggestive 
level in other doses of that drug. A peak was considered replicated if the maximum LOD score in 
that region surpassed the suggestive threshold for that drug-dose phenotype on that chromosome. 
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To establish a pattern of QTLs related to a mechanistic class, peaks identified as significant for 
one member of a class were queried at the suggestive level for all other drug-dose phenotypes 
within that mechanistic class. 
Testing for overrepresentation of QTLs within mechanistic classes suggests that compounds 
which share similar chemical structures shared similar genomic profiles (Figure 4-4). A list of all 
significant QTLs can be found in Table A4-4. Genome-wide patterns of QTLs were distinct for 
each mechanistic class. For example, QTLs in a similar location on chromosome 3, 5, 14, and 19 
were shared by the platinum analogs, carboplatin and oxaliplatin (Figure 4-5 and Figure 4-6). 
This pattern was distinct from the shared QTLs on chromosomes 1 and 11 for the tubulin 
stabilizing agents, paclitaxel and docetaxel. (Figure 4-4) depicts the overall patterns of significant 
and suggestive QTLs for each drug by mechanistic class. Significant QTLs identified for cellular 
growth in each vehicle did not overlap with any significant drug QTLs. In addition, with the 
exception of the camptothecins all drug classes shared a broad QTL on chromosome 7. Chemical-
specific QTLs were also identified as significant to one drug within a mechanistic class. For 
example, 2 out of 4 doses of oxaliplatin possessed a significant QTL on chromosome 12 which is 
not shared by carboplatin. Similarly, carboplatin has a significant QTL on chromosome 6 which 
was replicated in all four doses but not present in oxaliplatin. 
DISCUSSION 
A system for determining key molecular targets and genes related to the activity of chemicals 
using a panel of cancer cell lines was first developed in the National Cancer Institute [7, 9, 22, 
30]. It was later suggested that a good correlation between a drug’s mechanism of action and its 
fingerprint, biological and/or genomic profile(s), could be observed in any panel of cell lines with 
diverse chemosensitivities [28]. We explored the potential of natural genetic variation within the 
CEPH cell lines to stratify anticancer agents according to mechanism of action using biological 
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and genomic profiling. We examined the antiproliferative activity of 22 anticancer agents against 
125 CEPH LCLs derived from 14 pedigrees and observed differential activity across the whole 
cell panel. Linkage analysis revealed genomic regions related to the observed inter-individual 
differences in sensitivity to each drug. Hierarchical clustering on the biological activity profiles in 
CEPH classified drugs with a similar mode of action (such as a tubulin binders or Top1 
inhibitors) into the same cluster (Figure 4-2), which were the same as the clusters established for 
NCI60 [9, 22]. Moreover, patterns of QTLs shared among compounds belonging to the same 
mechanistic class were distinct from compounds belonging to other mechanistic classes. 
While we have identified class-specific QTLs, we note that for most mechanistic classes 
significant linkage peaks were not observed in the genomic region bearing the primary targets. 
This is not alarming. Peters et al. commented on the failure of an earlier linkage analysis study of 
5-fluoruracil toxicity to identify a significant linkage peak on chromosome 18 around thymidylate 
synthetase (TYMS), the presumed primary target of 5FU [13, 31]. Genetic variants in TYMS 
were subsequently correlated to cytotoxic response in a subset of the HAPMAP LCLs [13, 31]. 
The region containing TYMS may not have been identified because of the density of genotype 
data used in linkage analysis  and low to moderate effect sizes of genetic variants TYMS. The 
genotype density improved when going from the microsatellite markers used in the preliminary 
linkage analysis study of 5FU to the SNP data available for HAPMAP cell lines; the HAPMAP 
data enabled the detection of an association between 5-FU cytotoxicity and TYMS.  
QTLs common to multiple classes as well as chemical-specific QTLs were also observed. QTLs 
common to multiple classes such as the one present on chromosome 7 are likely to possess genes 
which are not drug specific but are important in cell proliferation, survival and death. It is also 
plausible that distinct but closely linked genes are contributing to the cytotoxic response to these 
drugs. We have also observed QTLs which are unique to compounds within a mechanistic class, 
ie. chemical-specific QTLs. It is generally accepted that subtle changes in structure within a 
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mechanistic class do result in changes in the metabolism, antitumor profiles, mechanisms of 
resistance, and even molecular targets [32, 33]. While highly correlated, oxaliplatin clustered 
away from carboplatin according to biological activity in the CEPH (PCC = 0.69). Moreover, 
there were subtle distinctions in QTLs which were identified as significant to cytotoxic response 
(Figure 4-4). Oxaliplatin and carboplatin clustered separately according to biological activity 
profiles in two different cancer line panels [28, 34]. Subtle distinctions between the biological 
activity and genomic profiles of oxaliplatin, carboplatin, and cisplatin have been attributed to 
differences in mechanisms of activity and resistance [28, 34-36].  
Peters et al. chose to only examine QTLs which were associated with the highest heritable doses 
[37]. More highly heritable traits have a greater proportion of phenotypic variation explained by 
genetic effect and tend to have significant linkage scores. However, drug-dose phenotypes with 
lower heritability estimates did have significant linkage peaks associated with response. For 
example, the 10 uM 9NC drug-dose phenotype (hP2P = 0) had a significant QTL on chromosome 6 
from 0-29 cM. In these cases, often the pedigrees contribute to overall significance and can 
explain why LOD scores can be high for lower heritability traits. Three pedigrees contribute 
considerably to the overall score with LODs of 0.77, 0.44, and 0.59 while the LOD scores from 
the other pedigrees range from -0.07 to 0.12. In many cases, these QTLs have been replicated in 
additional drugs within a mechanistic class. For example, the QTL on chromosome 6 for 9AC is 
replicated at the suggestive level in multiple doses of 5 out of six of the camptothecins. Earlier 
reports involving the identification of genomic regions influencing the response to anticancer 
agents in CEPH, have observed differences in QTL patterns for a single drug at different doses 
[13, 21]. It is certainly plausible, given different mechanisms may predominate at different doses. 
For example, genes related to cell survival mechanisms may be critical at lower doses while at 
higher doses genes related to cell death and apoptosis might be more important. Filtering on the 
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highest heritable dose may result in a loss of important information regarding drug mechanism. 
All significant QTLs identified for all drug-dose phenotypes were used in this study. 
Peak position (start and end cM) varied as much as 5-20 cM for QTLs which were considered 
significant and replicated across numerous drug-dose combinations within a class. For example, 
significant QTLs on chromosome 20 were detected in at least four of the six camptothecins and 
also replicated in all six camptothecins at the suggestive level. Peak start and end positions for 
these peaks varied, but shared considerably overlap (Table 4-3). Consequently, the whole region 
from 40-101 cM is considered shared and replicated by the camptothecins as a class. With such 
variation in the position the question becomes: (a) Can these findings result from the same gene 
or different genetic factors and (b) can we truly consider linkage at these QTLs “replicated” 
multiple times? This issue is not limited to our study. Many independent studies of complex traits 
report evidence for linkage in nearby regions on the same chromosome: chromosome 6p for 
schizophrenia [38-40] and chromosome 12p for Alzheimer disease [41-43]. 
Substantial variation in the location of a linkage signal has been shown in simulations for 
complex phenotypes even when linkage was the result of a single gene [44]. The authors studied 
frequency distributions and the variation in peak location when increasing family size in a study. 
As the number of families increased, the distribution becomes taller and more narrow (ie. 
variation in peak location decreases and the frequency of observations increases in the central part 
of the distribution). In fact, variation in position covered as much as 10s of cM with family sizes 
of 200 and 400. Our own linkage study was performed with considerably less than 200 families 
(n = 14); the number of families picked for this study was powered to detect heritability not 
linkage. The degree of variation observed is considered consistent with linkage studies where the 
effect size is weak. Moreover, every genetic mapping study is specific to the environment in 
which the experiment was conducted. Despite our best efforts to control environmental 
variability, there are environmental factors which can result in differences in cytotoxic response 
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[45, 46]. This emphasizes the need for complimentary studies to narrow down these chromosomal 
regions of interest indentified in our linkage studies. On the other hand, it seems at least plausible 
that QTLs identified across all compounds within a mechanistic class may in fact be the result of 
the same gene despite variation in location. 
Taken together these results are encouraging. Preliminary evidence suggests that the biological 
and genomic profiles established in the CEPH cell lines may stratify compounds by mechanism. 
The ultimate goal of this project is to use the biological and genomic profiles of compounds as a 
predictive model for drug discovery. An expansion of the database, validation of QTLs and 
biological profiles identified as class specific, and progress in data-mining methodology are 
necessary to reach this end. Additional compounds with known mechanisms can be seeded into 
the chemical library. For example, this process could be repeated with the NCI Developmental 
Therapeutics Approved Oncology Plated drug set which includes 88 compounds (some of which 
were covered in this study) 
(http://dtp.nci.nih.gov/branches/dscb/oncology_drugset_explanation.html). Additionally, while 
compounds could be stratified by mean viability at the 50GI  future studies should include a full-
dose response curve to ascertain GI50s for individual cell lines. An informatics model which 
could rapidly assess and compare patterns of QTLs associated with a drug to others previously 
evaluated in this system is highly desirable. Moreover, integration of the in vitro sensitivity data 
such as the GI50 or AUC associated with each cell line and each drug could further serve to 
stratify compounds by mechanism. These advancements would further support investigations to 
identify genes involved in drug mechanism which influence cytotoxic response and make 
predictions about the activity and action of novel compounds as they become available.  
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Figure 4-1. Distribution of mean viabilities for CEPH cell lines at 50GI . Line represents median 
viability across population, box represents 90 and 10th percentiles, and whiskers represent 
maximum and minimum viabilities. 
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Figure 4-2. Hierarchical clustering of 22 
anticancer drugs based on cell viability at 
50GI . Cell viability for each cell line was 
z-score transformed prior to cluster analysis 
using the complete linkage method using the 
Pearson correlation as distance. On the color 
scale, red represents resistance (positive z-
score), green represents sensitivity (negative 
z-score), and black color indicates Z-score = 
0 (median resistance value). The brighter the 
color the greater the value from 0, with max 
brightness set at 2.5. 
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Figure 4-4. Genome wide pattern of QTLs for mechanistic set. Drugs are divided into mechanistic 
classes A-H as described in Table 4-1. Each chromosome was partitioned into 10 cM regions. Each 
drug-dose combination that resulted in a significant QTL (LOD >significance threshold) is indicated 
in blue. Intensity of the shading indicates the number of doses replicating that QTL at either the 
suggestive or significant level. Regions which also had a suggestive QTL (LOD > suggestive 
threshold) are indicated in green with color intensity referring to the number of doses replicating this 
peak. 
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Figure 4-5. Genome-wide QTL map for oxaliplatin and carboplatin. These platinum analogs are two 
structurally and functionally related drugs. Each chromosome is represented by a different color. 
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Figure 4-6. Shared QTL on chromosome 3 for oxaliplatin and carboplatin.  
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Table 4-1. Chemotherapeutic agents used in this study. 
 
Drug Name Abbreviation Mechanism of action 
5-Fluorouracil 5FU Thymidylate synthase inhibitor 
Floxuridine Flox Thymidylate synthase inhibitor 
Epirubicin Epi DNA intercalators and topoisomerase 2 inhibitors 
Doxorubicin Dox DNA intercalators and topoisomerase 2 inhibitors 
Daunorubicin Daun DNA intercalators and topoisomerase 2 inhibitors 
Idarubicin Ida DNA intercalators and topoisomerase 2 inhibitors 
Vincristine Vinc Microtubule destabilizers 
Vinorelbine Vino Microtubule destabilizers 
Vinblastine Vinb Microtubule destabilizers 
Docetaxel Doc Microtubule stabilizers 
Paclitaxel Pac Microtubule stabilizers 
Oxaliplatin Oxal DNA crosslinkers 
Carboplatin Carbo DNA crosslinkers 
Etoposide Etop Topoisomerase 2 inhibitors 
Teniposide Teni Topoisomerase 2 inhibitors 
Topotecan TPT Topoisomerase 1 inhibitors 
Camptothecin CPT Topoisomerase 1 inhibitors 
Irinotecan CPT-11 Topoisomerase 1 inhibitors 
7-ethyl-10-hydroxy-
camptothecin 
SN38 Topoisomerase 1 inhibitors 
9-aminocamptothecins 9AC Topoisomerase 1 inhibitors 
9-nitrocamptothecin 9NC Topoisomerase 1 inhibitors 
Bleomycin Bleo Other 
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T able 4-2.T Heritability estimates and shared QTLs for mechanistic sets. 
 
Drug 
Identified in this study Previously reported 
Ref. 
h P2 P(%) 
shared QTLs 
(Chr) h P
2 
P(%) 
shared QTLs 
(Chr) 
Bleo 0.00-15.09 2,7,8,16    
5FU 0.00-30.85 3,7,9,13,19 
26-65 9,16 [13] 
Flox 11.41-25.54    
Epi 2.30-62.40 
1-6, 8, 11, 13,16 
   
Daun 13.40-37.12 18-63 4,16 [21] 
Dox 0.01-34.12    
Ida 3.93-48.95    
Carbo 13.51-40.57 2,3,5,7,11,20 
38-47** 1,12** [14] 
Oxal 13.03-49.74    
Pac 7.77-53.24     
Doc 13.45-31.17 1,7,11 21-70 5,6,9 [13] 
Etop 23.76-42.42 6,7,12,13,18 
   
Teni 19.94-37.72    
Vinb 0.01-35.86 
1,7 
   
Vino 0.00-36.75    
Vinc 9.00-24.40    
9AC 0.00-22.72 
1,5,6,11,16,20 
   
9NC 0.00-24.72    
CPT 0.00-23.49    
CPT11 0.00-23.79    
SN38 0.00-18.24    
TPT 0.00-25.92    
 
Growth-rate adjusted heritability estimates were calculated for each drug-dose phenotype and a listed 
as a range. Drugs are arranged by mechanistic class. 
*In some cases, heritability estimates were previously reported following evaluation in CEPH cell 
lines. 
**Heritability estimates for increasing concentrations of cisplatin.  
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Table 4-3. Variation in peak location for significant QTLs on chromosome 20 shared by 
camptothecins. 
 
Drug Dose (M) Peak start cM 
Peak end 
cM LOD 
SN38 8.00E-06 42.28 86.98 2.134
SN38 5.00E-06 42.28 77.75 1.731
SN38 8.00E-05 40.55 72.27 1.673
CPT11 0.002 46.71 78.29 1.704
CPT11 0.006 42.28 72.27 1.577
CPT11 0.01 42.28 72.27 1.705
TPT 1.00E-08 42.28 46.71 1.033
TPT 1.00E-08 72.91 101.22 1.749
CPT 8.00E-05 47.52 54.09 1.106
CPT 8.00E-05 55.74 61.77 1.273
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1. SUMMARY 
The pharmaceutical industry is suffering from a severe productivity crisis. The number of new 
drugs entering clinical development, being submitted to regulatory agencies, and being made 
available to patients appears to be declining at the same time that the cost to bring therapeutics to 
market is escalating. Bringing a new molecular entity (NME) to market is associated with 
considerable expense; an estimated $800 million is spent on drug discovery, evaluation and 
clinical trials for every NME which enters the market. This represents an estimated a 54% 
increase in the cost from 1995-2002 [1]. Unfortunately, the number of drugs reaching market is 
not proportionate to the exponential rise in pharmaceutical research and development costs. In 
fact, the last decade has seen a decline in the number of new drugs. In 2006, only 18 drug 
approvals for new molecular entities were granted by the FDA, an 84% drop from a peak of 110 
new drugs in 1996 [2]. Finally, the drug discovery process has generally been rather slow. It has 
typically taken 10-15 years, and often very much longer, to progress from the start of the 
discovery phase to the launch of a successful new drug product. Drug development is becoming 
increasingly challenging, inefficient, and costly.  
Many argue that the decline in productivity coincides with the industry’s switch from the 
phenotypic to the target based drug discovery approach. The limitations of this approach are 
significant [2-5]. The greatest weakness is our inability to predict safety and efficacy in man, the 
most frequent cause of drug failure [6]. If productivity is to improve, the FDA suggests new and 
innovative drug discovery tools are needed: 
“Not enough applied scientific work has been done to create new tools to get 
fundamentally better answers about how the safety and effectiveness of new 
products can be demonstrated in faster time frames, with more certainty, and 
lower costs. In many cases, developers are using the tools and concepts of last 
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century to assess this century’s candidates. As a result, the vast majority of 
investigational products fail that enter clinical trials [7].” 
The FDA tasks the industry with developing highly effective drugs with minimum or predictable 
side effects and toxicity, cheaper and faster. Consequently, tools which give us greater insight 
into a drug’s mechanism of action, toxicity, and resistance are in high demand. 
The use of genomics as a tool to identify pharmacokinetic and pharmacodynamic genes which are 
associated with lapses in drug safety and/or efficacy is on the rise [8-13]. However, many genes 
and their gene products are investigated based on a priori knowledge of their involvement in drug 
action. Our limited knowledge of drug action is insufficient and will be unable to explain all of 
the observed differences in toxicity and efficacy between patients. Research is ongoing to identify 
genomic tools which might be able to offer incisive information about a drug’s global mechanism 
of action, proteins involved in its ADME, primary and secondary targets associated with efficacy, 
and all affected molecular pathways. The most prominent example of this effort is the 
chemogenomic database developed with the NCI. More than 100,000 compounds have been 
screened for biological activity in the NCI60, a panel of human cancer cell lines. Compounds 
have been broken down into their molecular scaffolds and their biological activity linked to the 
gene expression profiles of the NCI60. This enables researchers to make predictions about which 
key structural features will be biologically active, the genes which might be critical to their 
activity, and the cancers which are sensitive or resistant to active compounds. 
Our lab is in the preliminary stages of developing a drug discovery tool that uses natural genetic 
variation in normal healthy human cell lines to make inferences about drug mechanism. The 
objective of Chapter 2 was to demonstrate that pharmacological and genomic profiles in the 
CEPH cell lines can be established for compounds sharing a mechanism of action. To this end, 
cell growth inhibition in 125 CEPH cell lines (14 families) was evaluated following treatment 
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with a panel of camptothecin analogues. Considerable phenotypic variation was observed across 
and within families. The cytotoxic response to each agent was shown to be a heritable trait. We 
estimated genetics accounts for 23.1 ± 2.6% of the variation in response to the camptothecins. 
Linkage analysis was used to identify a relationship between genetic markers and the response to 
camptothecins. The camptothecins shared ten quantitative trait loci (QTL) on chromosomes 1, 3, 
5, 6, 11, 12, 16 and 20. Nine of these QTLs were independently validated in a second set of 
camptothecin analogues. Moreover, the genomic profiles of the camptothecins were quite distinct 
from those of the podophyllotoxins, Top2 inhibitors. 
In Chapter 3, we sought to independently validate these QTLs and identify which might be 
associated with the general mechanism of Top1 inhibition versus camptothecin-specific induced 
cytotoxicity. We repeated the phenotyping study for seven of the original camptothecins from 
Chapter 2. Seven of the nine QTLs were reproduced. CEPH were then phenotyped for sensitivity 
to the indenoisoquinolines, Top1 inhibitors, and nonparametric linkage analysis was used to 
identify QTLs associated with response. Four QTLs were shared between all of the camptothecins 
and the indenoisoquinolines; the remaing three were specific to the camptothecins. Eight were 
linked to the indenoisoquinolines alone. 
In Chapter 4, we tested whether specific patterns of biological and genomic profiles could be 
defined for mechanistic classes of compounds. The goal was to evaluate whether pharmacological 
and genomic profiles in CEPH cell lines could be used to stratify drugs by their mechanism. 
Twenty-two anticancer agents belonging to eight mechanistic classes were evaluated for cellular 
sensitivity in a panel of CEPH cell lines. Heritability estimates ranged from 5-64%. Then, linkage 
analysis was used to correlate variation in response to variation in regions of the genome for each 
drug investigated. We were able to show using cluster analysis, correlation coefficients, pattern 
recognition, and principle components analysis that these biological and genomic profiles in 
CEPH are unique to each mechanistic class. 
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Taken together, we have shown illustrative studies in which this model can be used to (i) 
establish a pharmacological and genomic profile for compounds sharing a mechanism, (ii) refine 
regions of the genome influencing drug activity to those which are associated with the general 
mechanism and those which are class-specific and (iii) stratify compounds by mechanism using 
biological and genomic profiling. Our results may have a positive impact on the drug discovery 
process which has been tasked with developing safer and more effective drugs by cheaper and 
faster means. The conventional phenotypic based screening approach to drug discovery is 
hindered tremendously by target identification which can take as much as 10 years or more [14]. 
Likewise, the ability to predict off target effects for small molecules discovered through the 
target-based approach is limited [2]. Without a clear understanding of mechanism, drugs derived 
from these routes have an increased risk of failure due to unanticipated toxicity. The nature of our 
assay permits mechanism elucidation by simultaneously screening of all possible genes and 
pathways in a single experiment, consequently streamlining the drug discovery process. 
Moreover, the genomics component of this strategy makes it possible for us to make predictions 
about which patients would benefit or be harmed by a given therapy prior to its use in costly 
clinical trials. 
2. FUTURE DIRECTIONS 
Regardless of the method used to identify potential genes and proteins involved in drug activity, 
the most important step is to confirm their involvement in mechanism. In Chapters 2 and 3, QTLs 
likely to contain the genes important for the observed differences in response to all Top1 
inhibitors, were identified using genome-wide linkage analysis. This method has narrowed the 
search for the causative genes from the entire genome to a significantly smaller and more 
manageable subset. Specifically, the effects of camptothecins and indenoisoquinolines were 
mapped to chromosomes 1, 5, 11, and 16. By narrowing these regions of interest further to genes 
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which are expressed in the CEPH cell lines, an unbiased candidate gene list can be formed (Table 
3-5). The whole genome linkage studies, such as those described in this dissertation, require 
family based samples, are typically powerful for genes with large effect sizes and indentify large 
regions of the genome linked to the phenotype of interest. Alternatively, association studies use a 
large collection of unrelated individuals are powerful for detecting genes with small effect sizes 
and will pinpoint small intervals of the genome associated with a phenotype. Cytotoxic response 
to chemotherapeutic agents is a dependent on multiple genes, each with have a small independent 
effect. Follow-up genome wide association studies (GWAS) in an independent sample could not 
only be used to independently replicate regions of the genome identified through linkage analysis, 
but to minimize false discovery, and narrow these broad QTLs down to smaller intervals. Both 
the Children’s Hospital of Oakland Research Institute (CHORI) 
(http://www.chori.org/Principal_Investigators/Krauss_Ronald/krauss_research.html) and the 
National Heart, Lung, and Blood Institute’s Farmingham Heart Study 
(http://www.framinghamheartstudy.org/participants/index.html) have collected and genotyped 
large collections of lymphoblastoid cell lines from unrelated Caucasian individuals which could 
be used for drug response profiling and genome wide association studies. 
Any candidate genes identified through GWAS or from linkage analysis which are attributed to 
the general mechanism of Top1 inhibition and camptothecin-specific induced cytotoxicity (Table 
3-5) can also be pursued using RNA interference (RNAi). Functional validation of candidate 
genes from CEPH studies have previously been reported using gene knockdown by RNAi. For 
example, in a study to identify genes influencing sensitivity to carboplatin knockdown of CD44 
expression through small interfering RNA (siRNA) resulted in increased cellular sensitivity in 
CEPH cell lines [15]. Also in the CEPH model, down regulation of NT5C3 and FKBP5 by 
siRNA was associated with altered sensitivity to gemcitabine and cytosine arabinoside (AraC) 
respectively [16]. Our lab is working to develop a high throughput method to study all potential 
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genes under QTLs of interest using gene expression knockdown with short hairpin RNAs 
(shRNA). Additionally, individual CEPH LCLs used in this study which were highly sensitive 
and resistant to the camptothecins (upper and lower 10% of IC50s) have been identified (Table 
A2-3). Candidate genes identified from gene knockdown experiments can be sequenced in this 
subpanel to ascertain whether genetic variants correlate to the observed variation in response. We 
should also examine whether gene expression correlates to genotype using real-time quantitative 
RT-PCR. This same process can be applied to the QTLs unique to the other mechanistic classes 
in this study. 
The ultimate goal of this project is to use the biological and genomic profiles of compounds as a 
model for getting at the mechanism of action for drugs. In Chapter 4, the preliminary ground 
work was laid for this objective. An expansion of the database (ie. more drugs), validation of 
QTLs and biological profiles identified as class specific, and progress in data-mining 
methodology are necessary to reach this end. Currently, investigations of genomic relationships 
with cellular sensitivity are often completed by analyzing a summary measure of the dose-
response curve such as the GI50. A considerable number of significant QTLs were identified 
across multiple doses of each drug investigated, more than were identified by linkage analysis for 
variation in GI50 for each drug. An informatics model which could rapidly assess and compare 
patterns of significant QTLs associated with all doses of a drug to the others previously evaluated 
would be helpful. Moreover, a number of systems have been described which summarize the 
biological performance of a compound in a cell line panel by a single parameter such as the GI50. 
Investigating other parameters such as slope or area under the curve (AUC) might lend more 
insight into drug action. Not only might they prove ideal biological parameters for classifying 
drugs according to mechanism, but linkage analysis on slope or AUC may identify genomic 
regions directly related to the differences in therapeutic indexes (ratio of amount of drug required 
to produce a therapeutic effect to amount which causes a toxic effect) among individuals. Both 
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slope and AUC would also be rapidly amenable to database generation for biological profiling of 
compound libraries. 
In addition to validating the reported genomic regions and genes influencing the activity of the 
drugs in this investigation, some technical limitations of this study need to be addressed. The 
technique used to immortalize LCLs has the potential to confuse results. LCLs used in this study 
are derived from normal B-lymphocytes which have been immortalized using the Epstein Barr 
virus (EBV), a member of the herpesviruses family. EBV is not unusual as it infects over 90% of 
the human population and persists in the latent phase for the lifetime of the host 
(http://www.cdc.gov/ncidod/diseases/ebv.htm). EBV genes critical for the immortalization of B 
cells have been identified and extensively studied. Some of these gene products can induce 
differential expression in host cells [17]. To date, it is unclear whether EBV transformation has 
affected gene expression and drug sensitivity in CEPH LCLs. Welsh points out natural variation 
in gene expression in CEPH LCLs clusters by family which suggests that gene expression is 
directed by genetic factors rather than EBV transformation [18, 19]. The EBV genome contains 
the capacity to express at least 80 gene products, only 11 of which are expressed in LCLs [20, 
21]. Treatment with sodium butyrate or phorbol esters can induce the lytic cycle and expression 
of the EBV genome in EBV-immortalized B cells [22]. Drugs used in this study could also 
activate the viral lytic phase, resulting in genetic changes which may confound cellular sensitivity 
results [23]. The expression of EBV viral proteins has also been linked to the inactivation of cell 
cycle checkpoints and DNA repair machinery induced by drug exposure in B-cell lymphomas 
[24-26]. The apoptotic response to some but not all anticancer drugs has been altered in EBV-
positive lymphomas [19, 27, 28]. More research is required to ascertain whether this also occurs 
in normal immortalized B-lymphocytes. Moreover, differences in sensitivity to several anticancer 
agents were noted pre- and post-immortalization of LCLs [29]. Clearly, this could pose a problem 
in the identification of genes responsible for the therapeutic activity of many anticancer agents. 
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A thorough investigation of the effect of EBV transformation on gene expression and drug 
sensitivity in the CEPH cell lines is essential. The presence of the viral proteins BZLF1 and 
BRLF1 indicate activation of the viral lytic phase. To rule out the contribution of EBV to cellular 
sensitivity, the expression levels of these genes can be quantified by real-time RT-PCR before 
and after treatment with increasing concentrations of each drug used in this study [30]. Treatment 
with sodium butyrate or tetradecanoyl phorbol acetate (TPA) activate the viral lytic phase in 
Daudi, Akata or Raji cell lines (EBV-positive B cell lymphomas) and could be used as positive 
controls. EBV-negative B lymphocytes such as, DG75 [31], BJAB, or Ramos could be used as 
negative controls. Epstein-Barr virus (EBV) genome-chips have also been employed to examine 
EBV gene expression patterns in tumor biopsies [32]. Finally, the UNC Lineberger 
Comprehensive Cancer Center Tissue Culture Facility uses a protocol for EBV-immortalization 
of B-lymphocytes which is similar to the methods outlined in publications for the collection of 
CEPH LCLs (http://www.unclineberger.org/tcf/protocols_GPI.asp) [33]. It may be possible to 
perform a genome wide analysis of cellular genes differentially expressed pre and post-EBV 
immortalization of primary human B-lymphocytes [34].  
Another potential confounder is the variation in LCL growth rate observed over time and between 
individuals. One study reported that EBV copy number, ATP levels, and growth rate were 
confounders in cellular sensitivity to a number of drugs including the anticancer agents: 5-
fluouracil, methotrexate, and 6-mecapoturine [35]. While the Dolan laboratory found no 
correlation between EBV copy number or ATP levels and sensitivity to chemotherapeutic agents, 
cellular growth rate did appear to have a direct relationship with cellular sensitivity (Dolan, ME, 
communication IPIT visiting scholar seminar series). This was not unexpected. Many antitumor 
agents are preferentially toxic to rapidly proliferating cells, therefore the rate of cellular 
proliferation is related to cellular sensitivity  [36]. Dolan et al., also reported a strong correlation 
between cell proliferation rate and cytotoxic response to the anticancer agents, carboplatin and 
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cytarabine arabinoside (ara-C) [37, 38]. Heritability estimates of cellular growth rate in CEPH 
LCLs across vehicles in these studies ranged from 1-14%. To account for the effect of growth 
rate on response to chemotherapeutic drugs, dose-response curves can be adjusted for growth rate 
[35]. 
CONCLUDING REMARKS 
High throughput screening in the CEPH cell lines has the potential to be an awesome predictive 
tool for drug discovery. Biologic and genomic profiles could be established for compounds 
belonging to the same mechanistic class. Results suggest that intraclass pharmacological and 
genomic profiles in the CEPH are more similar to each other than to compounds belonging to 
distinct mechanistic classes. Structurally unrelated compound belonging to the same mechanistic 
class produced similar but distinct profiles. These results suggest that with further work, profiling 
might not only suggest mechanisms of action for novel compounds (based on biological and 
genomic profiles), but point to the genes which are critical to drug action, and enable 
investigators to predict which patients will be sensitive or resistant to that drug.  
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INTRODUCTION 
Current therapies for the majority of cancers consist of radiation chemotherapy, and small 
molecule therapies including DNA alkylating agents, antimitotic agents, DNA antimetabolites, 
and Topoisomerase inhibitors. Unfortunately, the response to these agents varies widely. 
Commonly used chemotherapeutic drugs provide a cure for some, confer no therapeutic benefit or 
even trigger severe side effects in others. The pharmacological effect of a drug, its mechanism of 
action, is determined by its interplay with numerous proteins involved in pathways of drug 
absorption, distribution, metabolism, and effect; variants in any one of these processes may affect 
drug response. In addition, most proteins involved in these processes function in complex 
networks with several mechanisms of regulation. Being able to predict the therapeutic response 
and potentially life threatening toxic effects associated with a particular chemotherapeutic agent 
requires extensive knowledge of the direct target effects and cellular consequences associated 
with a drug’s activity. 
A multigenerational collection of lymphoblastoid cell lines derived from the Centre d’Etudie 
Polymorphisme Humain (CEPH) have been used in a global approach to identifying genes and 
gene products responsible for a drug’s cytotoxic effect. Waters et al. (2004) and Dolan et al. 
(2004) have used CEPH families to identify genes influencing the cytotoxicity activity of 5-
fluorouracil and cisplatin respectively. In each case, CEPH pedigrees were phenotyped for 
sensitivity to an anticancer agent. Phenotyping allowed researchers to establish heritability, the 
proportion of variation in response resulting from a genetic component, and then regions of the 
genome responsible for cytotoxicity.  
In this work we will use familial genetics to identify genes linked to the cytotoxicity of 
structurally similar pharmacologically active agents and use those genes to further elucidate 
mechanisms of action. We will establish a correlation between chemical substructure, mechanism 
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of action, and inherited response. The following is a detailed method to design, and optimize an 
in vitro CEPH cytotoxicity phenotyping assay. This assay will be used to conduct high 
throughput screens to establish mechanisms of action for large compound libraries. 
MATERIALS AND METHODS 
Cell lines. Epstein-Barr virus-immortalized lymphoblastoid cells derived from 14 CEPH 
reference pedigrees (35, 45, 1334, 1340, 1341, 1350, 1362, 1408, 1420, 1447, 1451, 1454, 1459) 
were purchased from Coriell Cell Repositories (Camden, New Jersey). Cells were maintained in 
RPMI medium 1640 (Invitrogen, Rockville, MD) supplemented with 15% fetal bovine serum, 
incubated in a 5% CO2 atmosphere at 37◦C, and passaged 2 times per week. Exponentially 
growing lymphoblastoid cell lines with greater than 85% viability, at passages 3-7 were used for 
experimentation.  
Length of Alamar Blue Exposure and Optimal Cell Count. Black-clear bottomed 384 well 
plates obtained from Corning (Corning, NY) were used for these and all other experiments. Cells 
were counted in the log phase of growth using a Z1 Coulter Particle Counter (Beckman, 
Fullerton, CA) and plated at densities ranging from 500-40,000 cells per well (45 ul/ well). 
Control wells of medium alone were used to provide the background signal for fluorescence 
readings. Alamar Blue (5 ul, Invitrogen) was then added to each well and plates incubated in 5% 
CO2 at 37◦C for 4, 6, 12, or 24 h before reading the plate using a Beckman DTX 880 fluorescence 
microplate reader (Ex = 535 nm and Em = 590 nm). 
To evaluate the quality of the assay for high-throughput screens (HTS), the coefficient of 
variance (CV), signal-to-background ratio (S:B) and the Z’-factor were determined using the 
following formulas [1] (Zhang et al., 1999): 
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(1)   CV = σn/ μn 
(2)   S:B = μs/μb  
(3)   Z’ = 1 – [(3σs+3σb)/(μs-μb)] 
where the subscript n refers to the replicate viability measures, s refers to the maximum assay 
signal and subscript b is the minimum signal, σ is the standard deviation, and μ is the mean signal 
in each condition. An assay is considered robust enough for HTS when conditions result in CVs 
for replicates < 10%, Z’ > 0.5 and S:B > 5. 
Plate Uniformity and Signal Variability Assessment. Uniformity tests were conducted on three 
types of signals varied systematically so that over all plates on a given day each signal is 
observed in every well. The maximum signal, cells treated with vehicle (0.1% DMSO), was 
considered 100% cell viability. Minimum signal or background was achieved by treating cells 
with 10% DMSO. Camptothecin (16 nM) was selected to give values between the maximum and 
minimum signals. Cells (4000 cells/well) were exposed to treatment for 72 h, alamar blue added, 
and the plate read at 96 h. The plate uniformity assay was performed twice over 2 consecutive 
days. Cell viability was assessed using the following equation:  
(4)   ⎟⎟⎠
⎞
⎜⎜⎝
⎛
−
−=
backveh
backdrug
RFURFU
RFURFU
Viability 100(%)  
where RFUdrug is the average relative fluorescence units (RFU) of cells in the presence of test 
compounds (i.e., camptothecin), RFUback is the average RFU in the presence of 10% DMSO, 
RFUveh is the average RFU of cells treated with PBS (0.1% DMSO). 
Automated Pipetting Accuracy. Several programs designed for the delivery of 5 ul (the volume 
used for both drug and alamar blue dispensing) to each well on 384 well plate using the Biomek 
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3000 were compared for accuracy. For each program, fluorescein (1mM, 5 ul/well) was dispensed 
into all wells of two replicates plates and fluorescence read using a DTX 880 fluorescence 
microplate reader (Ex = 535 nm and Em = 590 nm) to determine dispensing CVs for each plate. 
Between-run, Intra- and Inter-day Variability. To examine between-run variation, two 
separate 10 mM stock solutions of camptothecin in DMSO were prepared, serially diluted (0.01 
nM–100 uM camptothecin, final concentration 0.1% DMSO), and added to two separate 96 well 
master plates. Drug solutions (5ul) from master plates were transferred in quadruplicate to 384 
well plates using the Biomek 3000. Cells (4000 cells/well) were exposed to drug for 72 h, alamar 
blue added, and the plates read at 96 h. Percent viabilities and IC50s were compared between the 
different drug preparations. For intraday (or plate-to-plate) and interday (or day-to-day) 
variability, a single set of drug serial dilutions was prepared in a 96 well master plate and 
transferred to four 384 well plates. Half of the 384 well plates were used for experimentation that 
day. The remaining half of the 384 well plates were stored at -20 C and used the following day 
for interday variability assessment of the cytotoxicity assay. These experiments were performed 
using all camptothecins and evaluated in 3 different CEPH cell lines. 
pH and Long Term Stability. Stock solutions were made by dissolving the pure drugs in DMSO 
to 10 mM. Working solutions were made by diluting the stock solutions in PBS at pH 7 or citrate-
phosphate buffer at pH 3.0. Five 384 well plates were prepared which contained working 
solutions of camptothecin, 9-aminocamptothecin, and SN38 in both pH 7 and pH 3 buffer. Three 
of these plates were frozen and used for interday, week-to-week, and month-to-month stability 
studies. Cells (4000 cells/well) were added to two -384 well plates containing increasing 
concentrations of drug and incubated for 72 h. Alamar blue was added, fluorescence read after 24 
h exposure, and intraday variability assessed. This experiment was evaluated using three different 
cell lines. 
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RESULTS AND DISCUSSION 
Cell-based assay optimization begins with optimizing the number of cells per well and 
maximizing the difference between maximum and minimum raw fluorescence signals. 
Optimization of specific assay conditions (drug concentrations, pH, DMSO compatibility, etc) 
follows. Once the assay is developed, it is assessed for HTS compatibility by testing fluorescent 
signal stability, drug stability, and assay variability. These are critical factors for determining 
throughput and capacity of the assay and the ability to reliably identify distinctions between 
compound sensitivity. Finally, the fully developed and optimized high-throughput assay can be 
used for the screening of compound libraries in CEPH cell lines.  
Cell Number and Length of Alamar Blue Exposure. There are many commercially available 
vital dyes used for cell viability and cytotoxicity assays. The generic alamar blue wasvchosen 
because it is non-toxic, readily detectable by fluorescence and absorbance, and has increased 
sensitivity in cytotoxicity assays when compared to other vital dyes such as MTT [2]. Moreover, 
the lack of cell washing, media removal, and multiple pipetting steps makes the assay ideal for 
HTS cell viability and cytotoxicity measurements. An assay is considered robust enough for high 
throughput screening if z’ is greater than 0.5 and S:B is greater than 5. Plating 4000 cells/well 
with 24 h alamar blue exposure reproducibly met these conditions. 
Cells were seeded into 384 well plates at densities ranging from 500-40,000 cells per well (45 
ul/well) and fluorescence was measured following 4, 6, 12, or 24 h exposure to alamar blue. At 
each time point, relative fluorescence increased with increase in cell number. Higher cell 
densities and longer Alamar blue exposure resulted in a departure from linearity (Figure A1-1a). 
The data in Figures 1 and 2 were used to calculate S:B and Z’-factor values as an indicator of 
stability of the assay for HTS. Z’-factor and S:B improve for longer incubation at lower cell 
numbers leading to an increase in assay sensitivity (Figure A1-1). Growth rate for cell lines does 
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vary (Figure A1-1b), results in a difference in relative fluorescent intensities and has an impact on 
the assay Z’-factor (Figure A1-1c). The average Z’-factor for 24 h incubation with alamar blue at 
5000 cells/well was 0.67 and 0.83 for the slow growing CEPH cell line 12771 and the fast 
growing cell line 12141 respectively. For 12771, S:B and Z’-factor improve significantly with 
increase in cell number at 24 h Alamar Blue exposure (Figure A1-1c).  
Plate Uniformity and Signal Variability. Percent viability should be tight at each signal 
(maximum, midpoint, or minimum) across all well locations on a plate. A scatter plot of viability 
for each signal type against well number (Figure A1-2) can indicate sources of systematic 
variability such as drift or edge effects within an assay. Values are sufficiently tight across plates 
for mid and min signals with no apparent drift. However, signals in the outer perimeter of the 
plate are consistently greater than those from interior wells (Figure A1-2). These edge effects are 
often the result of evaporation or plate stacking. When designing drug plate formats, this 
information was taken into account. Negative control (10% DMSO) and the highest drug 
concentrations were applied to the plate perimeter and concentrations likely to yield the most 
variation for our study were placed in the interior. 
Automated Pipetting Accuracy and Drug Plate Preparation. This assay depends on accurate 
and reproducible delivery of drug and alamar blue with a liquid handler. Because the 
concentrations of drugs are volume dependent, inaccurate volume transfers will directly impact 
assay results. We used the fluorescent dye, fluorescein, to assess dispensing reproducibility J 
Biomol Screen 2004; 9; 726. Two different programs were designed to prepare 384 well plates 
with 4 replicate dispenses of 5 ul. For each program, fluorescein to all wells of two replicates 
plates. Program 1, which aspirated 25 ul of dye and dispensed 5 ul four times to four wells, had 
an average CV of 18.6% for each plate. Program 2, which was a single 5 ul aspirate followed by a 
single 5 ul dispense over four replicate wells, resulted in average CVs of 5.3%. Programs using a 
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single aspirate and dispense for delivering drug or alamar blue to assay plates were subsequently 
used for all experiments. 
Cytotoxicity Assay and Concentration Profiling. To identify the appropriate drug exposure 
time for CEPH cell lines, cytotoxicity was evaluated using the camptothecins over a wide 
concentration range (0.1 nM-10 uM). Cell viability was monitored after 48, 72, and 96 h exposure 
to drug (Figure A1-3). The 96 h drug incubation was considered appropriate for our purposes 
since 100% viability was observed at the lowest concentrations and the curve went below 20% at 
the highest concentrations for all drugs studied. For all drug studies, cells were plated and treated 
with drug for 72 h, alamar blue added, and the plates read at the 96 h time point. 
Assessment of Between-run, Intra- and Inter-day Variability. If the concentration of buffer 
components or drug serial dilutions prepared in stock plates differs between runs then assay 
results could be affected. This difference will only show up when comparing one run to another 
run and is defined as between-run variation. To examine between-run variation, two separate 10 
mM stock solutions of camptothecin in DMSO were serially diluted to the same concentrations 
and percent viability assessed. There was no observed difference between the two runs (Figure 
A1-4a). Similarly, plates prepared and drug cytotoxicity assessed on Day 1 were compared to 
plates thawed and used two days later (Figure A1-4b). No significant difference was observed 
between days. 
Effect of pH on Viability and Assay Stability. Camptothecins have a labile lactone form that 
exists in a pH dependent equilibrium with the inactive carboxy form. At basic pH, the carboxy 
form predominates. Changing the pH of working solutions buffers from pH 7 to pH 3 was 
expected to increase the concentration of active camptothecin. Greater cell kill is observed at 
lower concentrations when pH 3 buffer is used and the dose-response curve shifts to the left when 
compared to pH 7 (Figure A1-5a). There appears to be little intraday variability for both working 
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solutions at pH 3 and pH 7 within the slope and right tail of the curves (Figure A1-5b and A2-5c). 
To examine long term stability of these pH 3 and pH 7 working solutions cytotoxicity was 
examined 2 days (Figure A1-6), 1 week (Figure A1-7), and 1 month (Figure A1-8) after -20 C 
storage. Both preparations appear quite stable over all several freeze thaws and time frames 
studied. For HTS, working solutions prepared using citrate-phosphate buffer at pH 3 will be used. 
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Figure A1-1. Optimizing CEPH Phenotyping assay. (A) RFU as a function of cells plated per 
well following 4, 6, 12, or 24 h exposure to alamar blue. (B) Fluorescence signal following 24 h 
exposure to alamar blue for fast (12141) and slow growing (12771) cell lines. (C) Z’-factor and 
S:B values as a function of cell number. 
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Figure A1-2. Optimizing CEPH Phenotyping assay. Plate Uniformity and Signal Variability. Cell 
viability (%) following 96 h exposure to vehicle, drug, or 10% DMSO. All treatments were 
applied such that signal for every treatment was observed in every well on a 384 well plate (n=3 
plates). 
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Figure A1-3. Optimizing CEPH Phenotyping assay. Identifying duration of Drug exposure. Cell 
viability (%) following 48, 72, or 96 h exposure to increasing concentrations of camptothecin. 
The same cell line was used in each case. 
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Figure A1-4. (A) Between-run variability in response to camptothecin (r = 0.95). (B) Comparison 
of intra- and interday variability in cytotoxic response to increasing concentrations of 
camptothecin. (intraday r = 0.98; interday r = 0.96). 
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Figure A1-5. Representative examples of the effect of camptothecin stock solution pH on cell 
viability and assay stability. The same cell line was exposed to increasing concentrations of 
camptothecin in each case. (A) Camptothecin was diluted in PBS at pH 7 or citrate-PBS at pH 3. 
(B) Intraday variability in cytotoxic response at pH 3. (C) Intraday variability in cytotoxic 
response at pH 7. 
148
10 -2 10 -1 10 0 10 1 10 2 10 3 10 4 10 5
0.00
0.25
0.50
0.75
1.00
pH 3 day 1, IC50 5.2 nM
pH 3 day 2, IC50 4.5 nM
Concentration, nM
Vi
ab
ili
ty
 
10 -2 10 -1 10 0 10 1 10 2 10 3 10 4 10 5
0.00
0.25
0.50
0.75
1.00
pH 7 day 1, IC50 9.9 nM
pH 7 day 2, IC50 12.4 nM
Concentration, nM
Vi
ab
ili
ty
 
 
Figure A1-6. Representative examples of the effect of camptothecin stock solution pH on assay 
stability. The same cell line was exposed to increasing concentrations of camptothecin in each 
case. (A) Camptothecin was diluted in citrate-PBS at pH 3 and interday variability between plates 
compared. (B) Camptothecin was diluted in PBS at pH 7 and interday variability between plates 
compared. 
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Figure A1-7. Representative examples of the effect of camptothecin stock solution pH on assay 
stability. The same cell line was exposed to increasing concentrations of camptothecin in each 
case. (A) Camptothecin was diluted in citrate-PBS at pH 3 and week to week differences in cell 
viability assessed. (B) Camptothecin was diluted in PBS at pH 7 and week to week differences in 
cell viability assessed. 
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Figure A1-8. Representative examples of the effect of camptothecin stock solution pH on assay 
stability. The same cell line was exposed to increasing concentrations of camptothecin in each 
case. (A) Camptothecin was diluted in citrate-PBS at pH 3 and month to month differences in cell 
viability assessed. (B) Camptothecin was diluted in PBS at pH 7 and month to month differences 
in cell viability assessed. 
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Table A2-1. List of significant QTLs for the camptothecins 
 
Chr Drug Dose (mM) 
Peak 
Start 
(cM) 
Peak 
End 
(cM) 
Max 
Peak 
LOD 
1 9NC 1.00E-02 67.22 70.41 1.115 
1 9NC 1.00E-02 71.13 73.21 1.185 
1 SN38 2.00E-03 116.72 142.24 1.363 
1 hCPT 1.00E-03 125.51 136.34 1.495 
1 9NC 1.00E-02 145.45 147.6 1.073 
1 9NC 1.00E-02 149.2 150.27 1.184 
1 9NC 1.00E-02 162.57 168.52 1.269 
1 SN38 2.00E-03 229.13 252.12 1.389 
1 TPT 8.00E-05 232.81 252.12 1.855 
1 SN38 8.00E-05 233.38 252.12 1.501 
1 CPT11 6.00E-03 237.73 247.23 1.411 
1 CPT11 1.00E-02 237.73 247.23 1.295 
1 CPT11 5.00E-02 240.19 252.12 1.457 
2 IC50_hCPT 1.00E+00 215.78 216.31 1.031 
3 CPT 8.00E-05 5.54 8.31 1.216 
3 hCPT 2.00E-03 22.33 50.25 2.042 
3 SN38 3.01E-06 44.81 47.44 1.072 
3 SN38 3.01E-06 48.09 49.18 1.032 
3 SN38 3.01E-06 50.94 61.52 1.115 
3 SN38 3.01E-06 62.05 78.64 1.682 
3 CPT11 1.50E-03 65.26 75.41 1.675 
3 IC50_mCPT 1.00E+00 84.11 97.75 1.315 
3 IC50_mCPT 1.00E+00 99.38 101.55 1.103 
3 9NC 1.00E-02 151.49 173.34 1.638 
3 TPT 1.00E-02 151.49 158.38 1.375 
3 9NC 1.00E-02 173.76 174.94 1.088 
3 hCPT 5.00E-03 198.68 207.73 1.686 
3 9NC 1.00E-02 209.41 213.64 1.193 
4 CPT11 1.60E-05 161.04 166.85 1.112 
4 CPT11 1.60E-05 199.93 211.65 1.251 
5 CICPT 4.00E-01 0 6.67 1.961 
5 CICPT 2.00E+00 0 6.67 2.272 
5 CICPT 3.00E+00 0 6.67 1.864 
5 CICPT 4.00E+00 0 5.43 1.626 
5 mCPT 2.50E-02 49.54 51.99 1.174 
5 9NC 1.50E-05 54.79 74.07 1.853 
5 9NC 8.00E-06 63.6 68.63 1.242 
5 9NC 1.50E-05 92.38 93.59 1.045 
5 9NC 1.50E-05 102.62 123.45 1.54 
5 9NC 8.00E-06 111.97 140.72 1.709 
5 9NC 1.50E-05 124.47 136.33 1.394 
5 CPT 2.00E-06 137.39 161.4 1.685 
5 9NC 8.00E-06 141.82 155.92 1.19 
5 hCPT 8.00E-02 146.73 152.62 1.101 
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Chr Drug Dose (mM) 
Peak 
Start 
(cM) 
Peak 
End 
(cM) 
Max 
Peak 
LOD 
5 mCPT 8.00E-02 148.63 149.48 1.022 
5 hCPT 8.00E-02 162.16 174.8 1.384 
5 mCPT 8.00E-02 167.69 174.8 1.408 
5 mCPT 2.50E-02 171.06 177.92 1.746 
5 hCPT 8.00E-02 177.06 184.66 1.246 
5 mCPT 8.00E-02 177.06 187.81 1.305 
5 9NC 8.00E-06 182.35 189.23 1.356 
6 9AC 2.00E-03 0 29.93 1.528 
6 9AC 1.00E-02 9.18 11.89 1.304 
6 IC50_hCPT 1.00E+00 32.62 33.43 1.202 
6 IC50_hCPT 1.00E+00 42.27 42.98 1.008 
6 TPT 1.50E-05 42.27 53.81 1.652 
6 TPT 1.50E-05 57.96 65.14 1.106 
6 SN38 8.00E-06 68.65 80.99 1.376 
6 9AC 2.00E-03 76.62 78.85 1.112 
6 9AC 8.00E-06 87.29 89.23 1.125 
6 SN38 8.00E-06 87.29 89.23 1.195 
6 SN38 8.00E-06 91.34 117.29 1.613 
6 9AC 8.00E-06 92.25 107.25 1.659 
6 9AC 8.00E-06 112.2 124.64 1.252 
7 mCPT 1.00E-03 30.9 38.48 1.281 
7 CICPT 2.00E+00 58.86 62.87 1.085 
7 IC50_CPT11 1.00E+00 59.39 62.07 1.073 
7 CICPT 7.00E-01 61 125.15 2.604 
7 CICPT 5.00E-01 62.87 120.61 1.662 
7 IC50_CPT11 1.00E+00 62.87 72.78 1.611 
7 CICPT 1.00E+00 67.43 78.65 1.211 
7 CICPT 4.00E-01 70.64 73.84 1.198 
7 IC50_CPT11 1.00E+00 73.84 74.38 1.108 
7 CICPT 2.00E+00 77.91 78.65 1.087 
7 CICPT 1.00E+00 80.42 122.48 1.657 
7 CICPT 2.00E+00 80.42 125.15 2.351 
7 CICPT 3.00E+00 93.1 123.01 2.023 
7 CICPT 4.00E-01 97.38 120.61 1.62 
7 CICPT 4.00E+00 97.89 123.01 1.702 
9 9AC 1.60E-05 0 12.78 1.588 
9 9NC 1.00E-08 0 18.06 1.211 
9 CICPT 4.00E-01 83.41 104.48 1.772 
10 CPT 1.00E-07 2.13 13.49 1.475 
10 CPT 1.00E-07 32.8 37.9 1.111 
10 IC50_CPT11 1.00E+00 46.23 49.43 1.213 
10 IC50_CPT11 1.00E+00 56.89 69.7 1.626 
11 CPT11 1.00E-02 2.11 4.84 1.049 
11 IC50_9AC 1.00E+00 54.75 58.4 1.299 
11 IC50_9AC 1.00E+00 61.78 93.12 1.842 
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Chr Drug Dose (mM) 
Peak 
Start 
(cM) 
Peak 
End 
(cM) 
Max 
Peak 
LOD 
11 hCPT 8.00E-03 104.03 105.74 1.082 
11 IC50_hCPT 1.00E+00 104.03 105.74 1.051 
11 hCPT 8.00E-03 110.73 123 1.896 
11 CPT11 1.00E-02 126.21 129.02 1.352 
12 9AC 1.20E-05 0 6.42 1.705 
12 CPT11 4.00E-06 19.68 38.5 1.277 
12 CICPT 7.00E-01 95.56 104.65 1.627 
12 CICPT 1.00E+00 95.56 101.98 1.442 
12 CICPT 2.00E+00 95.56 104.12 1.646 
12 CICPT 3.00E+00 95.56 106.52 1.714 
12 mCPT 2.00E+00 95.56 119.55 2.052 
13 TPT 1.00E-08 0 19.36 1.365 
14 hCPT 5.00E-03 0 21.51 1.747 
14 TPT 8.00E-06 0 13.89 1.286 
14 hCPT 3.00E-03 8.28 34.43 1.673 
14 IC50_9AC 1.00E+00 8.28 9.36 1.029 
14 IC50_9AC 1.00E+00 12.46 13.89 1.014 
14 mCPT 2.00E-03 21.51 36.76 1.973 
14 hCPT 5.00E-03 26.59 27.01 1.026 
14 hCPT 3.00E-03 92.69 95.89 1.094 
14 hCPT 3.00E-03 98.96 111.27 1.15 
14 TPT 8.00E-06 98.96 111.27 1.677 
14 IC50_9AC 1.00E+00 105 134.3 2.354 
14 hCPT 3.00E-03 113.17 114.81 1.043 
14 hCPT 3.00E-03 115.2 125.88 1.242 
14 hCPT 3.00E-03 134.3 138.18 1.177 
15 mCPT 2.00E+00 20.24 39.72 1.81 
16 CPT 3.01E-06 1.08 10.36 1.345 
16 CPT 3.01E-06 29.97 34.22 1.019 
16 mCPT 3.00E-03 38.51 59.68 1.537 
16 mCPT 1.00E-03 40.65 66.1 1.318 
16 hCPT 1.00E-03 44.45 69.05 1.769 
16 mCPT 5.00E-03 57.79 65.77 2.287 
17 CICPT 3.00E+00 93.98 126.46 2.198 
17 CICPT 2.00E+00 95.99 126.46 1.985 
17 CICPT 7.00E-01 97.56 126.46 1.583 
17 hCPT 1.00E-04 98.14 114.41 1.557 
17 CICPT 5.00E-01 99.21 126.46 1.599 
17 CICPT 4.00E+00 99.21 126.46 1.684 
18 IC50_mCPT 1.00E+00 95.46 99.04 1.2 
20 SN38 8.00E-05 40.55 72.27 1.673 
20 CPT11 6.00E-03 42.28 72.27 1.577 
20 CPT11 1.00E-02 42.28 72.27 1.705 
20 SN38 5.00E-06 42.28 77.75 1.731 
20 SN38 8.00E-06 42.28 86.98 2.134 
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Chr Drug Dose (mM) 
Peak 
Start 
(cM) 
Peak 
End 
(cM) 
Max 
Peak 
LOD 
20 TPT 1.00E-08 42.28 46.71 1.033 
20 CPT11 2.00E-03 46.71 78.29 1.704 
20 hCPT 1.00E+01 46.71 48.85 1.144 
20 CPT 8.00E-05 47.52 54.09 1.106 
20 hCPT 1.00E+01 49.71 79.91 1.508 
20 CPT 8.00E-05 55.74 61.77 1.273 
20 TPT 1.00E-08 79.91 101.22 1.749 
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Table A2-2. Genes of interest and associated GO terms under chromosome 20 
 
GO terms Genes 
GO:0003677: DNA binding 
MYBL2, TAF4, HBF4A, CTCFL, SALL4, SYCP2, VSX1, PHF0, 
CHD5, 
TOP1, CST1, TFAP23, ZNF341, SPO11, ZHX3, ZNF337, TCEA2, 
SOX18, INSM1, TGIF2, TCFL5, CST2, FOXA2, ZNF334, ZBP1, 
GZF1, MYT1, ZNFX1, FKHL18, SNA1, NKX2-2, MAFB, 
L3MBTL, SCNAD1, TSHZ2, GMEB2, E2F1, PRIC285, ADNP, 
GATA5, PAX1, RTEL1, ZFP64, RBPJL, ZNF217, PLAGL2, 
RP11-227D2.4, CBFA2T2, WISP2, ZNF335, DNMT3B, HMG1L1, 
CEPB 
GO:0030154: cell differentiation 
NKX2-2, SPATA2, MAFB, BCL2L1, SCAND1, MYBL2, NCO86, 
DIDO1, PARD6B, CD40, E2F1, ELMO2, RPS21, NEURL2, 
PTGIS, TOP1, TFPA2C, EEF1A2, PAX1, LAMA5, EYA2, TGM2, 
CDH4, TNFRS6B, PLAGL2, SERINC3, SNTA1, SOX18, 
CDK5RAP1, NDRG3, CTNNBL1, INSM1, STK4, TCFL5, 
FOXA2, GDF5, CEBPB, ZNF313, BMP7, MYT1, TMEM189-
UBE2V1, BIRC7, MMP9 
GO:0008219: cell death 
TGMS, BCL2L1, TNFRSF6B, SCAND1, MYBL2, PLAGL2, 
SERINC3, 
CTNNBL1, DIDO1, CD40, STK4, E2F1, ELMO2, GDF5, PTGIS, 
CEBPB, TOP1, EEF1A2, BIRC7, MMP9 
GO:0007049: cell cycle 
DSN1, CEP250, RBL1, CTCFL, TPX2, MAPRE1, UBE2C, 
CABLES2, AURKA 
GO:0006350: transcription 
RBM39, C20ORF20, TAF4, POFUT1, NCOA3, ZNF341, TH1L, 
TCEA2, ADRM1, RP5-890O15.2, ZNFX1, FKHL18, L3MBTL, 
XRN2, TSHZ2, GMEB2, ASLX1, PRIC285, ZMYND8, ADNP, 
GATA5, ZFP64, ZBTB46, ZNNF217, ID1, NFATC2, HMG1L1, 
SLA2 
GO:0040007: regulation of growth OGFR, C20ORF10, GINS1, GHRH, ITCH 
GO:0050896: response to stimulus 
ASIP, ADA, PLUNC, SGK2, PROCR, VAPB, DEFB123, 
WFDC12, DEFB124, GNAS, TOP1, CHRNA4, TGM2, DEFB118, 
CD93, NTSR1, DEFB115, BPI, GSS, DEFB116, DEFB121, 
C20ORF185, CST7, LBP, THBD, DYNLRB1, SAMHD1, 
DEFB119, CST11, LIME1 
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Table A2-3. List of cell lines sensitive or resistant to the camptothecins 
 
    # Drugs cell lines are   
Family cell line resistant* sensitive** sum 
35 12615 1 0 1 
35 12616 0 2 2 
35 12617 1 3 4 
35 12618 1 4 5 
35 12619 1 3 4 
35 12620 0 3 3 
35 12621 0 4 4 
35 12622 1 4 5 
35 12623 0 3 3 
35 12624 1 3 4 
45 12698 0 1 1 
45 12699 1 2 3 
45 12700 0 1 1 
45 12701 0 3 3 
45 12702 1 3 4 
45 12703 1 2 3 
45 12704 2 0 2 
45 12705 1 2 3 
45 12706 1 3 4 
45 12849 1 0 1 
1334 10846 3 1 4 
1334 10847 0 5 5 
1334 12138 2 0 2 
1334 12139 1 2 3 
1334 12141 2 3 5 
1334 12142 1 1 2 
1334 12238 3 0 3 
1340 7008 0 3 3 
1340 7019 1 0 1 
1340 7027 0 1 1 
1340 7029 1 0 1 
1340 7040 0 3 3 
1340 7053 1 3 4 
1340 7062 2 0 2 
1340 7342 1 0 1 
1340 11821 1 3 4 
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Family cell line resistant* sensitive** sum 
1341 6991 3 1 4 
1341 7006 1 1 2 
1341 7010 0 1 1 
1341 7012 0 4 4 
1341 7020 1 0 1 
1341 7021 2 3 5 
1341 7044 0 3 3 
1341 7048 1 3 4 
1341 7343 0 3 3 
1341 7344 1 1 2 
1345 7345 0 2 2 
1345 7348 3 1 4 
1345 7357 1 1 2 
1350 10855 0 5 5 
1350 10856 1 1 2 
1350 11822 1 4 5 
1350 11824 2 2 4 
1350 11825 1 3 4 
1350 11826 1 0 1 
1350 11827 1 4 5 
1350 11828 2 3 5 
1362 10860 1 0 1 
1362 10861 2 0 2 
1362 11982 1 2 3 
1362 11983 1 3 4 
1362 11984 0 3 3 
1362 11985 0 3 3 
1362 11986 1 3 4 
1362 11987 0 4 4 
1362 11988 0 2 2 
1362 11989 1 3 4 
1408 10830 1 2 3 
1408 10831 1 0 1 
1408 12147 1 0 1 
1408 12148 2 1 3 
1408 12149 0 3 3 
1408 12150 0 4 4 
1408 12151 1 0 1 
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Family cell line resistant* sensitive** sum 
1408 12152 0 1 1 
1408 12153 2 0 2 
1408 12157 1 0 1 
1420 10838 1 0 1 
1420 10839 1 0 1 
1420 11997 1 3 4 
1420 11998 3 0 3 
1420 11999 2 1 3 
1420 12000 4 1 5 
1420 12001 4 0 4 
1420 12002 1 0 1 
1420 12007 1 1 2 
1447 12752 1 3 4 
1447 12753 1 0 1 
1447 12754 0 1 1 
1447 12755 0 3 3 
1447 12756 0 5 5 
1447 12757 1 3 4 
1447 12758 0 3 3 
1447 12759 0 2 2 
1447 12764 0 3 3 
1447 12765 1 2 3 
1451 12766 1 3 4 
1451 12767 0 5 5 
1451 12768 1 1 2 
1451 12769 0 4 4 
1451 12770 2 1 3 
1451 12771 2 0 2 
1451 12772 0 4 4 
1451 12773 1 0 1 
1451 12774 1 1 2 
1451 12848 1 0 1 
1454 12801 0 3 3 
1454 12802 1 0 1 
1454 12803 1 3 4 
1454 12804 1 2 3 
1454 12805 0 3 3 
1454 12806 0 4 4 
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Family cell line resistant* sensitive** sum 
1454 12807 1 3 4 
1454 12808 1 0 1 
1454 12809 0 3 3 
1454 12810 1 0 1 
1459 12864 0 2 2 
1459 12865 0 4 4 
1459 12866 0 4 4 
1459 12867 1 1 2 
1459 12868 0 5 5 
1459 12869 0 3 3 
1459 12870 0 4 4 
1459 12871 0 3 3 
1459 12876 1 3 4 
          
# cell lines resistant to >=3 drugs   7     
# cell lines sensitive to > 4 drugs     19   
# cell lines sens or resist to at least 4 
camptos       47 
     
*Resistance defined as IC50 > 90th percentile of all IC50s 
**Sensitivity defined as IC50 < 10th percentile of all IC50s 
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Figure A3-1. Genomewide map of QTLs for camptothecins set 1 (A), camptothecin set 1+2 (B) and 
indenoisoquinolines (B). Each chromosome was partitioned into 10 cM regions. Each drug-dose 
combination that resulted in a significant QTL (LOD >significance threshold) is indicated in blue. 
Intensity of the shading indicates the number of doses replicating that QTL at either the suggestive or 
significant level. Regions which also had a suggestive QTL (LOD > suggestive threshold) are 
indicated in green with color intensity referring to the number of doses replicating this peak 
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Table A3-1. List of significant QTLs for indenoisoquinolines 
 
Chr Drug Dose 
Peak 
Start 
cm 
Peak 
End 
cm LOD 
# 
replicate* 
doses 
2 Ind1 0.2 26.52 31.05 1.129 2 
6 Ind1 0.3 124.11 153.04 1.964 3 
6 Ind1 0.1 130 153.04 1.734 3 
6 Ind1 0.2 136.97 149.8 1.28 3 
7 Ind1 0.001 74.38 86.12 1.348 0 
9 Ind1 0.03 27.32 58.26 1.558 1 
9 Ind1 0.001 159.61 163.84 1.331 1 
10 Ind1 0.05 131.8 153.78 1.775 0 
11 Ind1 0.1 35.21 110.73 1.797 4 
11 Ind1 0.3 53.87 93.12 1.714 4 
11 Ind1 3 72.82 89.69 1.591 3 
13 Ind1 0.1 84.87 90.27 1.21 0 
14 Ind1 3 105.53 121.95 1.447 0 
16 Ind1 0.1 70.69 84.75 1.474 4 
18 Ind1 0.03 91.62 96.48 1.554 0 
19 Ind1 0.1 58.69 67.37 1.574 1 
1 Ind2 0.01 72.59 82.41 1.345 0 
4 Ind2 1 195.06 203.77 1.365 0 
5 Ind2 0.23 24.48 37.32 1.114 1 
5 Ind2 0.16 119.5 123.45 1.551 2 
6 Ind2 10 124.64 153.04 1.694 3 
6 Ind2 30 173.31 177.88 1.273 1 
7 Ind2 0.16 17.17 27.66 1.143 0 
7 Ind2 1 72.78 75.44 1.517 1 
8 Ind2 1 106.9 121.9 1.683 0 
11 Ind2 1 71.6 88.49 1.593 3 
16 Ind2 3 48.53 93.78 2.139 2 
2 Ind3 50 14.1 33.31 2.024 2 
3 Ind3 3 131.83 146.6 1.148 0 
3 Ind3 1 180.8 181.87 1.212 1 
3 Ind3 3 180.8 187.49 1.362 2 
3 Ind3 5 205.56 222.83 1.877 1 
3 Ind3 3 207.73 214.45 1.121 1 
4 Ind3 3 192.12 206.98 1.483 1 
6 Ind3 7 124.64 159.98 2.286 4 
6 Ind3 10 124.64 159.98 2.195 4 
6 Ind3 5 133.18 159.44 1.805 4 
6 Ind3 30 142.86 146.06 1.012 4 
6 Ind3 10 161.59 164.78 1.509 4 
6 Ind3 10 173.31 177.88 1.352 4 
10 Ind3 1 121.98 128.73 1.43 1 
11 Ind3 10 87.89 101.75 1.592 5 
11 Ind3 50 104.03 138.56 2.421 5 
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Chr Drug Dose 
Peak 
Start 
cm 
Peak 
End 
cm LOD 
# 
replicate 
doses 
12 Ind3 1 130.94 144.83 1.472 0 
13 Ind3 10 84.87 90.27 1.44 2 
14 Ind3 5 98.96 125.88 2.022 2 
16 Ind3 10 75.34 84.75 1.228 2 
16 Ind3 10 87.06 99.44 1.227 3 
 
* number of doses for this drug which replicated this QTL 
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Table A4-1 Drug concentrations and 50GI  for mechanistic set 
 
Drug Name Abbreviation 
Dose 1 
(mM) 
Dose 2 
(mM) 
Dose 3 
(mM) 
Dose 4 
(mM) 
5-
Fluorouracil 5FU 1.10E-03 4.94E-03 2.22E-02 1.00E-01 
Floxuridine Flox 2.33E-03 8.16E-03 2.86E-02 1.00E-01 
Epirubicin Epi 6.30E-06 2.50E-05 1.00E-04 4.00E-04 
Doxorubicin Dox 6.00E-06 1.30E-05 2.50E-05 5.00E-05 
Daunorubicin Daun 1.25E-05 2.50E-05 5.00E-05 1.00E-04 
Idarubicin Ida 5.00E-06 1.23E-05 2.78E-05 6.25E-05 
Vincristine Vinc 1.25E-05 2.50E-05 5.00E-05 1.00E-04 
Vinorelbine Vino 5.93E-05 8.89E-05 1.33E-04 2.00E-04 
Vinblastine Vinb 5.00E-06 1.00E-05 2.00E-05 4.00E-05 
Docetaxel Doc 1.28E-05 3.20E-05 8.00E-05 2.00E-04 
Paclitaxel Pac 1.85E-05 5.56E-05 1.67E-04 5.00E-04 
Oxaliplatin Oxal 3.70E-03 1.11E-02 3.33E-02 1.00E-01 
Carboplatin Carbo 1.28E-03 3.20E-03 8.00E-03 2.00E-02 
Etoposide Etop 1.17E-04 4.08E-04 1.43E-03 5.00E-03 
Teniposide Teni 2.56E-04 6.40E-04 1.60E-03 4.00E-03 
Bleomycin Bleo 8.00E-05 4.00E-04 2.00E-03 1.00E-02 
      
  50GI      
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Table A4-2. Cell lines sensitive and resistant to the mechanistic set, by family 
 
Family cell line
Drugs 
# Resistant* # Sensitive** 
35 12615 7 0 
35 12616 0 11 
35 12617 1 11 
35 12618 1 0 
35 12619 1 1 
35 12620 9 9 
35 12621 9 15 
35 12622 6 13 
35 12623 6 0 
35 12624 1 0 
45 12698 1 7 
45 12699 1 2 
45 12700 0 0 
45 12701 1 0 
45 12702 0 0 
45 12703 8 0 
45 12704 0 0 
45 12705 12 9 
45 12706 0 1 
45 12849 7 2 
1334 10846 6 3 
1334 10847 0 0 
1334 12138 1 0 
1334 12139 1 1 
1334 12141 0 2 
1334 12142 0 0 
1334 12238 0 0 
1340 7008 0 2 
1340 7019 1 1 
1340 7027 8 0 
1340 7029 10 0 
1340 7040 7 3 
1340 7053 0 0 
1340 7062 1 1 
1340 7342 1 0 
1340 11821 7 0 
1341 6991 0 0 
1341 7006 1 10 
1341 7010 0 1 
1341 7012 0 0 
1341 7020 0 0 
1341 7021 6 0 
1341 7044 1 0 
1341 7048 3 0 
1341 7343 0 7 
1341 7344 0 0 
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Family cell line Drugs # Resistant # Sensitive 
1345 7345 0 0 
1345 7348 2 0 
1345 7357 3 2 
1350 10855 8 0 
1350 10856 11 0 
1350 11822 10 0 
1350 11824 3 0 
1350 11825 4 0 
1350 11826 0 0 
1350 11827 0 9 
1350 11828 1 0 
1362 10860 0 0 
1362 10861 3 0 
1362 11982 0 0 
1362 11983 1 0 
1362 11984 9 0 
1362 11985 0 0 
1362 11986 11 0 
1362 11987 1 0 
1362 11988 2 3 
1362 11989 2 0 
1408 10830 0 15 
1408 10831 0 3 
1408 12147 1 0 
1408 12148 0 0 
1408 12149 0 0 
1408 12150 0 0 
1408 12151 0 0 
1408 12152 0 1 
1408 12153 1 0 
1408 12157 0 1 
1420 10838 1 0 
1420 10839 4 12 
1420 11997 0 5 
1420 11998 0 0 
1420 11999 1 0 
1420 12000 1 1 
1420 12001 0 0 
1420 12002 0 0 
1420 12007 2 0 
1447 12752 6 2 
1447 12753 3 0 
1447 12754 0 0 
1447 12755 0 1 
1447 12756 1 0 
1447 12757 0 0 
1447 12758 0 0 
1447 12759 1 0 
1447 12764 0 0 
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Family cell line Drugs # Resistant # Sensitive 
1447 12765 1 0 
1451 12766 0 0 
1451 12767 0 16 
1451 12768 0 0 
1451 12769 0 1 
1451 12770 7 0 
1451 12771 0 0 
1451 12772 0 2 
1451 12773 3 1 
1451 12774 0 0 
1451 12848 0 0 
1454 12801 0 4 
1454 12802 0 10 
1454 12803 0 0 
1454 12804 0 0 
1454 12805 0 0 
1454 12806 1 0 
1454 12807 2 0 
1454 12808 0 1 
1454 12809 0 0 
1454 12810 0 0 
1459 12864 0 4 
1459 12865 1 0 
1459 12866 0 4 
1459 12867 0 0 
1459 12868 0 3 
1459 12869 0 1 
1459 12870 1 0 
1459 12871 0 7 
1459 12876 0 0 
 
*Resistance defined as mean viability> 90th percentile of mean viability at 50GI  
**Sensitivity defined as mean viability < 10th percentile of mean viability at 50GI  
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Table A4-3. Heritability estimates for all drug-dose phenotypes of mechanistic set 
 
Growth-rate 
adjusted h2 
Dose 1 Dose 2 Dose 3 Dose 4 
Bleo 15.09 9.49 5.74 0.00 
5FU 23.84 30.85 22.91 0.00 
Flox 25.03 25.54 16.03 11.41 
Carbo 37.17 40.57 16.74 13.51 
Oxal 49.74 30.92 13.03 20.61 
Epi 62.40 53.68 43.70 2.30 
Daun 37.12 22.98 13.40 17.51 
Dox 34.12 28.71 0.01 0.01 
Ida 48.95 27.85 6.00 3.93 
Doc 23.04 24.26 31.17 13.45 
Pac 53.24 34.23 7.77 27.57 
Etop 42.42 38.10 33.26 23.76 
Teni 32.95 29.13 37.72 19.94 
Topo 45.78 26.14 0.00 0.71 
Vinb 0.07 0.01 13.76 35.86 
Vino 36.75 2.83 8.19 0.00 
Vinc 24.40 9.00 23.39 10.93 
* refer to Table A4-1 for doses 
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Table A4-4. List of significant QTLs for mechanistic set 
 
Chr Drug Dose (mM) Peak Start
cm 
Peak End 
cm 
LOD 
1 Doc 8.00E-05 8.85 16.22 1.231
1 Doc 0.0002 33.75 52.7 1.341
1 Doc 8.00E-05 168.52 190.98 1.623
1 Oxal 0.1 20.61 23.35 1.12
1 Oxal 0.1 24.68 56.19 2.091
1 Pac 0.0001667 23.35 60.01 1.921
1 Pac 0.0005 33.75 54.3 1.685
1 Vinb 1.00E-05 191.52 201.58 1.208
1 Vinb 1.00E-05 214.08 237.73 1.596
2 Bleo 0.01 218.45 229.14 1.503
2 Carbo 0.0032 94.05 103.16 1.354
2 Carbo 0.0032 106.84 119.22 1.164
2 Carbo 0.0032 120.29 137.93 1.701
2 Carbo 0.0032 185.13 195.65 1.246
2 Carbo 0.0032 196.85 204.53 1.375
2 Oxal 0.0037037 215.78 227 1.511
2 Vinb 2.00E-05 1.95 14.1 1.59
2 Vinb 2.00E-05 137.93 147.4 1.257
2 Vinb 2.00E-05 149.89 161.26 1.196
3 5FU 0.004938 190.43 207.73 1.648
3 5FU 0.004938 212.61 214.45 1.124
3 Flox 0.0023324 187.49 198.68 1.941
3 Flox 0.0285714 187.49 206.43 2.094
3 Flox 0.0081633 189 201.14 1.801
3 Flox 0.1 190.43 203.28 1.571
3 Oxal 0.0333333 187.49 228.14 2.179
3 Oxal 0.1 190.43 214.45 1.712
4 Dox 2.50E-05 180.01 199.93 1.47
5 Carbo 0.00128 0 1.72 1.126
5 Carbo 0.008 0 5.43 1.48
5 Carbo 0.008 140.72 144.06 1.073
5 Carbo 0.00128 152.62 155.92 1.058
5 GR_1_DM
SO 
1 142.92 155.92 1.5
5 GR_1_DM
SO 
1 159.77 162.47 1.061
5 GR_10_D
MSO 
1 134.72 156.47 2.13
5 GR_10_D
MSO 
1 157.02 167.69 1.25
5 GR_H20 1 144.06 153.17 1.502
5 GR_H20 1 160.87 162.16 1.027
6 Etop 0.000408 37.79 74.28 1.493
6 Etop 0.000408 76.62 87.29 1.217
6 Etop 0.000408 100.91 103.45 1.045
7 5FU 0.1 97.89 98.44 1.103
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Chr Drug Dose (mM) Peak Start
cm 
Peak End 
cm 
LOD 
7 5FU 0.1 103.63 113.92 1.173
7 5FU 0.1 137.83 155.1 1.971
7 5FU 0.022222 140.63 155.1 1.41
7 5FU 0.022222 159.53 168.98 1.195
7 Bleo 0.0004 23.29 47.08 1.929
7 Bleo 0.0004 48.69 52.7 1.064
7 Bleo 0.0004 155.1 181.97 1.635
7 Carbo 0.02 57.79 78.65 1.854
7 Carbo 0.008 58.86 73.84 1.385
7 Carbo 0.0032 61 76.71 1.647
7 Carbo 0.008 74.38 78.65 1.471
7 Carbo 0.02 79.24 90.42 1.363
7 Carbo 0.0032 83.99 86.12 1.038
7 Carbo 0.008 84.52 86.12 1.019
7 Carbo 0.02 91.67 104.86 1.48
7 Carbo 0.008 94.87 100.05 1.061
7 Carbo 0.008 140.63 149.9 1.313
7 Carbo 0.02 141.29 148.11 1.047
7 Daun 0.0001 143.33 149.9 1.257
7 Daun 0.0001 160.09 161.21 1.007
7 Doc 8.00E-05 128.41 181.97 1.652
7 Doc 3.20E-05 168.98 181.97 1.595
7 Epi 0.0001 112.32 113.92 1.026
7 Epi 0.0001 140.63 155.1 1.443
7 Flox 0.0285714 146.28 155.1 1.227
7 Flox 0.0081633 156.33 170.94 2.013
7 Flox 0.0285714 159.53 170.94 1.521
7 Flox 0.0285714 178.41 181.97 1.032
7 Ida 2.78E-05 104.86 105.39 1.045
7 Ida 2.78E-05 106.46 123.01 1.286
7 Ida 6.25E-05 112.32 113.92 1.033
7 Ida 2.78E-05 134.55 165.18 2.285
7 Ida 6.25E-05 138.42 162.33 1.839
7 Oxal 0.0333333 54.11 67.43 1.374
7 Oxal 0.0333333 75.98 77.91 1.038
7 Oxal 0.0333333 103.63 126.75 1.857
7 Teni 0.004 140.63 161.21 1.97
7 Teni 0.000256 162.33 181.97 1.887
7 Vinb 5.00E-06 163.03 181.97 2.061
8 Bleo 0.0004 103.69 111.68 1.55
8 Carbo 0.00128 87.52 102.62 1.325
9 5FU 0.004938 81.92 96.46 1.5
9 5FU 0.004938 150.92 159.61 1.075
9 Ida 1.23E-05 88.16 88.92 1.023
9 Ida 1.23E-05 90.4 105.82 1.643
9 Ida 1.23E-05 110.91 116.67 1.33
11 Doc 0.0002 11.05 33.02 1.485
11 Doc 0.0002 35.21 50.88 1.185
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Chr Drug Dose (mM) Peak Start
cm 
Peak End 
cm 
LOD 
11 Doc 3.20E-05 45.94 54.75 2
11 Doc 3.20E-05 91.47 98.45 1.439
11 Etop 0.000117 110.73 112.87 1.067
11 Etop 0.000117 116.07 127.33 1.186
11 GR_1_DM
SO 
1 90.89 100.05 2.088
11 GR_1_DM
SO 
1 100.62 101.75 1.043
11 GR_10_D
MSO 
1 91.47 100.05 1.852
11 GR_Blank 1 89.69 101.75 1.751
11 GR_H20 1 90.29 100.05 2.067
11 GR_H20 1 100.62 101.75 1.053
11 Oxal 0.0037037 51.42 53.02 1.067
11 Oxal 0.0037037 83.83 89.69 1.229
11 Oxal 0.0111111 88.49 96.85 1.334
11 Vinc 0.0001 14.52 50.88 1.343
11 Vino 0.0002 12.92 51.95 1.541
12 Teni 0.0016 17.72 29.73 1.499
12 Teni 0.0016 90.77 94.49 1.151
12 Teni 0.0016 139.61 144.83 1.121
12 Vino 8.89E-05 9.52 19.68 1.581
12 Vino 8.89E-05 125.31 153.33 1.685
13 Daun 5.00E-05 0 17.21 1.362
13 Teni 0.00064 0 16.2 1.622
14 5FU 0.004938 0 13.89 1.728
14 Carbo 0.02 0 13.89 1.643
14 Carbo 0.02 21.51 31.13 1.345
14 Etop 0.001429 21.51 25.87 1.124
14 Etop 0.001429 26.59 36.76 1.454
14 GR_1_DM
SO 
1 93.76 118.68 1.42
14 GR_10_D
MSO 
1 53.19 63.25 1.209
14 GR_10_D
MSO 
1 78.2 84.16 1.066
14 GR_10_D
MSO 
1 92.69 125.88 1.801
14 GR_H20 1 57.43 57.98 1.012
14 GR_H20 1 93.76 118.68 1.414
14 GR_Media
_FCS 
1 93.76 117.3 1.469
15 Dox 5.00E-05 6.11 19.12 1.108
15 Vinc 5.00E-05 82.84 102.21 1.524
16 Bleo 0.0004 73.2 85.94 1.471
16 Epi 6.30E-06 73.2 87.06 1.536
18 Epi 6.30E-06 0 35.46 1.907
18 Epi 6.30E-06 66.66 68.3 1.253
18 Etop 0.001429 64.48 66.66 1.05
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Chr Drug Dose (mM) Peak Start
cm 
Peak End 
cm 
LOD 
18 Etop 0.001429 67.21 74.93 1.356
18 Vino 8.89E-05 9.26 16.54 1.194
18 Vino 8.89E-05 35.46 49.55 1.065
18 Vino 8.89E-05 66.66 76.15 1.588
19 5FU 0.1 100.01 105.02 1.713
19 Carbo 0.008 100.01 105.02 1.568
19 Carbo 0.02 100.01 105.02 1.761
19 Dox 5.00E-05 100.01 105.02 1.338
19 Ida 2.78E-05 89.73 105.02 1.965
19 Ida 6.25E-05 100.01 105.02 1.404
20 Oxal 0.0111111 36.58 48.85 1.559
20 Oxal 0.0111111 58.48 61.77 1.327
20 Vinb 2.00E-05 6.25 8.97 1.325
20 Vinb 2.00E-05 9.53 17.19 1.504
20 Vinb 2.00E-05 37.65 47.52 1.357
20 Vinb 2.00E-05 55.74 74.47 2.08
20 Vinc 5.00E-05 42.28 77.75 1.858
21 Pac 0.0005 9.72 40.43 1.685
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Figure A4-1. Boxplots for variability in response for the mechanistic drug set. The CEPH cell lines  
(n =125) were treated with increasing concentrations of each drug (4 doses) and mean viability 
measured relative to control. The line within each box represents the median (50%) viability for the 
population (n = 125) at the specified dose, the upper edge of the box indicates the 75th percentile 
of the data set, and the lower edge indicates the 25th percentile. The range of the middle two 
quartiles is the inter-quartile range (IQR). The whiskers are 1.5 times the IQR. Circles 
outside the whiskers are considered outliers. 
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